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chapter 1
Introduction
This introductory chapter starts with a description of HIV problem in Indonesia and the role 
of people who inject drugs in HIV transmission. The intervention programs to handle HIV 
transmission driven by people who inject drugs are described; this is followed by the concept 
of biopsychosocial approach. Finally, an overview of the aims and structure of this thesis 
is presented. The previous term for people who inject drugs is injecting drug users (IDU), 
which will be used in most of the chapters. 
HIV epidemic in Indonesia 
The first case of Acquired Immunodeficiency Syndrome (AIDS) in Indonesia was notified in 
19871 and it was not until 1995 that the first AIDS case among injecting drug users (IDU) 
was reported2. Since then, IDU have constituted to be a major component of the country’s 
HIV epidemic and being the main route of transmission in large parts of Indonesia, 
especially in urban areas of Java, North Sumatra, and South Sulawesi, followed by hete-
rosexual transmission, especially in Papua3. Injecting drug users may constitute 50% of all 
HIV-infected individuals in Indonesia (see figure 1), compared with 0.6% for South Africa 
and 3% for Kenya4,5.
In the Indonesian report on the follow up of the declaration of commitment on  
HIV/AIDS, it was shown that the estimated annual number of new HIV infections in South 
and South-East Asia decreased from 450,000 (150,000-800,000) in 2001 to 340,000  
(180,000 - 740,000) in 2007. In spite of this improvement, in South-East Asia and  
particularly in Indonesia, the prevalence of HIV is growing. The increasing number of new 
HIV infections in Indonesia makes the epidemic one of the fastest growing in Asia, even 
though the aggregate national prevalence is as low as 0.16%6. 
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Figure 1.1 Trend of cumulative AIDS cases and IDU percentage among new AIDS cases7.
Injecting drug users in the context of HIV epidemic in Indonesia
Similar to various other countries, it was the HIV epidemic that drew the first attention to 
the increase of drug-taking practices in Indonesia. Until 1998, all data indicated that the HIV 
prevalence in Indonesia was low, even in the traditional high risk groups, such as men who 
have sex with men, female sex workers, and people who inject drugs. 
A survey in the major drug treatment centre in the capital, Jakarta, found no indication for 
HIV infection among those tested from 1996 to 1998, however, because of limited numbers 
of IDU under treatment, only between 50 and 60 a year were tested. In the next survey in 
2000, 39 out of 247 (15%) from IDU were tested HIV-seropositive. Two years later, HIV 
prevalence among injectors at this sentinel site was recorded at 48% - by far the highest 
prevalence rate among any risk population in Indonesia8. The Indonesian Ministry of Health 
reported HIV seroprevalence among IDU to be 43 - 56%9, a very high rate compared to 
other Asian countries such as Pakistan (8-24%)10, China (18-50%)11, Vietnam (34%)10, 
Thailand (38%)12. 
The estimation number of Indonesian people who inject drugs in 2003 was 145,000 
to 170,0008. IDU in Indonesia13-15 are younger and had higher education (most of them 
graduate from senior high school or higher education) compared to IDU in Australia, 
Canada, China, Iran, Israel, Netherland, Poland, Thailand, and USA16-20. Several Indonesian 
studies reveal that almost all IDU reported risky injecting practices13, 21, 22. Findings from 
the Indonesian Behavioural Surveillance Survey (BSS) in 2004-2005 indicated that IDU 
tend to gather in groups to ‘shoot up’ together in a particular circle with an average size of 
7-14 people23. Apart from transmission of blood-born infections among peers, IDU may also 
spread these infections to the general populations. A study conducted in 2002, showed that 
over two-thirds of IDU were sexually active with high sexual risk behaviour, consistent 
condom use was reported by 10%, and almost half of them also reported having multiple 
sexual partners,13. 
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Indonesian programs for the prevention of HIV transmission
A variety of prevention strategies have been adopted and implemented in Indonesia to 
reduce the emerging HIV epidemic. Many governmental organizations play a role in the 
control of the HIV/AIDS epidemic, primarily the KPA or the National AIDS Comission 
(NAC), which has been a part of the Presidential Cabinet from July 2006. The Ministry of 
Health is responsible for implementing the response to the HIV/AIDS epidemic, comprised 
of four departments. The Pharmacy Department is responsible for all medications 
including anti-retroviral treatment (ART). The Centre for Diseases Control includes the 
National AIDS Program which is responsible for program development, building local 
human resources and for all matters related to epidemiology. The Department of Medical 
Services runs all the hospitals, the Drug Program (including methadone clinics), and all 
laboratories. Lastly, the Community Health Department is responsible for the Community 
Public Health Centres (Puskesmas) programs. 
The National Narcotic Board (BNN), which is related to the National Police, is responsible 
for drugs demand and supply reduction. Demand reduction includes prevention (family 
based, school based, community based and workplace based), treatment and rehabilitation 
activities in public, non-government organizations (NGO), and private facilities, employing 
various modalities. Supply reduction strategies are implemented through more intensive 
eradication of cannabis cultivation, intensive investigations and raids of clandestine manu-
facturers and applying strict airport and seaport interdictions. Also related to this effort is the 
Ministry of Justice and Human Rights, which runs prisons in the country and is responsible 
for every intervention inside the prison system24. Supply and demand reduction approaches 
are complemented by a harm reduction (HR) approach. 
The role of NGO in HR activities has been notably instrumental since late 1990s2, and 
it was not until early of January 2007 that the official national policy has been stipulated. 
The national HR policy aims to prevent HIV transmission among IDU and their partners, 
prevent HIV transmission from IDU and their partners to general population; and integrate 
HR approach into public health system through HIV/AIDS prevention, care, support and 
treatment (CST) services as well as drug addiction rehabilitation service. It is implemented 
through 12 programs or services by involving multi-sectorial agencies and institutions and 
by 2010 the programs should provide corresponding services for at least 80% of the IDU 
population25.
Among the twelve HR programs, the methadone maintenance treatment (MMT) is stated as 
priority programs by the Ministry of Health7. The opioid substitution treatment has shown 
its effectiveness in reducing injecting drug use, unsafe injection practices, unsafe sexual prac-
tices, and seroconversion rates for HIV26-28. By 2008, twenty-four MMT clinics are opera-
tional in seven provinces29 and 110 service points of needle and syringe exchange programs 
(NSP) are operational in Indonesia30. The national Integrated Biological and Behavioural 
Surveillance Survey (IBBS) in 2007 revealed that most of those who received MMT were still 
injecting drugs31 and despite receiving needles from needle exchange program (NEP), IDU 
still shared needles, ranging from 9% in Semarang to 63% in Jakarta31, leading to question 
about its effectiveness. 
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Apart from continuing needle sharing, the coverage of HR programs is still low and the 
drop-out rate is high. WHO-SEAR and Indonesian ministry of health (2007) reported that 
there were a total of 1,546 MMT clients registered in 12 MMT clinics by the end of 2006, 
in which only 752 of them (49%) were still in treatment1. Furthermore, in 2006, the total 
number of IDU residing in the cities in which the clinics operated was estimated to be not 
less than 42,0009. It implies that only 4% of IDU ever used the service. 
Many studies have shown that pharmacotherapy is an effective HR strategy. Methadone and 
buprenofine are commonly used with positive effects as described above26-28. However, the 
complex nature of addiction may ask for additional interventions, such as HIV-related or 
psychiatric medical care. For patients in need, the provision of these additional support 
services is indeed associated with improved drug treatment retention and lower relapse 
rates28, 32. Besides stabilization and reduction of the injecting risk behaviour, abstinence could 
be a legitimate goal of harm reduction33-36 and preferable when feasible37, 38. Finally, it should 
be noticed that the different HR programs not only reduce the harmful consequences of drug 
use of individuals but are beneficial from a public health point of view as well. 
Context of IMPACT
The work that is presented in this thesis has been performed as a part of the EU-funded 
IMPACT program. IMPACT stands for Integrated Management of Prevention And Control 
and Treatment of HIV/AIDS. The official project name is “Prevention Control and 
Treatment of HIV/AIDS of intravenous drug users in West Java Indonesia (EC contract 
number SANTE/2005/105-033). 
Figure 1.2. Framework for comprehensive measures to control the HIV epidemic in West Java
This 5 year project (principle investigators Dr B Alisjahbana and Prof Dr A van der Ven) 
used a comprehensive and integrated approach combining the following main activities 
(figure 1.2): 1) information, education and communication about HIV-related risk 
behaviour in adolescents; 2) scaling-up voluntary counselling and testing (VCT) and 
improving its accessibility for injecting drug users (IDU) in the community, prison and 
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hospital; 3) harm reduction strategies, including Methadone maintenance; 4) scaling-up 
care for HIV/AIDS, including antiretroviral treatment; 5) capacity building and transfer of 
knowledge about IDU and HIV/AIDS. The present work is mostly focussed on objective 3 
but was done in collaboration with researchers focussed on the other IMPACT objectives. 
Concept of biopsychosocial approach
There are several concepts of addiction, such as the moral model, pharmacological model, 
symptom model, disease model, and learning mode, and different treatment types that can 
be offered depending on the model39. One of the latest introduced models was the biopsy-
chosocial model. This model views addiction as a disease with continuum of severity with 
biological, psychological and social causes and consequences40, 41. Changes in one area could 
result in changes in other areas and the combination, interactions and the weightings of 
specific factors will be different for each individual40.
IDU in Indonesia are suffering from addiction as a chronic brain disease often in co-occur-
rence with HIV and other somatic, psychiatric and social problems. All of these co-occurring 
problems and their treatment interact in a complex way. Furthermore, like other Asian 
countries, Indonesia is a collectivist society. People are integrated from birth onward into 
strong, cohesive in-groups, often extended families42. Involvement and support from the 
family or non-related subjects are strongly associated with better physical and psychological 
adjustment, improving the well being of patients43, 44. However, families with high stress may 
also transfer psychological distress to other family members45. Therefore, family members can 
be seen as a source of support from one side but may act as a source of stress from the other 
side46. 
Aims and outline of the thesis
As outlined above, IDUs contribute significantly to the recent emerging HIV epidemic in 
Indonesia. Harm reduction is part of the comprehensive approach to prevent, control and 
treat HIV among IDU. The implementation of harm reduction strategies in West Java, 
Indonesia asks for several considerations which form the basis of this thesis. The following 
specific aims were formulated:  
Implementation of harm reduction program in Indonesia faces great challenges. Until
recently, a common view of the general public and some health care providers in Indonesia
was that drug addicts are weak or bad people, unwilling to control their behaviour and  
gratifications47, 48. 
1      To review the biopsychosocial paradigm in people who inject drugs (chapter 2, 6) 
2      To describe the socio-demographic characteristics and risk behaviours of people                      
        who inject drugs as well as the determinants of access to drug treatment (chapter 3, 4)
 
3      To describe the co-occurring problems and the relation with the quality of life in 
        patients participating in a Methadone Maintenance Treatment program (chapter 5)
 
4      To explore factors that influence family involvement in HIV care (chapter 7)
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On the other hand, health care providers and societies may also view drug dependence as a 
curable, acute condition and not as a chronic disease. These viewpoints may have an impact 
on the treatment strategies and outcome expectations41. In chapter 2, the existing theory 
about the etiology of addiction, including genetics, drug induced changes in the brain, and 
environmental factors is therefore reviewed. Studies in Indonesia and other countries about 
drug addiction, associated risk behaviour, and co-occurring physical, psychiatric and social 
problems are also discussed. At the last part of this chapter, the consequences regarding 
addiction as a complex biopsychosocial phenomenon for prevention and treatment are 
discussed.
There is a considerable number of IDU who change from injection to non-injection drug 
administration. These subjects are called former injecting drug users when no drugs have 
been injected in the previous 6 months49, 50. The high HIV, Hepatitis B and C prevalence in 
former IDU is important since these infections can be further transmitted to others through 
sexual risk behaviour, sharing of non-injection drug-use implements such as straws and crack 
pipes, and other practices such as tattooing51-54. In chapter 3, the HIV risk behaviour among 
former IDU in comparison with current IDU in Indonesia is explored. 
There is an indication that the access to treatment and care is limited for IDU3. Drug use is 
illegal and highly stigmatized; factors that influence treatment entry among drug users may 
differ from factors that influence treatment utilization for other types of health needs. 
In chapter 4 characteristics of the IDU who had accessed substance abuse treatment are 
compared and types of substance abuse treatment which are associated significantly with 
HIV programs are determined
The retention and the coverage of the MMT programs in Indonesia remains very low24. 
Care for co-occurring problems will increase the effectiveness and higher utilization of 
services28 and integrated services should be established based on the patients’ characteris-
tics and problems55. In chapter 5, the prevalence of physical, psychiatric, and drug abuse 
co-occurring disorders among MMT patients in Indonesia is described and the association 
between the severity of the co-occurring disorders and the quality of life is determined.
The prevalence of psychiatric disorders in IDU is high (20, 56-63). The psychiatric problems 
are associated with HIV infection and its treatment (64-66) and drug use (16, 61).  
In chapter 6, the prevalence of psychiatric disorders and the interaction of drug addiction 
and physical co-occurring disorders and their treatment which lead to psychiatric 
co-morbidity are reviewed, focusing to IDU in Asia and Africa, where HIV prevalence is 
high and still increasing.
Involvement and support from the family or non-related intimates are strongly associated 
with better physical and psychological adjustment in HIV-infected patients43, 44. However, 
data regarding factors that may influence the support of non-related intimates is still limited.  
In chapter 7, an explorative study is described in 123 respondents: 36 family members of 
HIV patients with IDU history; 43 family members of HIV patients without IDU history; 
and to 44 family members of patients with tuberculosis for comparison. The satisfaction of 
the family members in services received from health care providers, problems they are faced 
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with in helping sick relatives, and their hope concerning the future of their sick relatives are 
described.
A summary and general discussion (chapter 8) completes the thesis by emphasizing the key 
findings, the recommendation, the limitation of the study, and the direction for the future 
research.
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chapter 2
Prevention and treatment of HIV addicted patients : 
a biopsychosocial approach
Iskandar S, van Crevel R, Siregar IM, Achmad TH, van der Ven AJ, de Jong CAJ. Prevention and 
treatment of HIV addicted patients: a biopsychosocial approach. Acta Med Indones. 2009 Jul;41 
Suppl 1:38-44.
Abstract
Injecting drug use is the main route of HIV transmission in many parts of Indonesia. 
Efforts to prevent HIV-transmission through injecting drug use mostly focus on subjects 
who actively inject. In scientific publications the term ‘injecting drug users’ tends to be used 
without a clear definition and without specifying the pattern of drug use as current or former 
drug use, frequency, duration, type of injected drug(s) or context (e.g. imprisonment). 
Actually, injecting drug users (IDUs) have different drug use patterns, risk behavior, somatic 
co-morbidity, psychiatric co-morbidity, and psychosocial problems. In fact, these patients 
are suffering from addiction as a chronic brain disease in co-occurrence with somatic and 
psychiatric disorder and many social problems. Failing in addressing the problems compre-
hensively will lead to the failure of drug treatment. This is why addiction can be best studied 
and treated from a biopsychosocial perspective. Accordingly, treatment goals can be differen-
tiated in crisis intervention, cure or recovery (detoxification, relapse prevention), and care 
or partial remission (stabilization and harm reduction). In summary, injecting drug use in 
Indonesia is not a single entity and patient oriented prevention and care for IDUs, especially 
focusing on their addiction, should be addressed to prevent the transmission of HIV/AIDS.
Key words : Drug addiction, HIV/AIDS, prevention, treatment
Introduction
The prevalence of HIV/AIDS has greatly increased in recent years in Indonesia1, 2. 
The number of infected cases increases because of the transmission of these viruses through 
injecting risk behaviour, sexual risk behaviour, and other risk behaviour, but injecting drug 
use is mostly underlying this trend3. Compared to other countries, Indonesia has the highest 
HIV-prevalence rates among IDUs, ranging from 43 – 56% in official reports4. 
A recent survey in Bandung showed that 75% of 210 IDUs recruited through respondent-
driven sampling reported to be HIV-tested, and 63% of them to be HIV-positive (Iskandar, 
unpublished report). Injecting drug use is mostly a result of drug addiction, and we can 
therefore conclude that drug addiction and injecting drug use are the main factors driving 
HIV-infection in Indonesia.
Generally, the concept of injecting drug use is overly simplified, with little attention for 
the underlying problem of drug addiction. Too often, service providers and policy makers 
propagate needle exchange programs and/or pharmacotherapy as the ‘one fits all’ harm 
reduction without having properly characterized all problems of the addicted patient(s). In 
order to reduce the spread of HIV, a state of the art of addiction has to be applied on the 
development of treatment programs. 
Until recently, the most common view was that drug addicts are weak or bad people, 
unwilling to control their behavior and gratifications5, 6. However, it has been shown that 
addiction is a chronic brain disease5, 7.  In one important study of more than 3,000 twin 
pairs, Tsuang and colleagues reported that both environmental and genetic factors influenced 
abuse and dependence for several types of drugs, with genetic factors accounting for over 
50% of the variance for opiate abuse or dependence8, 9. A family study found that the adjus-
ted odds ratio for having the same drug disorder in adult first-degree relatives was over 7 for 
cocaine and over 10 for opioids, again indicating an involvement of genetic factors10. 
This change in paradigm has serious consequences for the way professionals should look at  
addicted patient and their disease. In this article we first give an overview of the current 
insights in the psychopathology and the consequences for their diagnosis. Then we will ad-
dress the etiology, including genetics, drug induced changes in the brain, and environmental 
factors. The drug addiction and associated risk behavior are often accompanied by somatic, 
psychiatric and social problems, which will also be discussed. Finally, we will discuss the 
consequences regarding addiction as a complex biopsychosocial phenomenon for prevention 
and treatment. 
Psychopathology and Diagnosis
At cellular level, all drugs of abuse share a common characteristic which underlies their 
abuse potential: initial use in the mode and pattern of abuse leads to rapid increase or  
decrease of receptor and/or transporter function, neurotransmitter/ neuropeptide activity, 
and secondary messenger signaling. Changes in the gene expression of target proteins follow  
frequent, repeated exposure. Cessation of drug use leads to similarly profound changes. 
Thus, recurrent “on-off” use of short-acting drugs produces long-term, perhaps permanent, 
alterations in these affected neuronal systems and underlies the development of tolerance, 
dependence, withdrawal, and relapse characteristic of the addictive diseases7, 8, 10, 11.
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One of the receptors which has a big role in developing addiction is mu opiod receptor12. 
MOR is included in the G-protein-coupled receptor (GPCR) superfamily. When agonist 
binds to the receptor, it induces the dissociation of alpha subunit and β/γ subunits. The α 
subunit inhibits the enzyme adenylyl cyclase leading to a decrease in intracellular cyclic AMP 
concentrations13. The β/γ subunits activate G protein–activated inwardly rectifying potas-
sium (GIRK) channels, and inhibit voltage-sensitive calcium channels8, 14, 15. The reduction 
in cAMP levels seems to be involved neither in the opening and closing of ion channels nor 
in the inhibition of transmitter release by opioids and to reduce transcription of several genes 
with cAMP-responsive promoter elements16.
The phosphorylation of receptors by GPCR kinases (GRKs) leads to the recruitment of 
arrestins. Interaction of arrestins with GPCRs results in an uncoupling of G-protein 
signaling from receptors (receptor desensitization) and a recruitment of the endocytic 
machinery leads to receptor internalization17. However, morphine induces only weak or 
partial desensitization and little to no endocytosis. This will lead to tolerance and 
dependence that occur with chronic morphine treatment18. 
In central nerve system, MOR has a widespread distribution with particularly high levels 
in the striatal patches (striatum), thalamus, nucleus tractus solitarius, and spinal cord19, 20. 
The ability of MOR ligands to modulate presynaptic norepinephrine and dopamine release 
and may be critical in behavioral arousal and reward systems20. The change in reward system 
function is regarded as the final common pathway to addiction. The change in the function 
of the frontal cortex makes a decrease of response inhibition and an increase in the salience 
of psychoactive substances. As a consequence, the imbalance between an impulsive part of 
the brain and the more reflective part is created which is mirrored in a behavioral imbalance 
between approach and avoidance of psychoactive substances. Before this imbalance results 
in inappropriate decision-making followed by the approach of a drug, the addicted patient 
is overwhelmed by ‘craving’, a strong longing for the drug. Although craving is regarded 
also as a central concept in addiction, it is hard to define because the gap between subjective 
experience and objective measurement of the phenomenon. Finally, the psychopathology of 
addiction is under influence of underlying vulnerability of the stress system in the hypothala-
mic pituitary adrenal axis21.
According to DSM-IV, the most widely used manual for the classification of psychiatric dis-
orders22, a diagnosis of substance dependence is met if three or more of the following occur 
in a 12-month period: 1) tolerance, defined by the need for increased amount of substance 
to achieve the desired effect or diminished effect with continued use of the same amount of 
the substance; 2) development of a characteristic withdrawal syndrome when the substance 
is stopped or the use of the substance to prevent the onset of withdrawal; 3) increased or 
prolonged use; 4) a desire or unsuccessful attempts to cut down or control use; 5) significant 
time spent in activities related to drug procurement, use, and recovery; 6) important social, 
occupational, or recreational activities are sacrificed because of substance use; and 7) ongoing 
use despite knowledge of ongoing physical or psychological harm related to substance use22. 
However, most research on which the DSM-IV criteria are based is from the late 80’s and 
early 90’s of the last century. New insights are missing in the DSM-IV or are not linked to 
the criteria yet. 
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Genetic factors
It has been estimated that genetic contribution to addiction is 30-60%8, 11, 23 and opioid 
system has the biggest role in it. One of the genes in opioid system that has received a lot 
of attention in addiction studies is OPRM1 gene encoding MOR12. MOR mediates 
positive reinforcement following direct (morphine) or indirect (alcohol, cannabinoids, 
nicotine) activation.  
Figure 2.1. Relationship between Mu opioid Receptor and Addiction
Mu opioid receptors12 are largely distributed along reward circuits where they mediate the reinforcing activities 
of morphine and several non-opioid drugs. The non-opioid drugs act at their own receptors (GABAA and 
NMDA receptors for alcohol, CB1 receptor for THC and nicotinic acetylcholine receptor for nicotine) and 
are likely to induce the release of endogenous opioid peptides that, in turn, activate mu receptors. Mu 
receptors, therefore, represent a convergent molecular gate in the initiation of addictive behaviors. Inadequate 
mu receptor activation might be one of the mechanisms underlying deregulation of reward pathways, which 
characterizes the addicted state63.
The most frequent Single Nucleotide Polymorphism in MOR was A118G24. The variant 
binds beta-endorphin with greater affinity, and activates K+ channels to a greater extent than 
the prototype receptor24. It has also been reported that the A118G allele expresses approxi-
mately one-half the OPRM1 mRNA and about one-tenth the mu-opioid receptor protein. 
Therefore, subjects with the A118G allele would probably have greater response of the vari-
ant receptor but also have reduced receptor expression25.
Another example of the genetic contribution is the inherited presence of an aldehyde 
dehydrogenase genotype (associated with alcohol metabolism) causes an involuntary skin 
“flushing” response to alcohol11. Those whose initial, involuntary physiologic responses to 
drug are extremely gratifying will be more likely to use the drug again than those whose 
initial reaction is neutral or negative. Individuals who are homozygous for the aldehyde de-
hydrogenase allele (approximately 35% of the Chinese population, and 20% of Jewish males 
in Israel) have an especially unpleasant initial reaction to alcohol, and virtually no alcoholics 
24
have this genotype26. 
Drug induced changes in brain function
Anatomically, the brain circuitry involved in most of the actions of addictive drugs is the 
ventral tegmental area connecting the limbic cortex through the midbrain to the nucleus 
accumbens27-29. Neurochemically, alcohol, opiates, cocaine, and nicotine have significant 
effects on the dopamine system, although through different mechanisms. Cocaine increases 
synaptic dopamine by blocking reuptake into presynaptic neurons; amphetamine produces 
increased presynaptic release of dopamine, whereas opiates and alcohol inhibit dopamine 
neurons producing increased firing rates. Opiates and alcohol also have direct effects on the 
endogenous opioid and possibly the g-aminobutyric acid systems5, 26. 
The ventral tegmental area and the dopamine system have been associated with feelings of 
euphoria. Animals that receive mild electrical stimulation of the dopamine system contingent 
on a lever press will rapidly start to press that lever again and again, ignoring normal needs 
for water, food, or rest. As such, cocaine, opiates, and several other addictive drugs produce 
supernormal stimulation of this reward circuitry26.
Social Context
External stressors are important environmental factors contributing to the development and 
relapse of addiction. Environmental factors include prenatal and perinatal events; events oc-
curring in early childhood; and later events, such as peer pressure, drug related cues, condi-
tioning, setting for drug self-exposure, and concomitant ongoing psychiatric disorders, such 
as depression or anxiety. For example, repeated pairing of a person (drug-using friend), place 
(bar, casino), thing (paycheck), or even an emotional state (anger, depression) with drug 
use can lead to rapid and entrenched learning or conditioning. Thus, in drug-dependent 
individuals who have been abstinent for long periods, an encounter with a person, place, or 
thing that previously was associated with their drug use, may produce a strong physiologic 
reaction, such as withdrawal-like symptoms, and a profound subjective desire or craving for 
the drug. These responses can fuel the “loss of control” that is considered a hallmark of drug 
dependence26. 
The etiological factors mentioned above influence both the initial and early perception of 
a self-administered drug and contribute to the progression from occasional to intermittent 
or regular use and addiction, or, alternatively, to early cessation of drug use8, 30, 31. A variety 
of personality factors and traits may also contribute to initiation of drug abuse, including im-
pulsivity and risk-taking, as well as intrinsic atypical stress responsiveness8.
Somatic Co-morbidity
It has been estimated that HIV-seroprevalence  is 52.4 % among Indonesian IDUs32.  
Because of addiction, drug users change their behavior, without regard to the potential or 
actual negative consequences8. Because of this, transmission of HIV remains a major public 
health challenge in persons who use illicit psychoactive drugs in many countries33. In Indo-
nesia, the recent Integrated Biological-Behavioral Surveillance conducted among most-at-risk 
groups in 2007 showed that many IDUs in six cities had shared needles in the week priori to 
the interview, ranging from 9% in Semarang to 63% in Jakarta34. 
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Transmission of HIV and other viruses through sexual behavior may be equally important. 
Pisani et al. (2003) reported that in three big cities in Indonesia, over two thirds of IDUs 
were sexually active, 48% reported multiple partners, and 40% had bought sex from a female 
sex worker in the preceding 12 months. Consistent condom use was reported by 10%35. 
The results from the Behavioral Surveillance Survey 2004-2005 showed that 96-99% of 
IDUs in several cities in Indonesia had multiple sex partners in the past year. Most of them 
knew that using condom can prevent HIV-transmission but only 25-38% used condoms in 
the last sexual contact with a sex worker, and only 10-29% of IDUs use condom consistently 
in the last year36, 37. This situation is not unique for Indonesia. In the Netherlands, this has a 
very effective harm reduction program, unprotected sex leads to continued HIV transmission 
among IDUs38. Finally, former IDUs, who compared with current IDUs, are more likely to 
have sexual contacts with people who do not use drugs39-42 may also bridge the HIV-epide-
mic among IDUs to the low prevalence non-drug-using general population39, 43.
Beside the risk behavior, direct effect of opioid on the immune system may increase both 
the risk of HIV infection and disease progression44, 45. Opioid administration affects both 
innate and adaptative immunity, such as antibodies production, natural killer activity, 
cytotoxicity, cytokine production, chimiotaxism, and phagocytosis44, 45. Morphine is also 
known to activate the hypothalamic–pituitary–adrenal axis and release glucocorticoid, which 
is immunosuppressive46. Besides, the ability of MOR activation to induce CCR5 expression 
suggests MOR agonists, such as morphine, may promote susceptibility to HIV-1 infection 
and disease progression associated with this infection47.
Other medical conditions which are common among IDUs are viral hepatitis, liver disease, 
and bacterial infections like endocarditis, pneumonia and tuberculosis. Four factors contri-
bute to drug users’ risk for medical conditions. First, illicit drugs may have direct toxicity. 
Second, certain risk behavior. Third, lower access to health service due to the stigmatization. 
Fourth, social-economic disadvantages lead to malnutrition. Another contributing factor is 
when drug users experience withdrawal symptom. IDUs in ARV treatment and experiencing 
withdrawal symptoms had a fivefold increased risk of death with respect to the others 48. 
Finally, disruption of daily routines by active drug use (impending self-care behavior such as 
medication adherence or appointment keeping), may adversely affect their health status.  
Psychiatric co-morbidity
Besides somatic problems, IDUs may also have more psychiatric disorders. A study among 
methadone patients in The Netherlands reported a concurrent prevalence of co-morbidity 
of psychiatric disorders of 59.3%49. Preliminary data in Bandung showed that more than 
one-third of methadone maintenance treatment (MMT) patients may have some kind of 
psychiatric problem (Hidayat, unpublished data). Some studies showed that drug use dis-
orders had strong associations with mood, anxiety, and personality disorders. Axis I and II 
comorbidity with drug use disorders has been associated with underachievement, decreased 
work productivity, poor health, neuropsychological impairment, human immunodeficiency 
virus infection, hepatitis, social dysfunction, violence, incarceration, poverty, homelessness, a 
lower probability of recovery, poor treatment outcome, and poor quality of life5, 8, 11, 26, 50-52. 
These social consequences are important in shaping the generally held view that drug 
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dependence is primarily a social problem that requires interdiction and law enforcement 
rather than a health problem that requires prevention and treatment26. The high drop-out, 
non-compliance, and relapse rates during and after treatment reaffirms the common view 
that drug dependence is not an acute medical illness. McLellan et al. (2000) have attributed 
the disappointing treatment results to the fact that current treatment strategies and outcome
expectations view drug dependence as a curable, acute condition and not like a chronic 
illness with other treatment and outcome expectations as a result26. 
Prevention and Treatment
For effective control of HIV in Indonesia, both prevention and treatment of addiction are 
important. Preventive programs to those with high susceptibility to addiction should be 
started at an early age by giving information, education, communication, and developing 
learned behavior techniques such as life skill training, cognitive behavioral therapy, etc. For 
those who have become addicted, optimal care should be delivered. Since each kind of drug 
has its own characteristics, prevention of spread of viral blood borne infections among IDUs 
could benefit from tailoring interventions according to the type of drug used53. 
 
Until recently, drug dependence treatment often dealt with acute problems only, and as a re-
sult many addicted patients only received detoxification. A review on drug dependence versus 
type 2 diabetes mellitus, hypertension, and asthma showed that medication adherence and 
relapse rates are similar across these illnesses. That is why, drug dependence has to be treated 
like the other chronic diseases. The type and the goal of the treatment should consider the 
complexity of IDU’s problem 26. There are 4 goals to be distinguished54-56:
Therefore, the approach should be started by screening. Screening is performed to evaluate 
the possible presence of a particular problem. Further assessment is continued for those 
who has problems. Assessment is used for defining the nature of that problem and develo-
ping specific treatment recommendations for addressing the problem 57. The assessment and 
diagnostic processes are important and should be as the basis for determining the treatment 
plan. The treatment plan should be made by integrating evidence, therapist knowledge and 
appraisal, and the patient preferences58-60 (table 2.1). 
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1      Palliation, palliation is aimed to reduce symptoms and to relieve suffering from chronic
        dependent patients of whom no care or cure is feasible.  
2      Care and stabilization, represented by maintenance treatment and based on 
        harm-reduction. It directed toward reducing illicit drug use, drug-related criminality 
        and health problems, ultimately resulting in improved health and social functioning.
 
3      Cure, represented by abstinence-oriented treatment aimed at stable abstinence and 
        ultimately resulting in recovery from addiction. This goal contains two treatment 
        phases, namely detoxification and relapse prevention.
4      Crisis intervention, crisis intervention is aimed at immediate survival and frequently 
        necessary after a high overdose rate.
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All of these steps have to consider the drug use, somatic and psychiatric comorbidity of the 
patients. Treatment for somatic comorbidity is described for the Indonesian setting in two 
publications 61, 62. 
Table 2.1. Diagnostic and Treatment Process
Adapted from SAMHSA, 200557
However, as in treatments for other chronic disorders, the major problems are medication 
adherence, early drop-out, and relapse among drug dependent patients. In fact, problems of 
poverty, lack of family support, and psychiatric co-morbidity were major and approximately 
equal predictors of noncompliance and relapse across all chronic illnesses. The best outcomes 
from treatments of drug dependence have been seen among patients in long-term methadone 
maintenance programs and among the many who have continued participating in support 
groups26.
Conclusion
The biopsychosocial approach does not consider one intervention superior above other ones. 
On the contrary, a combination of biological, psychological, socioculural interventions has 
to be implemented together according to the individual needs and problems of the patients. 
Failure in providing such a comprehensive treatment will worsen the overall condition of 
the patients. From a public health view, it will reduce the effectiveness of HIV/AIDS 
intervention programs. 
Screening
Assessment
Treatment
Planning
Integrated 
care
Determines the likelihood that a patient has other comorbidities besides 
the drug addiction problem. The purpose is not to establish the presence 
of specific type of disorders, but to establish the need for an in-depth 
assessment. Screening is a formal process that typically is brief and occurs 
soon after the patient presents for services.
Gathers information, conducts physical examination, laboratory test, 
X-ray or other required examination. Determines the patient’s readiness 
for change, identifies patient strengths or problem areas that may affect 
the process of treatment and recovery, and engages the patient in the 
development of an appropriate treatment relationship.
Develops a comprehensive set of staged, integrated program placements 
and treatment intervention for each disorder start with treating the acute 
problems. The plan is matched to the individual needs, readiness, 
preferences, and personal goals of the patient.
Performs integrated care and conducts routine meeting between experts to 
discuss the progression and problems during treatment.
Diagnostic and Treatment Process
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Abstract
Background : Injecting drug use is an increasingly important cause of HIV transmission 
in most countries worldwide, especially in eastern Europe, South America, and east and 
southeast Asia. Among people actively injecting drugs, provision of clean needles and opioid 
substitution reduce HIV-transmission. However, former injecting drug users (fIDUs) are 
often overlooked as a high risk group for HIV transmission. We compared HIV risk behavior 
among current and former injecting drug users (IDUs) in Indonesia, which has a rapidly 
growing HIV-epidemic largely driven by injecting drug use. 
Methods : Current and former IDUs were recruited by respondent driven sampling in an 
urban setting in Java, and interviewed regarding drug use and HIV risk behavior using the 
European Addiction Severity Index and the Blood Borne Virus Transmission Questionnaire. 
Drug use and HIV transmission risk behavior were compared between current IDUs and 
former IDUs, using the Mann-Whitney and Pearson Chi-square test. 
Results : Ninety-two out of 210 participants (44%) were self reported former IDUs. Risk 
behavior related to sex, tattooing or piercing was common among current as well as former 
IDUs, 13% of former IDUs were still exposed to contaminated injecting equipment. HIV-
infection was high among former (66%) and current (60%) IDUs.
Conclusion : Former IDUs may contribute significantly to the HIV-epidemic in Indonesia, 
and HIV-prevention should therefore also target this group, addressing sexual and other risk 
behavior.
Background
Worldwide, injecting drug use is estimated to account for just less than one-third of new  
infections outside sub-Saharan Africa1. HIV-prevention programs for injecting drug users 
(IDUs) therefore put emphasis on people actively injecting drugs, especially through needle 
exchange or opioid replacement. Besides active IDUs, people who have a previous history of 
injecting drug use (former IDUs) are probably also an important risk group for HIV trans-
mission. However, relatively little is known about this group. Sporadic studies from western 
countries have shown that former IDUs (fIDUs) may have a high risk of becoming HIV-
infected or spreading HIV to others2, 3.  To our knowledge, no studies on fIDUs have been 
reported from low- or middle-income countries.
Injecting drug use increased dramatically in the late ‘90s in Indonesia, acting as the main 
force driving the HIV-epidemic. Among the general population, the prevalence of HIV-in-
fection is still low (0.3%), but up to 50% or more of IDUs are already HIV-infected4. Drug 
use is illegal in Indonesia, and harm reduction programs, although officially supported by the 
Indonesian government, only reach a minority of IDUs. Apart from sharing needles, sexual 
risk behavior is also common among drug users5. In three large cities in Indonesia, over two 
thirds of IDUs were sexually active, of whom many reported having multiple partners (48%) 
and sex with female sex workers (40%) in the preceding year. Consistent condom use was 
only reported by 10% of sexually active IDUs5. 
We know of no reported data concerning HIV risk behavior among fIDUs in Indonesia, 
and fIDUs receive very little attention in current prevention programs in general. 
This may seriously limit the success of HIV-prevention focusing on drug injection, as a 
considerable number of IDUs change from injection to non-injection drug administration 
or completely abstain from illicit drug use6. The prevalence of HIV may be high in fIDUs. 
Transmission of blood borne viruses may continue to occur through sexual behavior and/or 
by contaminating equipment that is subsequently used by others for drug use, tattooing and/
or piercing2, 7, 8. 
Furthermore, fIDUs may also play an important role in transmitting HIV infections to the 
general population because, compared with current IDUs (cIDUs), fIDUs have more sexual 
contact with people who do not use drugs9, 10. Hopefully, a better characterization of former 
IDUs may contribute to improve HIV-prevention. Therefore, the aim of the present study 
was to explore the characteristics and the risk behavior of former IDUs in Indonesia in com-
parison with current IDUs. 
Methods
Setting and patients
From June to September 2008, 210 IDUs were recruited in Bandung, the capital of 
West-Java and epicenter of the epidemic of injecting drug use in Indonesia. Respondent 
driven sampling, a form of peer recruitment, was used for recruitment of IDUs from 
the community11. With help from local non-governmental organizations involved in outre-
ach to IDUs, three cIDUs and three fIDUs from different parts of Bandung were selected 
to act as ‘seeds’ for RDS and invited to a community clinic which has a specific program 
for IDUs. Following their inclusion in the study, these six seeds were asked to recruit two 
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other persons injecting drugs, either in the last six months (cIDUs) or longer ago (fIDU), by 
giving individually numbered coupons. IDUs presenting at the community clinic with the 
coupons, were asked themselves to recruit two other (current or former) IDUs. This process 
of recruitment continued until the desired sample size was achieved. Numerical simulations 
have shown that respondent driven sampling estimates converge to the true values even if the 
seeds are not drawn as desired12.
As a part of the RDS process, an incentive was offered for participating in the interview ($3) 
and for recruiting two injecting drug using peers ($2 per eligible peer recruited). After the 
initial seeds were recruited, only those people who presented coupons were permitted to 
participate in the study. The study was completely anonymous, but to prevent the same par-
ticipant from entering the study twice, physical marks such as tattoos, scars, or birth marks 
were recorded.
Only those candidates who were or had previously been IDUs were eligible to be included 
in the study. Two outreach workers from non-governmental harm reduction organizations, 
both with a previous history of drug use, confirmed that the respondents were indeed IDUs. 
To this purpose they looked for possible needle tracks, asked each respondent to demonstrate 
how he/she injected drugs, and to clarify specific ‘slang’ used by IDUs. All IDUs who pas-
sed this screening then provided informed consent. The study was approved by the regional 
medical-ethical committee (The Health Research Ethics Committee, Faculty of Medicine, 
Padjadjaran University / Dr. Hasan Sadikin General Hospital Bandung) and conducted wit-
hin the context of program on prevention and treatment of HIV in the context of injecting 
drug use in Indonesia13. 
Assessment
The interview was done at the community health center by trained interviewers who assured 
all participants that their anonymity would be strictly maintained. All participants who com-
pleted the interview session received a coupon for free HIV, HBV, HCV and syphilis testing 
at Hasan Sadikin hospital, Bandung. If found positive for HIV, participants were offered 
CD4–cell counts, chest X-ray and if needed, antiretroviral and/or syphilis treatment, all free 
of charge.
The interviewers used two validated questionnaires: the European Addiction Severity Index 
(EuropASI) and the Blood Borne Virus Transmission Questionnaires (BBV-TRAQ). 
The EuropASI is an adaptation of the Addiction Severity Index (fifth version). 
It is a semi-structured interview which takes about one hour, covering issues that may con-
tribute to patients’ substance-abuse problems, such as medical status, employment/ support 
status, drug/ alcohol use, legal status, family social relationship, and psychiatric problems14. 
Participants are asked if they ever used a number of listed drugs regularly (more than 3 times 
or 2 consecutive days a week). 
For regularly used drugs, further information is recorded including the first time the particu-
lar drug was used, the duration of use in a life time, the frequency of drug use in the previous 
30 days, and drug route of administration14. 
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ASI has shown excellent reliability and validity across a range of types of patients and treat-
ment settings in many countries15. For the translation into Bahasa Indonesia, WHO transla-
tion procedures were used16. 
The BBV-TRAQ questionnaire assesses how often injecting drug users participate in specific 
injecting, sexual and other risk-practices that may expose them to blood-borne viruses. The 
instrument consists of 34 questions divided in three sub-scales which measure frequency of 
current risk behavior related to blood to blood transfer (20 questions); sexual practices (8 
questions); and other skin penetration activities (6 questions) in the previous month. With 
respect to possible blood to blood transfer, information is collected about contact with conta-
minated needles and syringes, other drug injecting equipment sharing and involvement of 
other people in the drug preparation and injecting process. Questions related to sexual risk 
behavior address unprotected vaginal, anal, oral, and manual sex with other people, with or 
without lubricant, and during menstruation or not. Other questions address skin penetration 
risk behavior (tattooing and piercing), and shared use of toothbrush, razor, and personal hy-
giene equipment. The administration time for the instrument is short (around 15 minutes), 
and it has been shown good reliability and validity17, 18. 
Data analysis and statistics
A former IDU (fIDU) was defined as a person who reported to have injected an illicit drug 
at some point in his/ her life, but not to have injected any drugs in the six months prior to 
the interview17, 18. A current IDU (cIDU) was defined as a person who reported that he/ 
she had injected any type of illicit drug in the six months prior to the interview6, 10. Data 
were analyzed both descriptively and inferentially. Descriptive data are presented in terms 
of percentage, mean, and standard deviation. Subjects engaging in at least one risk taking 
behavior in a subscale of the BBV-TRAQ were regarded as taking risks in that domain. Data 
were analyzed inferentially for differences between fIDUs and cIDUs. Pearson Chi–Square 
was used for dichotomous data and the Mann-Whitney test for non-parametric continuous 
data. All tests were two-sided, with a P-value of 0.05 or less considered to indicate statistical 
significance. Analyses were performed with the use of SPSS, version 11.5. 
Results
Characteristics of IDUs in Bandung 
A total of 210 IDUs were recruited, of whom 194 were men (92%), 92 were fIDUs (44%), 
and 118 were cIDUs (56%). Thirty-three out of 92 fIDUs (35.9%) were invited by cIDUs, 
while 34 of 118 cIDUs (30.3%) were invited by fIDUs, showing extensive social linking 
between the two groups. Most of the demographic characteristics of fIDUs and cIDUs did 
not differ, except for the length of injecting drug and percentage of those who developed 
AIDS (table 3.1). The mean age was 28 (±4) years and most participants had graduated from 
senior high school and had been employed at some point in the last 3 years. They had 
started using drugs at a young age (14 (± 3) years). Injection of drugs had typically started 4 
years after non-injecting drug administration, and the period of injecting drugs averaged 7 
(± 4) years. 
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Table 3.1. Sociodemographic characteristics of former and current injecting drug users
All data are presented in percentage unless stated otherwise
* n=145; no data available for 12 subjects; 
** n=83; no data for 8 HIV-positive subjects
Three quarters of the participants had been tested for HIV and among those tested 63% 
reported to be HIV-infected. There was no significant association between the cumulative 
years of drug injecting and HIV-status (P = 0.47). One third of those who were HIV-infec-
ted reported to have developed AIDS. Although cIDUs had injected for a longer period than 
fIDUs, HIV-infected individuals in the latter group more commonly reported having AIDS 
(44% vs 18%; P=0,01).
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fIDUs
(N=92)
cIDUs
(N=118)
P
27,8 (3,8)
92%
14.0 (2.8)
18.0 (3.1)
7.1 (3.8)
30%
2%
11%
57%
41%
37%
5%
17%
6%
87%
7%
75%
63%
30%
total group
(N=210)
Age
Male gender 
Drug use
   Age of first drug use 
   Age of first drug injection 
   Years of injecting in life time 
Marital Status
   Married / remarried
   Widowed
   Separated / divorced
   Never married 
Employment in the past 3 years
   Full time
   Part-time
   Student
   Unemployed or housewife 
Education
   Junior high school or less 
   Senior high school
   Undergraduate or higher
HIV-AIDS
   Ever HIV-tested 
   HIV-infected*
   Have developed AIDS** 
28.1 (4.0)
89%
14.2 (3.3)
18.4 (3.1)
5.5 (3.6)
36%
3%
6%
55%
48%
36%
5%
11%
4%
88%
8%
71%
66%
44%
27.5 (3.8)
95%
13.8 (2.2)
17.8 (3.1)
8.4 (2.4)
25%
2%
14%
59%
36%
39%
4%
21%
7%
87%
6%
78%
60%
18%
0.64
0.12
0.35
0.31
0.17
<0.01
0.35
0.13
0.48
0.23
0.47
0.01
The most used substance by all participants was heroin. Ninety four percent of the total 
participants had at some point used heroin regularly (at least three times a week or for two 
consecutive days in a week for more than 6 months). The other most used substances were 
cannabis, benzodiazepines, and alcohol. More than three quarters of participants had ever 
used or still used different drugs at the same time (poly drug use) and 70% of the total IDUs 
had ever used or still used amphetamine or methamphetamine regularly (median 2 years 
(range less than 1 year until 15 years).
In the last 30 days, cIDUs had typically used more drugs than fIDUs but neither cIDUs nor 
fIDUs reported total abstinence in the last 30 days. The most used substances by fIDUs in 
the last 30 days were alcohol, licit or illicit methadone/buprenorphine while cIDUs mostly 
used licit or illicit methadone/buprenorphine, heroin, benzodiazepines, and cannabis (table 
3.2). Licit or illicit use of methadone or buprenorphin cannot be differentiated with the ASI.
Table 3.2. Drug use among former and current injecting drug users
* regular use (more than 3 times or 2 consecutive days a week). 
** > 3 drinks in 1-2 hours, > 3 times or 2 consecutive days a week. 
Note : Less than three participants used inhalant, hallucinogens or cocaine in the last 30 days. 
Risk behavior related to transmission of blood-borne viruses
Blood to blood transfer risk behavior was reported by 76% of cIDUs and 13% of fIDUs 
(X2 = 82,73; p<0,01) (table 3.3). Risk behavior of ninety cIDUs (76%) was related to sha-
ring of contaminated drug injecting equipment. Current IDUs often reported behavior as-
sociated with a very high risk of transmission of blood-borne pathogens, including injecting 
with another person’s used needle or syringe (reported by 15% of cIDUs), re-use of a needle 
or syringe taken out of a shared disposal/sharps container without using bleaching (9%), and 
sharp injuries from another person’s used needle/syringe (15%). 
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Kind of drug *
Any use of alcohol 
Alcohol, over treshold **
Heroin
Methadone or buprenorphine
Other opiates
Benzodiazepines
Amphetamine
Cannabis
Ecstasy (MDMA)
More than one substance
91%
66%
99%
33%
22%
66%
52%
84%
44%
78%
0.14
0.66
0.44
<0.01
0.87
0.06
0.89
0.55
0.40
0.38
59%
42%
79%
53%
5%
52%
9%
47%
14%
55%
97%
70%
100%
65%
23%
79%
53%
87%
37%
83%
42%
26%
0%
12%
1%
12%
1%
13%
9%
12%
0.03
0.02
<0.01
<0.01
0.14
<0.01
0.03
<0.01
0.28
<0.01
fIDU’s
(N=92)
PcIDU’s
(N=118)
life time drug use drug use in last 30 days
cIDU’s
(N=118)
fIDU’s
(N=92)
P
Table 3.3. Risk behavior among former (fIDUs) and current injecting drug users (cIDUs) in the last 30 days.
cIDUs also reported behavior associated with a somewhat lower risk of transmission. For 
example, they had exposure to contaminated drug injecting equipment included shared use 
of a tourniquet (43%); injecting a drug prepared with water previously used by another 
person (41%); handling another person’s used needle or syringe when wounded at his or her 
hand (34%); wiping his/her own injection site with an object that had been used by another 
person (27%); touching his/her own injection site soon after ‘assisting’ another person with 
their injection (26%); and injecting a drug that was prepared immediately after ‘assisting’ 
another person with their injection but without washing hands between activities (26%).  
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Blood-blood transfer
   Suck or lick a filter which had been  
     used by another person
   Inject a drug prepared with water which
     had been used by another person 
   Been injected by another person who  
     had already injected or assisted in  
     someone else’s injection 
   Receive an accidental needle-stick/prick 
     from another person’s used needle/ 
     syringe
   Re-use a needle/syringe taken out of 
     a shared disposal/sharps container
Sexual risk behavior
   Engaged in unprotected vaginal sex  
     with another person   
   Engaged in unprotected vaginal sex with 
     another person during menstruation 
   Engaged in unprotected anal sex with 
   another person
Tattoo or piercing
   Tattooed by someone who was not  
     a professional tattooist
   Been pierced by someone who was not 
     a professional piercer   
   Use another person’s tootbrush   
Risk Behavior
76%
14%
41%
20%
15%
9%
56%
47%
20%
8%
53%
15%
14%
14%
cIDUs
(N=118)
82.73
5.81
45.30
21.13
7.56
8.26
3.57
2.98
2.90
0.10
0.02
6.56
0.96
7.45
X2
<0.01
0.02
<0.01
<0.01
<0.01
<0.01
0.06
0.08
0.09
0.76
0.90
<0.01
0.327
<0.01
P
13%
4%
0%
0%
3%
0%
42%
35%
11%
7%
52%
4%
10%
3%
fIDU’s
(N=92)
While fIDUs did not inject anymore, 13% still had some risk of blood borne pathogens 
transmission, especially through accidental needle stick injuries and sucking or licking and 
other handling of another person’s used needle/syringe. 
Interestingly, benzodiazepine use was more common among IDUs engaging in risky injecting 
behavior, 56% vs. 39% among cIDUs (X2 = 2,26; P = 0,19) and fIDUs (33% vs 9%; X2 = 
5,99; P = 0,03). Injecting risk behavior was not associated with use of alcohol, cannabis or 
methadone/ buprenorphin (data not shown). Sexual risk behavior of some form was reported 
by 56% of cIDUs and 42% of fIDUs (X2 = 3,57; P = 0,06). 
The most common sexual risk behavior for cIDUs and fIDUs was unprotected vaginal sex 
(47% respectively 35%, NS); reported unprotected anal sex was much lower (8% respectively 
7%, NS). No statistical significant differences were found between former and current IDUs 
regarding oral and manual sex (data not shown). Excessive alcohol use was more common in 
IDUs engaging in risky sexual behavior, both among cIDUs (51% vs 33%; X2 = 3,86; P = 
0,06) and fIDUs (46% vs 11%; X2 = 14,14; P < 0.01). Other risk behavior such as tattooing 
and piercing, which confer a much lower risk of HIV transmission compared to needle-sha-
ring, was reported by half of all respondents (52% of fIDUs and 53% of cIDUs). 
Discussion
This cross-sectional study from Indonesia shows a high prevalence of HIV-infection among 
relatively young and well-educated former and current IDUs. Current IDUs obviously had 
much higher risks of viral transmission related to injecting drugs, but also former IDUs had 
risks related to blood to blood transmission. Importantly, both groups engaged in substantial 
risks related to sexual transmission of HIV. Almost half of respondents in our study were 
former IDUs, showing that this group may contribute significantly to HIV transmission.
Injecting drug use is the main factor driving the HIV-epidemic in Indonesia. In a large co-
hort of HIV patients in our setting, two thirds had a history of IDU19. In line with this fin-
ding, the prevalence of HIV-infection among fIDUs and cIDUs in this study was high (66% 
respectively 60%), similar or slightly higher compared with previous local and national data 
[4]. The prevalence of AIDS was higher among fIDUs; concern about their general health or 
the development of AIDS may cause them to move from injecting drugs6. 
Injecting with needles or syringe from other people (15%) or from shared disposal/sharps 
containers without bleaching (9%) was reported by a substantial proportion of IDUs, alt-
hough lower compared to previous research in Indonesia (24% - 80%)5, 20. 
The high rate of needle stick injuries is no surprise given the fact 40% of IDUs fail to discard 
used needles safely21. Risk related to injecting drugs was especially high in cIDUs, but fIDUs 
are experience certain things (e.g. needle sticks or sharing of injecting equipment) which may 
have a low risk of HIV-transmission, but which may pose a significiant risk of transmitting 
HCV. This is important, as the prevalence of HCV is very high among IDUs in this setting; 
among 633 HIV patients with a history of IDU 87.7% were HCV-infected19.
Both among current and former IDUs, sexual risk behavior may contribute significantly to 
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HIV transmission. Sexual risk behavior was equally high in both groups, which is in contrast 
with previous studies reporting associations between injecting drug use and unsafe sex22, 23. 
Condom use among IDUs has found to be inconsistent and especially low with sex workers 
and other risk groups for HIV transmission20. As IDUs often have multiple sex partners, 
including sex workers, HIV transmission may easily spread to people outside the IDU 
community. 
Heroin was the most frequently used drug among IDUs in this sample but many reported 
use of cannabis, benzodiazepines and alcohol as well, in line with reports from China, Thai-
land, Ukraine, Lithuania, and Poland24. The use of methadone or buprenorphine among cI-
DUs was higher compared to fIDUs. The EuropASI questionnaire does not allow us to verify 
whether this was as part of substitution treatment or not. Both drugs are officially registered 
in Indonesia for substitution treatment but illegal use is quite common. Buprenorphine 
injection has been reported in many countries including Indonesia, and can be regarded as a 
response to inadequate care, rather than simply as misuse25.
Alcohol abuse was common, and was associated with risky sexual behavior, as has been repor-
ted previously26. The same has been reported for methamphetamine and amphetamine use27, 
but this seems still relatively rare in this setting. Our study also showed a high prevalence of 
tattooing and piercing in former and current IDUs, both of which have may lead to trans-
mission of HIV and viral hepatitis8, 9, 28. 
This study suffers form the limitations of a cross-sectional study in a population which is 
difficult to reach, and the question is therefore how representative the samples are. By using 
RDS, we tried to minimize this risk12, 29. Numerical simulations have shown that the possible 
bias, even if the seeds are not drawn randomly, is extremely small (0.3%) for all sample sizes 
greater than 20012. Still, some IDUs who are not in the social networks with these partici-
pants can not be recruited through respondent driven sampling30. 
Conclusions
In conclusion, this study from Indonesia shows that former IDUs, when compared to current 
IDUs, may have similar high HIV prevalence rates and high sexual risk behavior. Specific 
programs focusing on the reduction of sexual risk behavior are needed among former and 
current IDUs, in order to prevent further transmission to the general community. Drug-use 
treatment and interventions that examine the relationship between drug use and sexuality 
should be conducted. In addition, earlier HIV treatment may lower transmission among 
IDUs by reducing the ‘community viral load31. We have recently shown that patients with a 
history of injecting drug use in our setting have a similar clinical and virological response to 
anti-retroviral treatment compared to non-IDUs19. Finally, evidence-based prevention should 
also be targeted at schoolchildren and young adolescents as injecting drug use starts at an 
early age in this setting.
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chapter 4
Successful testing and treating HIV/AIDS in Indone-
sia depends on the addiction treatment modality 
In review
Abstract
Background : In many settings, people who inject drugs (PWID) have limited access to HIV 
care. Substance abuse treatment (SAT) can be used as the entry-point to HIV programs. The 
aim of this study is to describe the characteristics of the PWID who had accessed SAT and 
determine which SAT modality associates significantly with HIV programs. 
Methods : PWID were recruited by respondent-driven sampling in urban setting in Java, 
Indonesia and interviewed with the Addiction Severity Index, Blood Borne Virus Transmis-
sion Questionnaires, and Knowledge on HIV/AIDS. 
Results : Seventy-seven percent of 210 PWID had accessed SAT at least once. PWID who 
had accessed a SAT modality reported more severe drug problems. The most widely used 
SAT were opioid substitution (57%) and traditional/faith-based treatment (56%). 
Accessing substitution treatment  (adjusted OR=5.8; 95%CI:2.5,13.9) or residential 
drug-free treatment (adjusted OR=3.7;95%CI: 1.4, 9.7) was significantly associated with 
HIV testing, whereas accessing substitution treatment (adjusted OR 3.8 (1.9 – 7.5)) or 
other medical services (adjusted OR 3.1 (1.1 – 8.7)) was significantly associated with HIV 
treatment. There was no significant association between accessing traditional/ faith based 
treatment and HIV testing and treatment.
Conclusion : Efforts should be made to link HIV services with traditional/faith-based 
treatment to increase the coverage of HIV program.
Keywords : HIV, addiction treatment, access to care, people who inject drugs
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Introduction
The worldwide number of people who inject drugs (PWID) in 2007 was estimated 15.9 
million while probably 3 million of them were infected with HIV1. Injecting drug use is 
also estimated to account for 30% of all new HIV infections outside sub-Saharan Africa2. 
Apart from HIV, PWID are often affected by co-occurring problems such as other infectious 
diseases including hepatitis and tuberculosis, psychiatric problems, and other substance use 
disorders. PWID with these co-morbidities are likely to engage in high-risk behaviors, and 
when untreated, continue to fuel the HIV epidemic3. In addition, engagement in high-risk 
sexual behavior may lead to further spreading of HIV into the general community4. Antire-
troviral treatment significantly reduces HIV transmission5, however different studies showed 
that PWID still had very limited access to HIV care6, 7. 
Clinicians and policymakers have underlined the crucial role of evidence-based substance 
abuse treatment (SAT) in HIV prevention and care programs8, 9. Many SAT modalities 
do   have the capacity of offering counseling and testing for HIV, providing interventions to 
reduce risk behavior, referring patients for HIV treatment, or prescribing and monitoring 
HIV treatment8, 9. However, PWID often have poor access to the regular SAT since drug 
use is illegal and highly stigmatized10. PWID and their families often hide the drug-related 
problems and avoid the regular SAT, as this may further increase the social ostracism faced 
by the families. Because of unawareness or absence of easily accessible treatment, particularly 
in resource-limited countries, PWID and family members may prefer to approach alternative 
service providers such as faith based treatment11. 
In traditional or faith based treatment it is believed that drug addiction is mostly due to a 
lack of religiosity. The therapy emphasizes for instance the important role of remembrance 
of Allah because only through remembrance of Allah, the self will always be aware and 
alert about the real purpose of this life. Only 30% of all Indonesian addiction professionals 
consider addiction as a brain disease, whereas about 70% consider faith-based and long-term 
residential treatments to be the most appropriate treatment modalities12. Spiritual leaders 
or people providing spiritual/ faith based treatment may however be insufficiently informed 
about medical problems such as blood borne infections like HIV and hepatitis B/C. Com-
munication and training of providers of spiritual/ traditional faith based treatment services 
may increase access to HIV care. In addition, faith based organizations might contribute to 
daily care for HIV-infected patients. Faith based organizations basically operate on the basis 
of religious missions. In Indonesia, faith based organizations usually have a large number of 
followers and/or members capable of  dissemination of knowledge throughout the country13, 
so influencing them to promote HIV testing and treatment could have a large effect.
In Indonesia, injecting drug use increased dramatically in the late `90s, acting as the main 
force driving the HIV-epidemic. Among the general population, the prevalence of HIV-
infection is still low (0.3%) but it is 50% or higher among PWID14. PWID in Indonesia en-
gage in high-risk behavior, both through needle sharing and unprotected sex15, 16. In response 
to the problems of drug use and HIV, specific intervention programs have been developed 
in Indonesia. The coverage of these programs remains very low: only 1% of the PWID are 
currently enrolled in Methadone Maintenance Treatment (MMT) programs; and only 6% of 
the HIV-infected PWID have been treated with antiretroviral (ARV) drugs7. The start of the 
services was funded by government and donor organizations, some services are still subsidi-
zed by the government. In Bandung (Hasan Sadikin Hospital), opioid substitution treatment 
and HIV services can be provided at the methadone clinic since 200917. Integration of opioid 
substitution treatment and ARV in other settings have not been fully established although at 
some places, both services are provided in the same building/hospital18.
The aim of the present study was therefore to investigate possible explanations of the low 
coverage of HIV testing in PIWD by comparing PWID who had accessed SAT and those 
who had not in terms of socio-demographic characteristics, health problems and treatments, 
and risk behavior for HIV transmission. Furthermore, the types of SAT accessed by PWID 
was explored and determined to reveal which SAT was associated with uptake of HIV testing 
and HIV treatment.
Methods
Participants
From June to September 2008, 210 PWID were recruited from all sub-districts in Bandung, 
the capital of West-Java and epicenter of the epidemic of injecting drug use in Indonesia. 
Respondent-driven sampling, a form of peer recruitment, was used for recruitment of PWID 
from the community19. All PWID who passed this screening then provided informed con-
sent. The study was approved by the regional medical-ethical committee (87/FKUP-RSHS/
KEPK/Kep./EC/2008).
Assessment
The interview was conducted at the community health center by trained interviewers who 
assured all participants that their anonymity would be strictly maintained. The interviewers 
used three validated questionnaires: the European Addiction Severity Index (EuropASI), 
Blood Borne Virus Transmission Questionnaires (BBV-TRAQ), and Knowledge Question-
naire on HIV/AIDS. 
The EuropASI is an adaptation of the Addiction Severity Index (ASI) 5th version. ASI has 
shown excellent reliability and validity across a range of types of patients and treatment 
settings in many countries20. For the translation into Bahasa Indonesia, WHO translation 
procedures were used21. ASI is a semi-structured interview which takes about one hour, and 
covers medical status, including questions about HIV testing and treatment, employment/ 
support status, drug/alcohol use, legal status, family/social relationships, and psychiatric pro-
blems. Each of these areas is examined individually by collecting information regarding the 
frequency, duration, and severity of symptoms of problems both historically over the course 
of the patient’s lifetime, and during the 30 days prior to the interview22, 23.  
In order to measure addiction severity in a more objective way, the selective combination of 
items from each of the ASI problem areas were used to calculate the composite score, which 
can be used as a general measure of patient status in each area. These measures have shown 
reliability and validity in several settings24. The information regarding the use of substance 
abuse treatment and HIV program were based on questions in EuropASI. They were asked 
whether in their life time they had ever accessed the type of substance abuse treatment or not 
and ever had HIV testing and treatment or not.
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The BBV-TRAQ questionnaire assesses how often injecting drug users participate in specific 
injecting, sexual, and other risk-practices that may expose them to blood-borne viruses. The 
instrument consists of 34 questions divided into three sub-scales which measure frequency 
of current risk behavior related to blood-to-blood transfer (20 questions); sexual practices 
(8 questions); and other skin penetration activities (6 questions) in the previous month. The 
administration time for the instrument is short (around 15 minutes), and it has shown good 
reliability and validity25. 
Knowledge on HIV/AIDS was evaluated using a questionnaire which included 10 questions 
that address three areas of HIV/AIDS knowledge: (a) general knowledge concerning HIV/
AIDS; (b) knowledge concerning HIV transmission; and (c) knowledge of prevention. The 
number of correct responses for the total scale and for each subscale was computed and 
higher scores indicate more knowledge. The reliability was high (Cronbach’s α = .97)26. 
Data analysis and statistics
Descriptive data were presented in terms of percentage, mean, and standard deviation. Data 
were analyzed inferentially for differences between those who had not accessed, and those 
who had accessed SAT in his/her life time. Pearson Chi–Square was used for dichotomous 
data and the Mann-Whitney test for non-parametric continuous data.  All tests were two-
sided, with a P-value of 0.05 or less considered to indicate statistical significance. All subjects 
that have accessed SAT were included in a multivariate logistic regression analysis to identify 
which type of SAT was associated with HIV testing and HIV treatment. In the adjusted mo-
del, all types of substance abuse treatments were included as variables. Analyses were perfor-
med with the use of SPSS, version 15.
Results
A total of 210 PWID came from all sub-districts area in Bandung indicating the represen-
tativeness of the sample. Seventy seven percent of them (161) had visited any type of SAT. 
Socio-demographic data did not differ between those who had not accessed SAT and those 
who had accessed SAT (Table 4.1). The mean age was 28 (SD 4) years and most participants 
had graduated from senior high school or higher education. 
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treatment :
Male gender, N (%)
Age, mean (SD)
Education, N (%) 
   Junior high school or lower 
   Senior high school
   Diploma or higher
Characteristics
Yes
(N=162)
X2/U PNo
(N=48)
148 (91)
28 (3)
7 (4)
124 (77)
31 (19)
1.05
1.037
8.93
0.54
0.32
0.6
46 (96)
27 (5)
5 (10)
40 (84)
3 (6)
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Marital status, N (%)
   Married
   Widowed, separated or divorced
   Never married
Income from employement in the last 
30 days (1000 rupiah), mean (SD)
Drug use
   Age first inject, mean (SD)
   Inject in life time, mean (SD)
   Inject in the last 30 days, N (%)
   Overdose, N (%)
   Cigarettes smoked in the last 30 days, 
     mean (SD)
   Drug composite score (0-1), mean (SD)
   Alcohol composite score (0-1), mean (SD)
Risk behavior, N (%) 
   Injecting risk behavior, mean (SD) 
   Sexual risk behavior, mean (SD)
   Other risk behavior, mean (SD)
Knowledge on HIV (0-10), mean (SD)
Medical condition
   Have chronic problem, N (%)
   Tested HIV, N (%)
   HIV+, N (%), (N total = 157)
   AIDS+, N (%), (N total = 91)
   HIV treatment, N (%), (N total = 91)
   Tested Hepatitis C, N (%)
   Hepititis C+, N (%), (N total = 125)
   Medical composite score (0-1), 
     mean (SD)
Body Mass Index (BMI) (kg/m2)
Psychiatric condition in life time
   Depression, N (%)
   Anxiety, N (%)   
   Memory problems, N (%)   
   Hallucination, N (%)
  
47 (29)
24 (15)
91 (56)
1,191 
(2,639)
18 (3) 
8 (4)
89 (55)
88 (54)
459 (252)
0.18 (0.13)
0.16 (0.20)
124 (77)
5 (8)
3 (5)
2 (3)
9 (2)
64 (40)
134 (83)
82 (66)
24 (29)
51 (62)
104 (64)
71 (68)
0.43 (0.22)
21 (3)
96 (59)
129 (80)
119 (74)
63 (39)
3.63
 
0.87
6.07
0.27
5.65
1.466
2.05
3.12
2.70
2.68
0.27
6.30
0.06
1.57
1.68
2.377
4.44
3.04
0.28
6.43
4.90
3.40
4.72
0.01
0.41
0.01
0.93
0.60
 
0.59
0.34
<0.01
0.02
<0.01
0.03
0.03
<0.01
0.11
0.95
0.23
0.26
0.02
0.24
<0.01
0.06
0.44
0.15
0.01
0.04
0.54
0.02
100
0.25
100
0.40
16 (33)
4 (8)
28 (59)
969 
(1,730)
18 (4) 
5 (4)
17 (35)
11 (23)
370 (205)
0.13 (0.10)
0.25 (0.18)
42 (88)
5 (10)
2 (3)
3 (4)
8 (2)
24 (50)
23 (48)
9 (43)
1 (11)
3 (33)
21 (44)
9 (43)
0.39 (0.20)
20 (2)
28 (58)
41 (85)
35 (73)
15 (31)
Table 4.1. The comparison of socio-demographic characteristics, drug use, medical, and psychiatric conditions of 
people who inject drugs who had never accessed and ever accessed substance abuse treatment.
PWID from both groups had started using injecting drugs at a young age (18, SD 3 years). 
Those who had accessed SAT had more severe drug problems compared to those who had ne-
ver accessed SAT. This was indicated by a longer period of injecting drugs, higher prevalence 
of drug use in the last 30 days, more episodes of drug overdose, more cigarette smoking, and 
a higher drug composite score. Interestingly, alcohol problems were more frequent among 
those who had never accessed SAT.
Despite the high score on knowledge about HIV, especially in PWID who had already 
accessed SAT, 78% of the respondents still engaged in risky behavior for HIV transmission. 
There were no differences in the percentage and frequency of injecting, sexual, and other 
risk-taking behaviors between the two groups. Those that had accessed SAT also did not 
differ with regard to the severity of medical and psychiatric conditions, nor in HIV preva-
lence rates.
Of all PWID, 75% have been tested for HIV, and 60% of HIV-positive PWID subsequently 
received antiretroviral treatment. Those who had accessed SAT were more likely to be tested 
for HIV (83% vs 48%) and hepatitis C (64% vs 44%), and treated for HIV (62% vs 33%), 
however due to the small numbers, the difference on HIV treatment were not statistically 
significant. Psychiatric treatment was not frequently given since 95% of all patients expe-
rienced psychiatric problems only 30% received such treatment. Those accessing SAT were 
more often treated for psychiatric disorders (33% vs 17%).
The most widely accessed SAT were substitution treatment (56%) and traditional/faith-
based treatment (57%) (Table 4.2). On average, PWID reported 5 (range: 1 - 27) episo-
des of accessing SAT. Table 4.3 showed that accessing substitution or residential drug-free 
treatment increased the probability to be tested for HIV (OR=5.8;95% CI: 2.5,  13.9) and 
(OR=3.7;95% CI: 1.4,9.7), respectively.  Accessing substitution treatment (OR= 3.8; 95% 
CI: 1.9, 7.5) or other medical services (OR =3.1; 95% CI: 1.1, 8.7) increased significantly 
the probability of HIV treatment.
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   Trouble in controlling violent, N (%) 
   Ever treated for psychiatric problems,  
     N (%)
   Psychiatric composite score (0-1), 
     mean (SD)
Characteristics (follow-up)
Yes
(N=162)
X2/U PNo
(N=48)
88 (54)
53 (33)
0.17 (0.20)
4.63
3.63
0.87
0.03
27 (56)
8 (17)
0.24 (0.16)
Table 4.2. Types of substance abuse treatment modalities ever accessed by people who inject drugs.
Table 4.3. Associations between types of substance abuse treatment with HIV testing and HIV treatment (N = 162).
Note : Day-care treatment was not included in multivariate analyses because one of the blocks in a two times two table 
was zero.
51
Substance abuse treatment modalities (N = 162) %
22 
26
57
12
36
7
15
13
56
Outpatien detoxification 
Residential detoxification
Outpatient substitution
Outpatient drug-free
Residential drug-free
Day care
Psychiatric care
Other medial services
Traditional/faith-based treatment
HIV testing 
   Outpatien detoxification 
   Residential detoxification
   Outpatient substitution
   Outpatient drug-free
   Residential drug-free
   Psychiatric care
   Other medial services
  Traditional/faith-based treatment
HIV treatment
   Outpatien detoxification 
   Residential detoxification
   Outpatient substitution
   Outpatient drug-free
   Residential drug-free
   Psychiatric care
   Other medial services
  Traditional/faith-based treatment
Type of HIV programs in several types 
of substance abuse treatment
Adjusted
OR (95%) CI
Unadjusted OR
(95%) CI
1.1 (0.3 - 3.4)
4.0 (0.8 - 19.1)
5.8 (2.5 - 13.9)a
1.1 (0.2 - 4.6)
3.7 (1.4 - 9.7)a
1.4 (0.4 - 5.7)
1.5 (0.3 - 6.8)
0.9 (0.4 - 2.0)
0.9 (0.3 - 2.2)
0.9 (0.4 - 2.2)
3.8 (0.4 - 7.5)a
1.9 (0.7 - 5.5)
2.0 (0.9 - 4.1)
1.8 (0.7 - 4.9)
3.1 (1.1 - 8.7)b
0.6 (0.3 - 1.3)
2.4 (0.9 - 6.4)
9.0 (2.1 - 38.7)a
6.6 (2.9 - 15.0)a
2.0 (0.6 - 7.2)
3.9 (1.6 - 9.7)a
2.7 (0.8 - 9.5)
2.3 (0.7 - 8.1)
1.6 (0.9 - 3.2)
1.7 (0.8 - 3.5)
2.0 (1.0 - 4.0)b
3.6 (1.9 - 6.7)a
2.1 (0.8 - 5.4)
1.7 (1.0 - 3.6)b
2.1 (0.9 - 4.8)
2.7 (1.1 - 6.6)b
1.1 (0.3 - 2.1)
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Discussion
In this cross-sectional survey from Indonesia, a group of relatively young and well-educated 
PWID showed that most of them had accessed SAT at least once, especially substitution and 
traditional/faith-based treatment. Importantly, those who had accessed substitution treat-
ment were more likely to be tested and treated for HIV, compared to those accessing other 
types of SAT.
In general, the percentage of the utilization of SAT by PWID in this study was higher com-
pared to other studies7, 27. The reason for this high percentage can be caused by a different 
period of time used, and the inclusion of traditional/faith-based treatments in this study.  A 
recent review concluded that information regarding other SAT besides substitution treatment 
was much less commonly available in many countries, and the inconsistencies and imperfect 
data on the estimation of PWID population limited the calculation of the coverage of the 
programs7.
The socio-demographic characteristics of the patients in this study were comparable with 
PWID in other big cities in Indonesia28. They are relatively young and well educated since 
almost all (94%) had completed their senior high school or higher education while only 
22,6 % of the citizens in Indonesia have completed senior high school29. Their income was 
slightly higher than the minimum wage according to the regional standard30. There was no 
correlation between the choice of SAT modality and the educational level12. PWID who had 
accessed SAT had more severe drug problems is in line with other studies which found that 
most PWID accessed treatment only when they were in emergency or crisis31, 32.
Alcohol problems were more common among PWID who had never accessed SAT. 
Although it has been reported that alcohol is associated with risky sexual behavior33 we have 
found no differences in sexual risk-taking behavior between those who had and had not 
accessed SAT. This may indicate that other drugs also influence the sexual risk behavior34. 
The percentage of PWID with injecting and sexual risky behavior was high and in line with 
other studies16, 35, 36. However, the frequency of such risky behavior was lower compared to 
previous studies37, 38.
We have found that PWID who had accessed SAT had better knowledge on HIV, better 
access to HIV testing and treatment, HCV testing, and psychiatric treatment. This finding 
indicates that besides handling drug problems, SAT can be used as an entry point for other 
harm-reduction programs and health services in Indonesia, similar to studies from other 
countries8, 9. Despite the differences between those that had not accessed SAT, and those 
who had, psychiatric treatment in general was grossly underutilized. It has been reported 
before that people who use drugs with psychiatric symptoms rarely want to be referred to the 
specialized facilities for psychiatric treatment39. It is however important to address this issue, 
since psychiatric co-morbidity can reduce the effectiveness of SAT program40. That is why 
interventions to increase referral and uptake from/to psychiatric treatment should be 
addressed41, 42.
Among PWID who had accessed SAT, substitution treatment was the most widely accessed 
treatment. The percentage of the utilization of substitution treatment in this study was in 
line with other national reports35, 36. It was shown in this study that the chance to be tested 
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and treated for HIV was most likely in those who had accessed substitution treatment. The 
integration of HIV programs in substitution treatment indicated effective results17, 43, and 
there were no differences in response to HIV treatment between PWID and the non-PWID 
groups44, indicating the importance of integrating drug and HIV treatment programs.
The second most widely used SAT modality was traditional/faith-based treatment. Other 
studies have reported the frequent utilization and satisfaction of traditional/faith-based treat-
ments by PWID and HIV-infected patients45-47. Belief in spiritual healing may however also 
interfere with adherence to antiretroviral treatment48. Therefore, despite the debate on the 
effectiveness of this approach49, close collaboration between drug-related interventions, HIV 
programs, and traditional/faith-based treatment is required to identify common goals and to 
ensure successful treatment48.
Our present study suffers from the general limitations of a cross-sectional study in a 
population which is difficult to reach, raising the question how representative the samples 
are. By using RDS, this risk can be minimized50. Numerical simulations have shown that 
the possible bias, even if the seeds are not drawn randomly, is extremely small (0.3%) for all 
sample sizes greater than 20050. Still, some PWID who are not in the social networks with 
these participants cannot be recruited through RDS51. It is not possible to know the num-
ber of accessing certain substance abuse treatment or which combination has the significant 
association with HIV program since there are too many possible combinations with limited 
number of sample. By using multivariate analysis and adjusted the odds ratio we can dif-
ferentiate which type of substance abuse treatment had the highest association with HIV 
programs. Furthermore, the generalization of the results to the overall condition in Indonesia 
should be carefully considered, since there were only 49 opioid substitution therapy sites in 
Indonesia52, mostly distributed in the big cities, while it was estimated that there were more 
than 219,000 PWID53.
Conclusion
PWID who had accessed SAT had better access to HIV testing, HIV treatment, and other 
treatment programs compared to those who had not accessed SAT. These findings underline 
the role of the SAT in HIV prevention and care. The coverage of HIV interventions for 
PWID may also be improved by introducing HIV programs to other types of SAT services 
beside substitution treatment, such as traditional/faith-based treatment.
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chapter 5
Severity of psychiatric and physical problems 
is associated with lower quality of life in 
methadone patients in Indonesia
Iskandar S, van Crevel R, Hidayat T, Siregar IMP, Achmad TH, van der Ven AJ, De Jong CAJ. 
Severity of Psychiatric and Physical Problems is Associated with Lower Quality of Life in Methadone 
Patients in Indonesia. Am J Addict (in press).
Abstract
The goal of methadone maintenance treatment (MMT) is to reduce the harm and to 
improve patients’ quality of life. However, the quality of life (Qol) is also influenced by other 
co-occurring disorders. Data regarding the Qol and the co-occurrence of these disorders is 
lacking in low-middle income countries. We therefore describe the prevalence of physical, 
psychiatric, and drug abuse co-occurring disorders among MMT patients in Indonesia and 
determine the association between the severity of the co-occurring disorders and the Qol. 
Data were collected in 112 IDUs attending a MMT program in West Java, Indonesia, using 
validated questionnaires, medical records and laboratory testing. For comparison, 154 IDUs 
not enrolled in MMT were recruited by respondent driven sampling. The most frequent 
co-occurring disorders were hepatitis C (92%), HIV (77%), benzodiazepine abuse (56%), 
and anxiety disorders (32%). IDUs in MMT had one (26%), two (47%) or three (27%) co-
occurring disorders. Higher severity in psychiatric and physical problems was associated with 
poorer Qol. IDUs not enrolled in MMT had similar co-occurring problems. The prevalence 
of co-occurring disorders in IDUs in Indonesia is high therefore comprehensive treatment, 
especially focusing on the common co-occurring disorders should be provided in MMT to 
improve the Qol.
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Introduction
Worldwide, an estimated 11 to 21 million people inject drugs. Because of this, injecting drug 
abuse is responsible for one third of HIV transmission outside Africa, especially in parts of 
Eastern Europe, South America, and East and Southeast Asia1,2. Opioids, such as heroin is 
one of the most used injecting psychoactive substances.  Opioids are powerful drugs that can 
induce a sense of well-being, deliver a boost to self-esteem and increase tolerance to pain. 
People taking opioids, whether for recreational use or for a medical condition, may become 
dependent on these drugs3.
Opioid substitution therapy with methadone or buprenorphine reduces injecting drug abuse, 
unsafe injection practices, unsafe sexual practices, and HIV transmission4-6, and improves 
quality of life7-9. However, in many countries, the coverage and retention of opioid 
substitution is still limited9-11. Some studies have shown that physical12 and psychiatric 13,14 
co-occurring disorders, and drug abuse15,16 reduce the effectiveness of the methadone 
maintenance  treatment. Lack of proper diagnosis and treatment of these co-occurring 
disorders can also be of influence on methadone dose and because of this it can cause serious 
side effects17-20.
Injecting drug abuse increased dramatically in the late ‘90s in Indonesia, acting as the main 
force driving the HIV-epidemic21. Methadone maintenance treatment was therefore establis-
hed in Indonesia in 2003 by the WHO and the Ministry of Health in two pilot projects. The 
expansion of methadone was initiated in 2006 however until now, the retention and the co-
verage of the MMT programs remains very low22. Only 1% of injecting drug abusers (IDUs) 
is covered by MMT programs while only 6% of the HIV-infected IDUs have received anti 
retroviral treatment (ART)1.
Care for co-occurring problems will increase the effectiveness and higher utilization of servi-
ces6 and integrated services should be established based on the patients’ characteristics and 
problems23. Furthermore, one of the parameters that can be used to measure functioning, 
well being, and life satisfaction of patients is health related quality of life24. Quality of life 
can also be used for planning clinical care of individual patients; for assessment of the health 
needs of populations; and for resource allocation25. 
Data regarding the co-occurring disorders and its correlation with the quality of life (Qol) 
is lacking in low-middle income countries. Therefore, the aim of the present study was to 
determine the prevalence of co-occurring physical, psychiatric, and drug abuse disorders in 
patients in a MMT program and to identify the association between the severity of the 
co-occurring disorders and the Qol. As methadone clients may constitute a selected group 
of IDUs with more severe co-occurring disorders, community IDUs were examined for 
comparison.
Methods  
Participants 
Methadone patients
All IDUs (n= 188) enrolled in a hospital-based MMT program from January 2008 until 
December 2010 in Bandung, the capital of West-Java and epicenter of the epidemic of 
injecting drug abuse in Indonesia were asked to participate in this study. Participation was 
voluntary and informed consent was given by 112 patients (60%) before the interview. 
Methadone sample and community sample
From June to September 2008, 210 IDUs were recruited in Bandung as well, through 
respondent driven sampling (RDS), a form of peer recruitment26.  For details regarding 
the process of RDS, we refer to our previous study27. From this group, 60 (29%) had never 
utilized drug substitution treatment, 94 (45%) had previously entered a drug treatment 
program but not in the last 30 days, and the rest (26%) were in outpatient substance abuse 
treatment.
All IDUs provided informed consent and the study was approved by the regional medical-
ethical committee (The Health Research Ethics Committee Faculty of Medicine UNPAD- 
Dr. Hasan Sadikin General Hospital Bandung). The study was conducted within a program 
on prevention and treatment of HIV in the context of injecting drug abuse in Indonesia28.
Assessment
Interviewing was done by trained interviewers who assured all participants that their ano-
nymity would be strictly maintained. In the community sample, the interviewers used the 
European Addiction Severity Index (EuropASI). In the methadone clinic, more detailed 
information was collected using the EuropASI, the Mini International Neuropsychiatric 
Interview (MINI), and the EuroQol-5D (EQ-5D). Besides that, laboratory results were 
retrieved from medical records.
The EuropASI has shown excellent reliability and validity across a range of types of patients 
and treatment settings in many countries29. For the translation into Bahasa Indonesia, 
WHO translation procedures were used30. ASI is a semi-structured interview which takes 
about one hour, covering medical status, employment/ support status, drug/ alcohol abuse, 
legal status, family/ social relationship, and psychiatric problems31. Each of these areas is 
examined individually by collecting information regarding the frequency, duration, and 
severity of symptoms of problems both historically over the course of the patient’s lifetime 
and during the thirty days prior to the interview. 
Within each of the problem areas, the EuropASI provides a 10-point, interviewer-deter-
mined severity rating of lifetime problems (0 (no real problem) to 4-5 (moderate problem, 
some treatment indicated) to 8-9 (extreme problem, treatment absolutely indicated) and a 
4-point, client rating scale for problem & treatment need in the last 30 days (0 (Not at all), 1 
(Slightly), 2 (Moderately), 3 (Considerably), 4 (Extremely))32.  In order to measure addiction 
severity in a more objective way, the selective combination of items from each of the ASI 
problem areas were used to calculate the composite score/severity index (0-1), which can be 
used as a general measure of patient status in each area. These measures have shown reliabi-
lity and validity in several settings33.
The MINI, a brief interview based upon the ICD10 criteria, was used to screen for 
psychiatric disorders. It assesses current and lifetime psychiatric disorders34. The questions 
are precise and carefully worded, requiring only ‘yes’ or ‘no’ answers. 
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The MINI diagnostic framework allows for multiple mental disorders, and distinguishes 
current mental disorders from those arising at an earlier stage of the subject’s life35. It is 
currently available in over 40 languages, including Indonesian.
The EuroQol-5D (EQ-5D) assesses five different domains of general health and functioning 
(i.e. mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) along a 
3-point scale (1=no problems, 2=some problems, 3=extreme problems). The scores for the 
five domains are then converted to compose a single summary index using a formula that 
is based upon EQ-5D evaluations for the general population (the UK algorithm was used 
to calculate the index as it has been used in numerous international studies, including the 
field of mental health). This EQ-5D index measures objective Qol and spans a scale from 
−.594 (state “33333”) to 1.0 (perfect health) with “as bad as being dead” by convention at 
0. Therefore, all states with a negative value are considered as worse than dead. Patients were 
also asked to rate their overall health related Qol on a visual analogue scale (EQ-5D VAS) 
consisting of a vertical line ranging from 0 (worst imaginable health status) to 100 (best 
imaginable). The EQ-5D VAS score therefore represents the subjective Qol.1436-38. 
Data analysis and statistics
Descriptive data are presented in terms of percentage, mean, and standard deviation. The 
differences between methadone patients and IDUs in the community who never accessed 
drug treatment and ever accessed drug treatment but not in the last 30 days and the dif-
ference between HIV-positive and HIV-negative patients were analyzed using Pearson 
Chi–Square for dichotomous data and Kruskal Wallis or Mann-Whitney test for continuous 
data.  All tests were two-sided, with a P-value of 0.05 or less considered to indicate statistical 
significance. To identify whether the co-occurring disorder groups had an impact on their 
subjective and objective Qol, a multivariate analyses of variance (MANOVA) was conducted.  
Forced entry multiple regression analyses using physical, psychiatric, and drug abuse severity 
index were then undertaken to determine the association between the severity of co-occur-
ring disorder and the objective and subjective Qol. Analyses were performed with the use of 
SPSS, version 15.
Results
Co-occurring disorders and its correlation with quality of life among methadone clients
Data from ASI-X, MINI, and laboratory test showed that 105 out of the 106 patients from 
the MMT program experienced co-occurring disorders (figure 5.1). Seventy-seven patients 
(73%) had more than one co-occurring problems and the most frequent co-occurring disor-
ders were chronic physical problems. 
The mean of the subjective Qol (EQ-5D VAS) was 73 (range 30 to 100) and was worst 
among patients with triple co-occurring disorders (physical, psychiatric, and drug abuse) 
(table 5.1). The mean of the objective Qol (EQ 5 D index) was 0.83 (SD 0.22) and the 
lowest mean was among those who had psychiatric disorder(s) in combination with the use 
of other drugs besides methadone. Multivariate analyses of variance (MANOVA) showed 
that co-occurring disorders had a significant effect on subjective and objective Qol ((Wilk’s Λ 
= .72, F(10,192) = 3.45, p < .001). In the forced entry multiple regression with EQ-5D VAS 
as criterion variable, physical, psychiatric, and drug abuse severity index accounted  
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for 22.6% of the variation o the EQ-5D VAS (R2 = 0.226, Adjusted R2 = 0.201). Only 
severity of physical problems that had significant correlation with EQ-5D VAS, resulting in 
the following equation: EQ-5D VAS = 80.5 + (-25.2 x physical severity index). For EQ-5D 
index, physical, psychiatric, and drug abuse severity index explained for 42.4% of the varia-
tion of the EQ-5D index (R2 = 0.424, Adjusted R2 = 0.406) and resulting in the following 
equation: EQ-5D index = 1.006 + (-0.179 x physical severity index) + (-0.609 x psychiatric 
severity index). 
Figure 5.1. Current prevalence of physical, psychiatric, and drug abuse problem among methadone patients.
Table 5.1. Physical problems among methadone clients. 
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12
16
Physical
problems
(N = 87)
Psychiatric
problems
(N = 43)
Co-occurring
drug abuse
(N = 80)
34
28
12
9
0
6
total patients = 106
1 patient without any occurring disorder
EQ 5D visual analog scale (0-100) 
   Physical 
   Drug abuse
   Physical and psychiatric
   Psychiatric and drug abuse
   Drug abuse and physical
   Physical, psychiatric and drug abuse
EQ 5D Index (0-1)
   Physical 
   Drug abuse
   Physical and psychiatric
   Psychiatric and drug abuse
   Drug abuse and physical
   Physical, psychiatric and drug abuse
N (%) Mean SD
15 (14)
12 (12)
9 (9)
6 (6)
33 (32)
28 (27)
16 (15)
12 (11)
9 (9)
6 (6)
34 (32)
28 (27)
74
84
75
74
73
67
90
95
77
60
89
73
10
13
17
17
17
12
12
11
18
39
14
27
Co-occurring problems
Physical problems among methadone clients
The large majority of IDUs reported physical co-morbidity. Sixty four percent of the patients 
had been hospitalized, the large majority (88%) within the last year. The most common 
chronic physical problems among methadone patients (table 5.2) were hepatitis C (92%) 
and HIV-infection (77%) while Hepatitis C and HIV co-infection was documented in 74%. 
Among HIV-infected patients the median CD4 cell count was 222 (range: 4 to 1445); 
48% had a CD4 cell count below 200 cells/ mm3. Chest X-ray examination were available 
for 38 patients and showed abnormalities in 21 patients (55%), including lesions suggesting 
tuberculosis in 11 patients (29%). The most frequent abnormal blood tests were elevated 
liver function tests and anemia. Abnormal laboratory test were more common among 
HIV-seropositive patients.
Table 5.2. Psychiatric problems among methadone patients (N = 112).
Psychiatric problems among methadone clients
In the MINI assessment for psychiatric disorders, 57% of IDUs reported psychiatric 
pathology, and 42% suffered from psychiatric symptoms at the time of interview (table 5.3). 
The most diagnosed disorders were within anxiety disorder category (32%). However, 
forty-nine patients (44%) had experienced a psychotic disorder in their life time. 
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Physical problems %
1
6
92
77
29
19
19
27
29
3
11
26
24
4
33
34
62
35
0
VDRL positive (N = 107)
HBsAg positive (N = 105)
HCV positive (N = 100)
HIV positive (N = 102)
CD4 (N = 85)
   Below 100
   Between 100 and 200
   Between 201 and 350
Hemoglobin below normal (N = 104)
Hematocrit below normal (N = 103)
Kreatinin above normal (N = 81)
Trombocytes normal (N = 103)
MCV below normal (N = 85)
MCH below normal (N = 75)
MCHC below normal (N = 75)
SGOT above normal (N = 105)
SGPT above normal (N = 109)
Gamma GT above normal (N = 77)
LDH above normal (N = 49)
Glucose above normal (N = 83)
The occurrence of psychiatric disorders in HIV-positive and HIV-negative patients did not 
show any statistical differences. 
Table 5.3. Drug abuse among methadone patients. 
* regular use (more than 3 times or 2 consecutive days a week) 
** > 3 drinks in 1-2 hours, > 3 times or 2 consecutive days a week. 
Note : Less than three participants used inhalant, hallucinogens or cocaine in the last 30 days.
Drug abuse among methadone clients
The large majority of patients used other substances beside methadone (figure 5.1), 
especially benzodiazepines, heroin, cannabis and alcohol (table 5.4). All of the patients had 
ever used heroin intravenously. Findings of urine drug tests were in line with the result from 
the interviews. Drug abuse among HIV-negative and HIV-positive patients was not statisti-
cally different.
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Psychiatric problems %
28
30
32
19
44
42
57
Current mood disorders
Life time mood disorders
Anxiety disorders
Current psychotic disorders
Life time psychotic disorders
Total current psychiatric disorders
Total life time psychiatric disorders
According to EuropASI questionnaire 
(N = 108)*   
   Any use of alcohol 
   Alcohol, over treshold **
   Heroin
   Other opiates
   Benzodiazepines
   Amphetamine
   Cannabis
   Ectasy (MDMA)
   More than one substance
Kind of drug* Last 30 days (%)Lifte time (%)
19
11
27
6
56
3
22
5
58
92
67
100
31
73
69
75
64
81
64
 Table 5.4. Drug abuse among methadone patients.
* regular use (more than 3 times or 2 consecutive days a week)
 ** > 3 drinks in 1-2 hours, > 3 times or 2 consecutive days a week. 
Note : Less than three participants used inhalant, hallucinogens or cocaine in the last 30 days.
Characteristics of methadone maintenance patients in comparison with IDUs 
in community
As methadone clients may constitute a selected group of IDUs with more and more severe 
co-occurring disorders, community IDUs were examined for comparison. IDUs in the 
community were younger compared to IDUs at methadone clinic (28 ±4 vs. 30 ±4 years), 
had a shorter history of injecting drug abuse, lower education, worse occupation, and lower 
income (data not shown). However, similar to IDUs enrolled in MMT, IDUs in the com-
munity perceived that they had moderate problems and treatment needs related to physical, 
psychiatric, and drug abuse conditions. 
The correlation between interviewer-rated severity for physical, psychiatric, and drug abuse 
problems and treatments need and problems and treatment need, as perceived by the IDUs 
themselves, was high (r = 0.49 - 0.66, P < 0.01). Furthermore, IDUs in the community who 
had accessed drug treatment at some point but not in the last 30 days, showed the most 
severe problems and the highest treatment needs, especially related to drug and psychiatric 
problems. 
Discussion
This study showed a high prevalence of co-occurring physical, psychiatric, and drug abuse 
problems in IDUs. Among those problems, the psychiatric co-occurring disorders had the 
highest negative association with objective Qol, while only physical co-occurring disorders 
was associated with lower subjective Qol of MMT patients in West Java, Indonesia.
The result on objective Qol was in line with other studies which showed that there was a 
significant correlation between psychiatric problems and Qol14,25.  However, the comparison 
of the means of the objective Qol index, using the same instrument and the same treatment 
setting, showed that the Qol in methadone patients in Indonesia was higher14,39. This can be 
due to the differences in ethnicity, socio-economic status40, and age among study population.
As well as psychiatric problems, physical problems had negative association with Qol. 
Drug urine test (N = 75)
   Opiate positive
   Amphetamine positive
   Cocaine positive
   Methamphetamine positive
   Cannabis positive
   Benzodiazepine positive
Kind of drug* (follow-up) Last 30 days (%)Lifte time (%)
3
1
0
0
10
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In addition, physical problems were the most frequent co-occurring disorders. Parental route 
of administration and injecting risk behavior are usually conducted by heroin users so their 
general well being and health is at risk by infectious diseases such as HIV and hepatitis18,41-43.
The prevalence of HCV and HIV among IDUs in the MMT program was very high, also 
compared to other countries9,17,41,44,45.  HIV will accelerate the progression of the liver disease, 
especially patients with low CD4 cell counts18. This is in line with the liver test abnorma-
lities as were observed in our study. Another physical problem found in almost one third 
of MMT patients was tuberculosis. Tuberculosis reactivation in HIV-infected drug abusers 
with latent tuberculosis infection is 9% per year while a similar but lifelong risk is present in 
HIV-seronegative subjects with latent tuberculosis18. However, we may have underestimated 
the prevalence of tuberculosis in our study since symptoms like fever, cough and weight loss 
are uncommon among HIV patients and chest radiography, as the only method used for 
screening of tuberculosis in this study, generally would detect only 25%46. 
Furthermore, the findings about current and life time psychiatric problems were comparable 
with other studies but the prevalence of a psychotic disorder was higher 14,44,47-50.  Based on 
the design of our study it is not possible to explain this difference. The treatment and the 
alleviation of the psychiatric problems improve the efficacy of MMT in the diminishment of 
drug use and retention in treatment18. 
Moreover, similar to other studies, we found that drug abuse among methadone patients 
was common14,49,51. A study showed that benzodiazepine abuse was common in methadone 
patients and was negatively influenced treatment outcomes16. Furthermore, in general, 
persisting co-occurring  any substance use disorder  has been associated with other negative 
outcome, including more frequent and longer periods of hospitalization, higher psychiatric 
disorder and relapse rate, higher non-compliance, and more extra pyramidal syndromes, 
unemployment, homelessness, violence, incarceration, suicide, and HIV infection52.
  
IDUs in the methadone clinic were compared with a group of IDUs recruited from the com-
munity in order to evaluate whether the results can be generalized. It proved that IDUs in 
the MMT program had similar problems and treatment needs as those from the community. 
Even though IDUs in MMT were older than those recruited from the West Java community,  
they were younger compared to patients in other methadone clinics in Australia, Canada, 
China, Iran, Israel, Netherland, Poland, Thailand, and USA; and also had the highest percen-
tage of using opioid intravenously9,13,14,16,17.
  
In addition, we found that IDU in MMT has a better socio-economic status compared to 
the community group which might indicate that the costs of treatment limit access to these 
services. Indeed, reports from other low income countries provides substantial evidence that 
bringing down the cost of treatment improves access and adherence, and in turn, the success 
of public health programs23,53-55. 
 
This study is limited because of an incomplete representativeness of the samples. In the me-
thadone clinic, data were obtained from 60% of the population and not all of participating 
patients completed the whole interview and examination. 
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IDUs in the community are difficult to reach. By using RDS, we tried to minimize the risk 
of unrepresentative sample56,57. Still, some IDUs who are not in the social networks with 
these participants can not be recruited through RDS58. 
Conclusion
In conclusion, this study from Indonesia showed that the co-morbidities are very common 
among IDUs and that the severity of psychiatric and physical problems is negatively associa-
ted with Qol. Providing one stop care in the methadone treatment is needed to increase the 
quality of life of the patients and increase the effectiveness of the treatment program.
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chapter 6
Psychiatric co-morbidity in injecting drugs users 
in Asia and Africa
Iskandar S, Kamal R, De Jong CAJ. Psychiatric comorbidity in injecting drug users in Asia and Africa. 
Curr Opin Psychiatry. 2012 May;25(3):213-8. Review.
Abstract
Purpose of review : The prevalence of psychiatric co-morbidity in injecting drug users
(IDU) in the Western countries is high and is associated with lower quality of life and 
reduces the effectiveness of treatment programs. The aim of this study is to provide a review 
about psychiatric co-morbidity in IDU in Asia and Africa, where HIV prevalence is high 
and still increasing.
Recent findings : Studies focusing on psychiatric co-morbidity in Asia and Africa are scarce. 
The prevalence of psychiatric co-morbidity is comparable with the prevalence in western 
countries. Psychiatric disorders can occur before or during drug abuse and are also associa-
ted with substance abuse and physical co-morbidity and its treatments. Childhood trauma 
followed by post traumatic disorders is a significant risk factor for substance abuse. Psychia-
tric co-occurring disorders influence the adherence to the physical and drug use treatment. 
Evidence-based treatment for psychiatric co-morbidity in IDU is still limited.
Summary : A better understanding of the prevalence of psychiatric disorders in IDU and its 
impact to the overall treatments is growing. However, more studies focusing on the treat-
ment for psychiatric co-morbidity in IDU in Asia and Africa are needed.
Keywords : psychiatric co-morbidity, injecting drug users , substance use disorders, HIV, 
Asia, Africa
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Introduction
Injecting drug users (IDU) has created major public-health problems. It was estimated that, 
in 2007, 15.9 million people (range 11.0–21.2 million) were IDU1. The transmission of 
blood borne viruses, in particular HIV, contributes substantially to the morbidity and 
mortality caused by illicit drug use2. IDU also has been associated with some of the most 
severe HIV epidemics worldwide3.
The prevalence of HIV in IDU in many countries is stable or decreasing. However, in most 
of the low and middle income countries in Asia and Africa, the prevalence still increases 
significantly4. Among 3.9 million (range 3.5 - 5.6 million) IDU live in south, east and 
south-east Asia2,  HIV prevalence ranges from 10 - 43%2. In Africa, the estimation number 
of IDU is still limited (500,000 to 3 million)5, however a large increase is reported and the 
prevalence of HIV in IDU is high (33-50%)4, 6. 
IDU with medical, psychiatric, and substance use disorder co-morbidities are likely to engage 
in high-risk behaviors, and when untreated, continue to fuel the HIV epidemic3. Further-
more, these co-occurring disorders complicate care.  Lack of proper HIV diagnosis and tre-
atment influence the effect of the overall treatment. The HIV treatment itself causes serious 
psychiatric side effects3, 7, 8.
Little is known about psychiatric problems in IDU in Asia and Africa2, 4, 9-11. Therefore, the 
focus of this present article involves the prevalence of psychiatric disorders and the occurren-
ce of psychiatric co-morbidity in association with substance use and blood borne infections. 
In the following chapters, existing data from western countries are compared with those from 
Asia and Africa.
Prevalence of psychiatric co-morbidity in IDU
IDU with psychiatric co-morbidity are likely to engage in high-risk behavior3. Psychiatric 
co-morbidity in IDU is associated with poorer quality of life12, 13. The results of two recent 
studies in Asia were in line with those findings. A study from China showed that IDU expe-
riencing negative affect may develop maladaptive thoughts, which compromise their moti-
vation to take care of themselves and to avoid the negative consequences of risk behaviors. 
In the context of high HIV and other blood borne diseases, these risk behaviors lead to the 
transmission of the diseases to other IDU and to the general population through injecting 
and sexual risk behavior14. In addition, regarding quality of life, a study from Taiwan showed 
that IDU with depression had poorer quality of life compared to those without depression15.
Even though giving attention to psychiatric co-morbidity is very important, most of the ar-
ticles in the last two years were focusing on physical co-morbidity, risk behaviors, and policy. 
Studies focusing on psychiatric disorders in IDU show that the prevalence is high10, 14-22 and 
comparable with the findings in western countries12, 23-25.
The percentage of dual diagnosis (according to DSM IV and ICD 10) in IDU is about 
40%10, 20. However, psychological distress, such as hating oneself very much or feeling very 
depressed, is experienced by more IDU (90%)14. The prevalence of suicidal ideation and 
suicidal attempts ranges between 50% to 93% and 43% to 87%, respectively16, 22. Poor 
sleep quality is experienced by 66-96%14, 19. The prevalence of anxiety ranges between 4 to 
53% and for depression between 18% to 72%10, 15, 18. Other frequent psychiatric co-morbidi-
ties are current pathological gambling (21%)21; psychotic disorders (12%); and adjustment 
disorders (9%)10. Different instruments and population sample of IDU influence the preva-
lence of psychiatric co-morbidity. 
All studies are cross-sectional which limited insight in the course of the psychiatric problems. 
Psychiatric problems can happen before or after drug addiction. Those who have progression 
from drug addiction to a psychiatric disorder were more frequently affected by mood 
disorders23, 26. Conversely, primarily mentally ill dual diagnosed patients were more frequent-
ly diagnosed as psychotic or as affected by anxiety disorders. Certainly, this chronological 
difference had consequences in the approach of the treatment. More research in Asia and 
Africa with bigger sample size and better methodology quality is needed.
Psychiatric risk factors for becoming non-injecting/ injecting drug users
Several psychiatric factors may increase the vulnerability to become a drug user. Frequently 
found are personality traits, such as negative temperament and disinhibition27; impulsivity, 
sensation-seeking, novelty seeking, reward-sensitivity28; antisocial personality29; and child-
hood trauma, including physical, sexual, and emotional abuse/neglect30. These psychiatric 
factors influence treatment outcome and are rarely addressed in treatment28.
Studies in Asia and Africa found similar results. A study from China showed that 80% of 
IDU reported at least one type of childhood trauma and greater physical and emotional 
abuse in childhood was associated with greater psychological distress later in life31. A study 
from Israel reported that 54% of the patients who experienced childhood sexual abuse 
developed a post traumatic stress disorder (PTSD). PTSD was associated with more frequent 
use of heroin32. In Africa, childhood sexual abuse among female IDU in Tanzania ranges 
from 21% to 46%. Seventeen percent of them used heroine as self medication for PTSD and 
depression33. A study among street children in Egypt showed that 93% of them faced harass-
ment or abuse and 62 % of them used drugs34. 
Psychoactive substances and psychiatric co-morbidities in IDU
A review show that 40-90% of individuals with a lifetime substance use disorder also have a 
lifetime history of at least one other mental disorder  and vice versa (35). A study in South 
Africa showed that 51% of psychiatric patients had substance use disorders (36). 
The abuse of several drugs (poly-drug use) is a common pattern among IDU and increases 
the vulnerability to suffer from psychiatric disorders23, 37. There are many potential 
explanations for the association that include: substances induce depressive symptoms; 
mood disturbances follow substance withdrawal; substance use promotes confrontation with 
stressors; substances are used to cope with depressed mood38. Furthermore, poly-drug use 
leads also to more frequent and longer periods of hospitalization, higher relapse rate, higher 
non-compliance, higher risk behavior, more extra pyramidal syndromes, unemployment, 
homelessness, violence, incarceration, suicide, and HIV infection39, 40. 
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The most injected substance in Asian countries is heroin although 70 to 80% of IDU have 
a history of poly-drug use. The most common drugs used in lifetime are alcohol, tobacco, 
opiates, cannabis, and depressants, and the most common combination of co-use is heroin 
with another depressant41-46. 
In Africa, heroin and crack/ cocaine are the most reported injected drugs5 and cannabis 
and alcohol are the most common drugs used in combination with injected drugs47. 
Additionally, in the last few years, the use of amphetamine type stimulants (ATS) is 
increasing in both continents4, 48-50. The use of ATS and heroin is possibly associated with 
the increase of injecting and sexual risk behavior by IDU48-51. 
Effect of physical co-morbidity and its treatment to the occurrence of psychiatric 
co-morbidity in IDU
Studies demonstrate that those with Hepatitis C Virus (HCV) infection have a higher 
possibility to experience headache, fatigue, depression, anxiety and neurocognitive deficits 
in attention, learning processes and memory52 while anti-HCV treatments can cause neuro-
psychiatric adverse effect, such as interferon alpha which can cause depression53. 
HIV infection is a risk factor for a psychiatric disorder via the virus’ effect on the central 
nervous system54, psychosocial factors55, and/or antiretroviral-related adverse effects such as 
cognitive impairment, depression, anxiety, and psychosis43. HIV-associated neurocognitive 
disorders (HAND) are associated with persistent systemic and CNS inflammation, and en-
hanced neuronal injury due to stimulant abuse (cocaine and methamphetamine), aging, and 
antiretroviral drugs. HAND prevalence may be higher in areas of Africa where different HIV 
subtypes predominate56.
So far, we found only two studies in Asia on this topic. A study in Malaysia showed that HIV 
positive IDU was significantly associated with non-substance induced psychiatric disorders10. 
A study in Thailand showed that patients in antiretroviral treatment with undetectable 
plasma HIV RNA showed low percentage of depression and anxiety57. More research in Asia 
and Africa related to this topic is needed because the genetic of the virus and the people, and 
drug use are different. 
Effect of psychiatric and injecting drug co-morbidities to physical 
co-morbidity and its treatment
Substance dependence is a relapsing chronic condition whereby multiple drugs are often used 
which increases complex drug interactions.  If a parental route of administration is applied, 
general well being and health is at risk by infectious blood borne diseases such as HIV and 
hepatitis3, 58-60. In addition, the use of psychoactive substances influences the immune system 
and increases the vulnerability to have infectious diseases in IDU. For example, heroin can 
decrease the natural killer cell activity, phagocytosis, antibody-dependent cellular cytotoxicity 
and causes alterations in cytokine and chemokine production43. Methamphetamine and 
cocaine enhances HIV replication and  production of neurotoxic factors, and increases 
defects in the blood brain barrier 56.
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IDU with psychiatric disorders use more substances, are hospitalized more frequently and 
for longer duration, have higher suicidal rate and higher impairment on medical status and 
are socially isolated16. Furthermore, psychiatric co-morbidity is associated with HIV disease 
progression61. Treatment for addictive and psychiatric disorders leads to an increase of 
adherence to medical regimes, thus reducing the risk of the early emergence of treatment-
resistant AIDS and tuberculosis3, 62, 63.
However, high stigmatization to those who had psychiatric disorders, especially to those 
who also used drug, leads to lower rate of help-seeking and serves as a major barrier to
treatment64. Many physicians are still reluctant to treat IDU because of fears of 
non-adherence and consequent development of antiretroviral resistance, although so far 
research proved that this assumption is not right65. A study from Indonesia showed that IDU 
with HIV tend to have more advanced disease than non addicted patients, but respond 
similarly to antiretroviral therapy66. A study from India shows that stigmatization to IDU 
leads to more drug use and relapse, reduce treatment seeking, and increase risk behaviors67. 
Reducing stigmatization and taking into consideration the psychiatric and drug use 
co-morbidities are very important in providing optimal physical treatment for IDU.
Psychiatric treatment for IDU 
One of the reasons for the limited use of psychiatric treatment is that drug users with 
psychiatric symptoms rarely want to be referred to  specialized facilities for psychiatric 
treatment68.  Interventions to increase referral and uptake from/ to mental treatment are 
needed69, 70. One of the approaches is to provide psychiatric treatment in an addiction clinic 
program71.
One of the most effective addiction treatments for opioid IDU is methadone maintenance 
treatment (MMT). A study from China showed that in MMT which provides physical and 
psychological therapy, mental health improved from treatment initiation to day 90. It is 
suggested that MMT enables outpatients to feel less stressed due to being free from the 
financial burdens of drug addiction. They do not need to worry about being arrested or 
having an overdose. After treatment initiation, they slowly become independent from heroin 
addiction, and their self esteem returns as a result. The support from the MMT doctors and 
family members for the patients is helpful in the improvement of the mental health of the 
patients72. 
Despite the effectiveness of MMT, the number of MMT in most of Asian and African coun-
tries is still limited73. The awareness among IDU about substance abuse treatment is low74. 
Furthermore, the offer of comprehensive treatment in general is still fragmented. The lack of 
specialized knowledge amongst professionals working within this field, as well as equipment 
and medication, and stigmatization of drug users contributes to the delay of providing 
appropriate interventions75.  
Conclusion
Psychiatric problems and disorders among IDU are very common and have direct and 
indirect consequences to the effectiveness of the physical treatment programs. 
75
Assessment and treatment should be conducted carefully because psychiatric problems can 
be present independently or as a result of HIV, HCV, substance abuse, other co-morbidity 
and their treatments. More research in this area, especially regarding treatment intervention 
options, are really needed in Asia and Africa where the physical problems are more complex 
and resources are limited.
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Data addressing psychiatric disorders and psychiatric interventions in IDU is limited
The prevalence of psychiatric co-morbidity in Asia and Africa is comparable with 
the prevalence in western countries
 
Psychiatric co-morbidity reduces quality of life, increase HIV risk behavior, associates 
with more drug use, and influence the adherence to the treatment programs
 
HIV infection and its treatment increase the vulnerability for developing psychiatric 
disorders via its direct effect in the central nervous system and psychological stress
The lacks of specialized knowledge amongst professionals working with IDU, as well as   
stigmatization of IDU, limits the quality level of psychiatric and medical interventions 
to IDU
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chapter 7
Family involvement in HIV and tuberculosis care in 
Indonesia : an explorative study
In review
Abstract
Involvement from the family is associated with a better outcome in HIV patients. 
This cross-sectional survey was conducted to explore factors that can influence family 
involvement. One hundred twenty three family members were recruited through purposive 
sampling: 36, 43, and 44 family members of HIV patients with IDU history, HIV patients 
without IDU history, and tuberculosis patients, respectively. Compared with family of 
tuberculosis patients, family of HIV patients showed higher satisfaction about the care given 
by health care providers especially about getting information. Family of HIV patients with 
IDU history were more worried about their sick relatives than two other groups. Hope for 
the future of their sick relatives was high and comparable in these three groups. Drug use 
and problems that have impact on the family of HIV patients with IDU history should be 
addressed by health care providers to support family, and heighten their involvement in 
the treatment.
Key words : Family involvement; HIV;  injecting drug use; Tuberculosis; substance related 
disorder 
Introduction
HIV patients have many medical problems (Altice, Kamarulzaman, Soriano, Schechter, 
& Friedland, 2010). The problems increase by stigma and discrimination. 
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Stigma and discrimination can lead to a more stressful life that can be worse than having the 
disease itself (Ahsan Ullah, 2011). Psychological distress can contribute to HIV progression 
(Ironson & Hayward, 2008). High levels of psychological distress are associated with a de-
crease in CD4 count, an increase in viral load, and a faster progression to AIDS (Ironson & 
Hayward, 2008). 
In recent year, the concept of family has been broadened to include people who are 
important to the patients. It can include spouses, boyfriends or girlfriends, same-sex partners, 
parents, siblings, children, extended family members, friends, co-workers, employers, 
members of the clergy, and others (SAMHSA, 2006). Family involvement is a multidimen-
sional construct that entails visiting, socio-emotional care, advocacy, financial assistance, 
support in the disclosure process, daily routine activities, medical assistance, psychological 
support, and the provision of personal care (Li et al., 2006). Family involvement also 
addresses the need to provide the families of those with long-term diseases with supportive 
interventions (Maglione, 2005).
Involvement from the family are associated with a better physical and psychological adjust-
ment in HIV patients, such as more positive affect, lower negative affect, reduced risk, and 
enhancement of health-related behaviors, better medical service utilization, better illness ma-
nagement strategies, including higher rates of medication adherence in HIV patients (Gor-
dillo et al., 2009). The importance of the family involvement for HIV treatment has been 
studied quite extensively; however attention to the family of HIV patients is still limited 
(Rotheram-Borus, Flannery, Rice, & Lester, 2005). Family can experience stress because of  
the suffering and stress of their family members with HIV (Howe, Levy, & Caplan, 2004). 
Increased levels of stress in one or more family members may result in decreased ability of 
family members to offer support to one another and increased distress for individuals in 
the family. HIV patients from families with high stress levels experience more psychological 
distress than those from families with lower average stress levels (Brincks, Feaster, & Mitrani, 
2010). In conclusion, family members of HIV patients can be both a source of stress as well 
as support (Owens, 2003).
In Indonesia HIV is prevalent for two decades (Pisani, Dadun, Sucahya, Kamil, & Jazan, 
2003) and the HIV epidemic is among the fastest growing in Asia (NAC, 2009). The epide-
mic, except for Papua, is mainly driven by injecting drug use (IDU) (NAC, 2009). Substance 
abuse problems make the overall problems more complex and lead to more stigmatization to 
HIV patients (Achmad et al., 2009). Like other Asian countries, Indonesia is a collectivist 
society. People are integrated from birth onward into strong, cohesive in-groups, often exten-
ded families (Hofstede & McCrae, 2004). Therefore, problems in HIV patients in collectivis-
tic societies may affect more other family members compared to individualist societies.
Factors in family involvement that influence the treatment of sick relatives include 
satisfaction in the care given by health care providers, perceptions of the problems, and the 
believe that problems can be changed (Mayberry & Heflinger, 2011). Therefore, the aims of 
this present study is to explore: (1) the satisfaction of the family on services received from the 
health care providers, (2) the problems that family perceive in helping sick relatives, and (3) 
their hope concerning the future of their sick relatives. As a comparison for the HIV group, 
we studied the family of patients with tuberculosis (TBC). We opted for TBC because this is 
also a chronic infectious disease, common in Indonesia, and known in the general commu-
nity for longer time. It can be cured, and it is less stigmatized (WHO-SEARO, 2009).
Methods
Participants
Respondents in this study were family of HIV or tuberculosis (TBC) outpatients who were 
in treatment in clinics of the Hasan Sadikin Hospital, the Bandung-based top referral hos-
pital of West-Java Province, Indonesia. The HIV group was classified into: with and without 
injecting drug use (IDU) history group. The inclusion criteria were: family members or sig-
nificant others with the most close relationship with the patients, the most important person 
for patients, or the most involved person during the treatment for minimal one month, and 
not suffering from TBC or HIV. They were chosen by purposive sampling. All respondents 
then provided informed consent. The study was approved by the regional medical-ethical 
committee (LB.02.01/C02.2/12857/XI/2010).
Assessment
Interviewing of the family was done by trained interviewers who assured all participants 
that their anonymity would be maintained. Besides the general information about the sick 
relatives and socio-demographic characteristic of the respondents, three validated question-
naires were used: the Family Contact Information Support (Family CIS), the Family Member 
Impact (FMI), and the Hopefulness-hopelessness (HOPE). The WHO translation procedu-
res were used (WHO, 2003) for the translation into Bahasa Indonesia of the three question-
naires.
The Family Contact Information and Support (Family CIS) (DeJong, Noppen, & DeJong-
Verhagen, 2009) was used for measuring satisfaction in services received from the health 
care providers. This scale was designed in the setting of psychiatric outpatients treated in a 
General Mental Health Care Institution in the Netherlands. The instrument consists of 22 
items and is divided into three sub-scales which measure perceived satisfaction in the relati-
onships and cooperation with health care providers (6 items); in receiving information from 
health care providers (12 items); and in getting emotional support (4 items). Each question 
with the answer “yes” gets score 1 and 0 for “no”.  All items were summed to make the final 
score. Each subtotal and total score is divided with the maximum score in each subscale or 
total scale. So, the subtotal and total score lie between 0 and 1.  Higher scores indicate better 
services given by health care providers.  The Family CIS shows a good internal consistency 
with Cronbach’s alpha for contact .81, for information .84, and for support .76 (DeJong et 
al., 2009).
The Family Member Impact (FMI) (Orford, Templeton, Velleman, & Copello, 2005) is a 
16-item questionnaire (table 7.3) and assesses the extent and the type of harmful impact that 
the family member perceives of their relatives’ disease in the last three months. 
Originally, this scale was designed in the drinking or drug-taking setting. Response options 
for each item are:  not at all, once or twice, sometimes, and often (0, 1, 2, and 3). Principal 
components analysis produced two interpretable factors: active disturbance (items 1, 2, 5, 6, 
7, 10) and worrying behavior (items 3, 4, 8, 9, 11, 12, 13, 14, 15, 16). 
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The internal consistency reliability for the total scale, worrying behavior and active distur-
bances parts are fairly good (.77 for the total score, .74 for active disturbances, and .69 for 
worrying behavior) (Orford et al., 2005). 
The Hopefulness–hopelessness (HOPE) scale (Orford et al., 2005) is a 10-item scale ques-
tionnaire which is designed to assess how hopeful family currently feels about the future of 
their sick relative. Several statements focused on the family’s own feelings (e.g. I feel more 
positive about things; things are beginning to pick up), the other more focused on percep-
tions of the relative (e.g. I worry that s/he will use till the end; I’m fearful about how s/he 
will get on). The maximum score per item is 5 (5–1 for positive items and 1–5 for negative 
items). A higher score indicates the higher hope. Earlier research in drug addiction settings 
has shown that the HOPE has good internal consistency (.86) (Orford et al., 2005). 
Data analysis and statistics
Descriptive data are presented in terms of percentage, mean, and standard deviation. The 
differences in the characteristics between groups (HIV with IDU history, HIV without IDU 
history and TBC) are analyzed using the Chi–Square for dichotomous data and one-way 
ANOVA for continuous data. In case of significant differences in characteristics, analysis of 
covariance (ANCOVA) will be used to adjust for the differences in Family CIS, FMI, and 
HOPE score among the three groups. Statistical significance (two-tailed) is indicated when 
the p value is 0.05 or less. Analyses were performed with SPSS, version 15.
Results
A total of 123 respondents participated: 36 family members from the HIV with IDU history, 
43 family members from the HIV without an IDU history, and 44 family members from the 
TBC group. The mean age of the TBC patients was significantly older compared to HIV 
without IDU history patients (table 7.1 A). Most of the patients with HIV and IDU history 
were male while the ratio of male and female in the other groups was equivalent. The dura-
tion of suffering from the disease was significantly longer in HIV patients, especially those 
with IDU history. 
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Characteristics
Patient characteristics reported by 
family
Age, M (SD) 
Gender, female, N (%)
Disease duration, N (%)
   < 1 year
   1-2 years
   2-3 years
   4-5 years
   > 5 years
32 (10)
55 (45)
44 (36)
31 (25)
14 (11)
10 (8)
24 (20)
30 (4)
9 (25)
1 (3)
7 (19)
1 (3)
5 (14)
22 (61)
29 (5)
21 (49)
7 (16)
19 (44)
10 (23)
5 (12)
2 (5)
35 (15)
25 (57)
36 (82)
5 (11)
3 (7)
0 (0)
0 (0)
<0.01
0.1
<0.01
total
N = 123
HIV IDU
N = 36
HIV-Non IDU
N = 43
TBC
N = 44
P
Table 7.1. The comparison of the socio-demographic characteristics of the patients and the family members of the 
HIV with IDU history, HIV without IDU history, and TBC patients.
Among HIV patients with IDU history, 14 of 36 patients were in methadone treatment. 
Most of the methadone patients (12/14) have been in the treatment for more than 1 year. 
All HIV patients have been treated with anti-retroviral treatment (ART). There was no 
significant difference in the length of ART between HIV patients with and without IDU 
history. Twenty-eight out of 79 patients have been treated with ART for more than 2 years, 
and only 12 of them in ART for less than 6 months.  Most of the TBC patients (34/44) have 
been in the TBC treatment for less than 6 months and only 4 patients have been treated for 
more than 1 year.
The most frequent types of relationships with family members were spouses or sexual part-
ners (30%), parents (28%), or close friends (17%) (table 7.1B). The mean age of the family 
members was 38 years (SD 12). In the HIV without IDU history group, most of the family 
members were close friends whereas in HIV with IDU history and TBC patients, most of 
the family members were spouses or sexual partners and  parents. Most of the family in TBC 
group (34/44) and in HIV with IDU history group (23/36) were female, whereas on the 
contrary in HIV without IDU history group (11/43). 
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Family member characteristics
Types of relationships with people live 
with HIV, N (%)
   Parents
   Son or daugther
   Sibling
   Other family member
   Spouse or sexual partner
   Close friend
   Others
Age, M (SD)
Gender, female, N (%)
Education, N (%)
   Junior Hight School or lower
   High School
   Diploma or higher
Drug use, N (%)
   Alcohol
   Other substances
   Alcohol and other substances
34 (28)
6 (5)
15 (12)
6 (5)
37 (30)
21 (17)
4 (3)
38 (12)
68 (55)
39 (22)
56 (46)
28 (22)
28 (23)
10 (8)
6 (5)
13 (36)
0 (0)
3 (8)
4 (12)
13 (36)
3 (8)
0 (0)
39 (13)
23 (64)
7 (19)
16 (45)
13 (36)
11 (31)
9 (25)
6 (17)
6 (14)
1 (2)
4 (9)
1 (2)
9 (21)
18 (43)
4 (9)
35 (12)
11 (26)
11 (26)
19 (44)
13 (30)
15 (35)
0 (0)
0 (0)
15 (34)
5 (12)
8 (18)
1 (2)
15 934)
0 (0)
0 (0)
39 (11)
34 (77)
21 (48)
21 (48)
2 (4)
2 (5)
1 (2)
0 (0)
< 0.01
0.28
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
The average education level was senior high school. In the HIV group the education was 
significantly higher. More alcohol was used by family of HIV patients (26/79) than of TBC 
patients (2/44). None of family members of HIV patients without IDU history and only one 
person in family of TBC patients used other psychoactive substances. Nine out of 36 family 
members of HIV patients with IDU history used other psychoactive substances and 6 family 
members used both alcohol and other substances.
Table 7.2 showed the comparison of the satisfaction of the family on the care received 
from the health care providers. Family of HIV patients perceived  better information about 
confidentiality and privacy during treatment, symptoms of the disease when it relapses, how 
to handle critical situation/ relapse, information about course/ training/ education, sup-
port group/ non-government organizations (NGOs), and contact person in support group/ 
NGOs. The further analysis on the subscales showed that satisfaction in care given by health 
care providers was higher among family of HIV patients with and without IDU history con-
cerning the information part. After controlling for the significant characteristic, univariate 
differences among groups (patient sex, patient age, type of relationship, sex, age and educati-
on of the family members), the contrasts between TBC and HIV groups was still significant.  
TBC patients group had significantly lower total score for Family CIS compared to HIV-
IDU group, t(114) = 2.18, p =0.03, and HIV-Non IDU group, t(114) = 2.10, p = 0.04. 
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Family Contact Information 
and Support Scale
Total score (0-1), M (SD)
Contact subscale 
Contact total score (0-1),M (SD) 
HCP actively involve overall treatment
HCP actively involve treatment plan
Opportunity to share pers. experience
HCP ever consider pers. experience of
   family treatment
Easy to contact HCP
HCP gives respect to family
Information subscale
Information total score (0-1), M (SD)
Confidentiality and privacy
Regulation in the treatment setting
Explanation about the disease
Treatment plan
The role of family in the treatment
Drugs and their side effects
Possible daily activitiets for the patient
0.79(0.19)
0.82(0.19)
117 (95)
116 (94)
84 (68)
72 (59)
100 (81)
114 (93)
0.76(0.24)
91 (74)
106 (86)
117 (95)
107 (87)
105 (85)
108 (88)
100 (81)
0.82(0.18)
0.82(0.18)
34 (94)
34 (94)
25 (69)
18 (50)
31 (86)
35 (97)
0.81(0.22)
30 (83)
30 (83)
33 (92)
29 (81)
31 (86)
33 (92)
30 (83)
0.85(0.17)
0.86(0.17)
40 (93)
41 (95)
34 (79)
29 (67)
38 (88)
39 (91)
0.85(0.20)
37 (86)
40 (93)
40 (93)
41 (95)
37 (86)
40 (93)
37 (86)
0.70(0.19)
0.78(0.21)
43 (98)
41 (93)
25 (57)
25 (57)
31 (71)
40 (91)
0.63(0.23)
24 (55)
36 (82)
44 (100)
37 (84)
37 (84)
35 (80)
33 (75)
<0.01
0.14
0.58
0.91
0.8
0.28
0.7
0.46
<0.01
<0.01
0.27
167
0.12
0.96
0.11
0.39
total
N = 123
HIV IDU
N = 36
HIV-Non IDU
N = 43
TBC
N = 44
P
Table 7.2. The comparison of the satisfaction received from the health care providers (Family Contact Information 
and Support Scale) by the family of HIV patients with IDU history, HIV patients without IDU history, and TBC 
patients. All data are presented in number (percentage) for the yes answer in each question unless stated otherwise.
HCP : health care providers; NGOs : non government organizations
There were several items open for improvement in all groups. Less than 60% of family 
members had had contact, information, and support related with using the personal expe-
rience of family in the treatment, information regarding courses/ training/ education about 
the disease, NGOs or support groups, and contact persons in the health care institutions/ 
NGOs. 
Problems faced by family were highest in the HIV with IDU history group, especially for the 
worrying behavior subscale (table 7.3). Specific problems were: the sick relative upsets family 
occasions; smoking/ alcohol/ drug use by the sick relatives bothers family’s social life; sick 
relative was late or unreliable; sick relative neglects his/her appearance or self-care; and sick 
relative’s mental state is becoming affected by the drinking/drug use/smoking. The differen-
ces  for FMI total score between the three groups after controlling for patient sex, patient 
age, type of relationship, sex, age and education of family members were also significant, F 
(2,114) = 4.41, p = 0.01. In general, family were worried about the very changeable moods, 
the sick relative’s physical health has been affected by his/her bad habit (drinking/drug use/
smoking), and sick relative’s mental state is becoming affected by his/her bad habit (drin-
king/drug use/smoking). 
The hope about the future of their sick relative’s in all groups was high and there was no 
significant difference among the three groups (table 7.4). Family believed that they will start 
to a new future; something good will come out of this for their sick relative; things are 
beginning to pick up; and feel more positive about things. However, they felt doubtful 
whether their sick relative will get on and whether their relative will smoke/ drink alcohol/ 
use drug till the end.
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Symptoms when the disease relapse
Handle the critical situation/relapse
Course/training/education
Support groups/NGOs
Contact person support groups/NGOs 
Support subscale
Support total score (0-1), M (SD)
Support and handle family emotional  
   problem
Being listened by HCP
Guidance in learning proces of 
   helping the sick relative
Guidance in planning daily activity 
   of the sick relative
97 (79)
80 (65)
71 (58)
72 (59)
68 (55)
0.83(0.26)
100 (81)
113 (92)
99 (81)
94 (76)
31 (89)
30 (83)
23 (64)
24 (67)
24 (67)
0.84(0.25)
32 (89)
34 (94)
28 (78)
27 (75)
37 (86)
32 (74)
29 (67)
35 (81)
36 (84)
0.84(0.26)
36 (84)
40 (93)
36 (84)
32 (74)
28 (64)
18 (41)
19 (43)
13 (30)
8 (18)
0.80(0.27)
32 (73)
39 (89)
35 (80)
35 (80)
<0.01
<0.01
0.5
<0.01
<0.01
0.74
0.16
0.60
0.79
0.83
Table 7.3. The comparison of the problems faced by family (Family Member Impact Scale) of HIV patients 
with IDU history, HIV patients without IDU history, and TBC patients.
a the comparison groups with significant difference in post-hoc analysis.
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Family Member Impact Scale
Total score (0-48)
Active Disturbance (0-3)
   Active Disturbance total score (0-18)
   Very changeable moods
   Communicate badly
   Pick quarrels
   Threaten
   People outside the family have 
     to be involved
   Upset family occasions
Worrying Behavior (0-3)
   Worrying Behavior total score (0-30)
   Steal/borrow money, not pay it back
   Affect family’s finances
   Come and go at irregular/awkward  
     times
   Drinking/drug use/smoking bother 
     family’s social life
   Fail to join family activities
   Later or unreliable
   Health condition affects work/study
   Drinking/drug use/smoking affects 
     physical health
   Neglect his/her appearance or 
     self-care
   Mental state is affected by drinking/
     drug use/smoking
M (SD)
14 (7)
4 (3)
1.7 (0.9)
0.9 (1.0)
0.5 (0.9)
0.1 (0.4)
0.7 (1.10)
0.2 (0.6)
10 (6)
0.2 (0.6)
1.3 (1.2)
0.5 (0.8)
0.7 (1.0)
0.9 (0.9)
0.8 (0.9)
1.4 (1.2)
1.7 (1.2)
1.1 (1.1)
1.5 (1.2)
M (SD)
17 (8)a
5 (3)
1.8 (0.9)
1.2 (1.1)
0.8 (1.1)
0.0 (0.0)
0.7 (1.1)
0.4 (0.8)a
13 (6)a
0.2 (0.6)
1.4 (1.1)
0.5 (0.7)
1.4 (1.3)a
1.2 (1.1)
1.2 (1.0)a
1.4 (1.2)
2.0 (1.0)
1.5 (1.1)a
1.9 (1.0)a
M (SD)
13 (6)a
4 (2)
1.7 (0.9)
0.8 (0.9)
0.4 (0.8)
0.2 (0.6)
0.5 (1.0)
0.3 (0.6)
10 (5)
0.2 (0.6)
0.9 (1.0)a
0.7 (1.0)
0.5 (0.8)a
0.8 (0.8)
0.8 (0.9)
1.3 (1.2)
1.7 (1.2)
1.2 (1.1)
1.4 (1.2)
M (SD)
12 (7)
4(3)
1.6 (1.0)
0.7 (1.0)
0.4 (0.9)
0.1 (0.4)
1.0 (1.1)
0.0 (0.2)a
8 (6)a
0.1 (0.5)
1.6 (1.3)a
0.3 (0.7)
0.2 (0.7)a
0.8 (0.9)
0.5 (0.8)a
1.5 (1.3)
1.4 (1.4)
0.8 (1.2)a
1.1 (1.3)a
< 0.01
0.16
0.79
0.8
0.17
0.24
0.15
0.1
< 0.01
0.68
0.2
0.7
< 0.01
0.8
< 0.01
0.75
0.12
0.4
0.1
total
N = 123
HIV IDU
N = 36
HIV-Non IDU
N = 43
TBC
N = 44
P
Table 7.4. The comparison of the hope of the family of HIV patients with IDU history, HIV patients without IDU 
history, and TBC patients (HOPE Scale) concerning their sick relatives  
Discussion
This explorative study from Indonesia shows that family from HIV patients have better 
satisfaction on the services received from the health care providers, especially in getting infor-
mation than family of TBC patients. They perceived more problems compared to the family 
of TBC patients. The problems were related to the harmful impact of smoking/ alcohol/ sub-
stance used by their sick relatives to themselves and to the family. There were no differences 
in the hope about the future of their sick relatives in the HIV with and without IDU history 
and TBC groups. 
The average age of the HIV patients in this study was young and all received ART. Most of 
HIV patients with an IDU history have been treated for their addiction problems. ART, ad-
diction treatment, and the combination of both treatments will improve patient well being 
(Altice et al., 2010). Some studies showed that younger HIV patients less adhered to the 
ART (Protopopescu et al., 2009). Perhaps more family involvement is needed to increase the 
adherence to ART (Ibrahim, Haroen, & Pinxten, 2011; Protopopescu et al., 2009). 
Most of the family members were young and they have a blood relation with the patients. 
These characteristics were similar to the characteristics of the social networks in other studies 
in Africa and USA (Green, Atuyambe, Ssali, Ryan, & Wagner, 2011; Owens, 2003). 
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Hopefulness-hopelesness HOPE scale
Total score (0-50)
Positive items (1-5)
Start to anticipate a new future
Something good will come out of this
Things are beginning to pick up
Start to get back the person I know
Feel more positive about things
Negative items (1-5)
Fearful about how s/he will get on
S/he is not looking at things seriously
Pessimistic about the immediate future
S/he is stuck, never going to be any
   change
S/he will use drug/drinking smoking 
   till the end
M (SD)
38 (4)
4.4 (0.6)
4.5 (0.5)
4.4 (0.5)
3.9 (0.9)
4.4 (0.7)
2.6 (1.1)
3.5 (1.1)
3.6 (0.9)
3.5 (1.0)
3.0 (1.3)
M (SD)
38 (5)
4.3 (0.6)
4.6 (0.5)
4.5 (0.5)
3.9 (1.0)
4.4 (0.7)
2.6 (1.0)
3.5 (1.0)
3.6 (0.9)
3.5 (1.0)
3.2 (1.3)
M (SD)
38 (4)
4.4 (0.5)
4.5 (0.5)
4.3 (0.5)
3.9 (0.9)
4.4 (0.7)
2.5 (1.1)
3.3 (1.1)
3.8 (0.8)
3.6 (0.9)
3.0 (1.2)
M (SD)
38 (4)
4.4 (0.6)
4.5 (0.5)
4.5 (0.50
3.9 (0.9)
4.4 (0.6)
2.6 (1.2)
3.6 (1.1)
3.5 (1.1)
3.3 (1.1)
3.0 (1.3)
0.94
0.43
0.53
0.13
0.98
0.99
0.98
0.29
0.33
0.61
0.79
total
N = 123
HIV IDU
N = 36
HIV-Non IDU
N = 43
TBC
N = 44
P
The use of alcohol and psychoactive substances in the family members, especially in HIV 
with IDU history group, pointed at the need to provide addiction counseling and treatment 
also for family members. External stressors, such as peer pressure, drug related cues, conditi-
oning, setting for drug self-exposure, and concomitant ongoing psychiatric disorders, such as 
depression or anxiety are important environmental factors contributing to the development 
and relapse of addiction (McLellan, Lewis, O’Brien, & Kleber, 2000). 
Positive interactions with health care provider are associated with better adherence to ART 
(Johnson et al., 2006). Family of HIV patients in our study perceived better satisfaction in 
the care given by health care providers compared to family of TBC patients, especially in 
getting information about confidentiality, symptoms and treatment of the disease, and sup-
port from NGOs. In the HIV testing guideline, the patients are encouraged to disclose their 
HIV status to their spouses, current sex partners, and previous sex partners and recommend 
that these partners be tested for HIV infection (Branson et al., 2006). Information about 
the disease and confidentiality, and informed consent were part of the routine HIV testing 
procedure (Branson et al., 2006). In addition, most of HIV patients in Indonesia come from 
populations at higher risk and there are several NGOs that provide out-reach, information, 
and support for the patients and also their family in these key populations. These NGOs also 
work together with health care providers (Altice et al., 2010).  
Our findings show that in general, the satisfaction in the care given by health care providers 
was high compared to a study using the same questionnaires in addiction patients in the Ne-
therlands (DeJong et al., 2009). Some factors can still be improved, such as involving family 
in the treatment planning of the sick relative and more information about accessible social 
supports and education. Management of chronic disease like HIV requires an active role in 
decision making, problem solving, and implementation of a personalized treatment plan to 
achieve better health outcomes (Swendeman, Ingram, & Rotheram-Borus, 2009). 
Furthermore, shared decision making will increase family involvement in the treatment 
(Mayberry & Heflinger, 2011).
The problems faced by the family in this study were lower compared to another study in an 
addiction population in England (Orford et al., 2005). Family of HIV patients with IDU 
history had more problems compared to the other two groups. They were more worried 
about the use of tobacco or alcohol or drugs of their sick relatives that bother their social life, 
that were late or unreliable, they neglect his/her self care, and that the mental state of them 
were affected by drinking/ drug use/smoking. As a response to those worries, health care pro-
viders can provide the integration of HIV and substance abuse treatment programs, that this 
could be effective (Achmad et al., 2009). In addition, family-based interventions can assist 
families in resolving stress and strain through in vivo negotiation on disagreements, role-play 
for handling hassles with persons outside of the family, and increasing support among family 
members by highlighting their shared stresses and goals. These approaches will help family to 
develop skills for confronting rather than avoiding problems (Ahsan Ullah, 2011).
The hope about the future of their sick relative’s was higher compared to the previous study 
in the family of addiction patients in England (Orford et al., 2005). All of the HIV patients 
were in ART and some of them were in methadone treatment. ART and methadone tre-
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atment have shown their effectiveness in reducing risk behavior and improving well-being 
(Achmad et al., 2009). The higher hope can perhaps be explained by the religious way of 
thinking in Indonesian people (Sallquist, Eisenberg, French, Purwono, & Suryanti, 2010). 
Beliefs and practices associated with religion/ spirituality are generally positively related to 
greater well-being, hope, optimism, purpose and meaning, adaptation to and coping with 
bereavement, and social support (Seybold, 2007).
This study suffers from the limitations of the representativeness of the sample due to the 
purposive sampling used and a modest sample size in a single, urban clinic. Patients who can 
access treatment in Indonesia are limited due to their affordability (Afriandi et al., 2009). 
However, the present study provides preliminary data about factors that influence family 
involvement and in our knowledge is the first study in Asia. In addition, only family who 
did not have the disease were included in this study to limit the effect of a disease itself, 
like HIV/AIDS or TBC to their perception.  Therefore, findings should be generalized with 
caution to other settings. 
Conclusion
The perceived satisfaction in the care given by health care providers is higher in family of 
HIV patients compared to family of TBC patients. Their hope about the future of their sick 
relatives is high and has no difference with family of TBC patients although family of HIV 
patients with IDU history perceive more problems. More attention for perceived worrying 
behavior of family should be given by the health providers, especially to the family of HIV 
patients with IDU history, to support their involvement in the HIV treatment program.
Disclosures
The authors report no real or perceived vested interests that relate to this article (including 
relationships with pharmaceutical companies, biomedical device manufacturers, grantors, or 
other entities whose products or services are related to topics covered in this manuscript) 
that could be construed as a conflict of interest.
91
Providing good contact, information, and support by the health care provider can 
improve the family involvement in the care of their sick relatives 
More attention from health care provider in the personal experience of family in 
the treatment is needed 
 
Drug use and problems that have impact on the family of HIV patients with IDU 
history should be addressed to reduce worry in the family
 
The high hope in the family should be maintained to ensure the support of the family 
to their sick relatives
Clinical Consideration
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chapter 8
Summary and general discussion 
Injecting drug users are fuelling the HIV epidemic in large parts of Indonesia and harm 
reduction has been implemented to prevent, control and treat HIV among drug users. 
Most of the intervention programs for reducing HIV transmission in Indonesia are based on 
data from industrialized countries and there may be a need to tailor these interventions to 
the socio-cultural context and specific conditions of Indonesia. The general aim of this thesis 
was to study the biopsychosocial characterization of people who use injecting drugs 
in relation with the implementation of harm reduction strategies in West Java Indonesia. 
The framework concept in this thesis is shown below: 
Figure 8.1. Framework of the thesis on people who inject drugs and HIV transmission in 
Indonesia: a biopsychosocial approach. Determinants, which include the interaction of 
genetics, environment, and personality factors, affect the vulnerability to have disorders. 
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Determinants Disorders Consequences
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Quality of life
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The most common disorders in people who inject drugs are substance use, psychiatric, and 
physical disorders. All of these comorbidities interact and are influenced by their treatments. 
The disorders and their treatments have consequences in the personality, environment, and 
the expression of the gene which at the end will determine the quality of life.
We implemented this framework concept by reviewing the existing theories of the aetiology 
of addiction and the interaction of addiction, physical comorbidity, and psychiatric comorbi-
dity from a biopsychosocial point of view. We also examined the socio-demographic charac-
teristics, the risk behaviours, co-occurring disorders, access to drug treatment, quality of life 
of people who inject drugs in Indonesia, and factors which influence family involvement in 
HIV care. This final chapter represents the key findings from our research, recommendations, 
and the strength and limitations of the study.
Key findings
Addiction is a multidimensional disorder so individualized interventions are need
The concept of injecting drug use is often overly simplified, with little attention for the 
underlying complex problems of drug addiction. Too often, service providers and policy ma-
kers propagate needle exchange programs and/or pharmacotherapy as the ‘one fits all’ harm 
reduction strategy without sufficient attention to the variety of main problems of addicted 
patients. 
Chapter 2 provides a review on the aetiology of addiction, including genetics, drug induced 
changes in the brain, and environmental factors; risk behaviours; co-occurring physical, psy-
chiatric, and social problems; and prevention and treatment. The vulnerability for addiction 
is a result of the combination of different biopsychosocial factors that are unique for every 
person. The results of our studies presented in chapter 3, 4, and 5, support this conclusion. 
Our studies show that people in Indonesia who inject drug can not be considered as a single 
entity. There are former and current injecting drug use presenting different physical, psycho-
logical, and addiction co-occurring problems. Proper assessment is needed to diagnose indi-
vidual problems and develop tailor-made treatment recommendations.1 Because problems of 
IDU are mostly complex, we propose the use of a biopsychosocial approach.
High risk behaviour among former and current injecting drug users
It has been reported in literature that a high number of injecting drug users (IDU) change 
from injection to non-injection drug administration2, 3. We performed therefore a study 
(chapter 3) in Bandung, West Java whereby people who inject drugs were recruited by 
respondent driven sampling and found that ninety-two out of 210 (44%) were self reported 
former IDU. HIV-infection was high among former (66%) and current (60%) IDU. 
In addition, we found that none of them was free from substance use in the 30 days previous 
to the interview and that excessive use of alcohol was significantly associated with sexual risk 
behaviour. Both former and current IDU were commonly having sexual risk behaviour as 
well as tattoos or piercings, while 13% of former IDU were still exposed to contaminated 
injecting equipment. Risk behaviour had no association with better knowledge of HIV 
transmission or ever accessing drug treatment program (chapter 4 and 5). 
Former IDU may contribute significantly to the development of the HIV epidemic in 
Indonesia because HIV is highly prevalent in this group while sexual risk behaviour is very 
common. Furthermore, compared with current IDU, former IDU also have more sexual 
contact with general population.  HIV prevention programs should therefore also target 
former IDU, emphasizing the need for testing and treatment of HIV and other blood born 
infections, as well as addressing sexual and other risk behaviour. 
Methadone maintenance and needle syringe programs, which have proven very effective in 
reducing injecting risk behaviour4-6, may not be indicated or even harmful for ex- or sporadic 
injectors. Former IDU might benefit more from relapse prevention or other psychosocial 
interventions addressing their current drug use and other non-injecting risk behaviour. 
Limitation of access to drug treatment facilities
Globally, IDU often have poor access to substance abuse treatment (SAT) facilities since 
drug use is illegal and highly stigmatized7. Our studies in people who inject drug whereby 
those who had not and had ever accessed SAT (chapter 4) showed that those who had ever 
accessed SAT had more severe drug problems and better education compared to those who 
had never accessed SAT. 
The comparison of people who inject drug and were in methadone treatment with those who 
never accessed drug treatment (chapter 5) showed that those who never accessed treatment 
were younger compared to methadone patients (28 ±4 vs. 30 ±4 years), had a shorter history 
of injecting drug use, lower education, lower level of occupation and income. However, the 
perceived problems and treatment needs related to physical, psychiatric, and drug abuse 
conditions among those groups were comparable.
Furthermore, injecting drug users accessing drug treatment at some point but not in the last 
30 days, showed the most severe problems and the highest treatment needs, especially related 
to drug and psychiatric problems. In conclusion, substance abuse treatment is mostly 
accessed by injecting drug users with severe (drug) problem and by those with higher soci-
oeconomic status. These findings are in line with other studies that found that most IDU 
accessed treatment only when they were in emergency or crisis8, 9. In addition, reports from 
other low income countries provide substantial evidence that the reduction of the treatment 
cost improves access and adherence, and in turn, the success of public health programs 10-13. 
Similar conclusions are made within the IMPACT program but will be extensively reported 
elsewhere.
 
Substitution treatment and traditional based treatment are the most commonly used drug 
treatment facilities but only substitution treatment is associated with access to HIV care
Antiretroviral treatment does not only dramatically improve life expectancy and quality 
of life but has been proven to reduce the transmission of HIV as well14, 15. From the 2010 
UNAIDS report, it has shown that the coverage of antiretroviral treatment is around 30% in 
East, South, and South-East Asia. Injecting drug users constitute a substantial proportion of 
the total population of HIV infected subjects and substance abuse treatment (SAT) can be 
used therefore as an entry-point for HIV care. 
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We performed a study (chapter 4) and recruited people who inject drugs by respondent-
driven sampling in an urban setting in Java, Indonesia and found that 77% of 210 IDU had 
accessed SAT at least once (chapter 4). IDU who had accessed SAT had better knowledge 
on HIV, better access to HIV testing and treatment, HCV testing, and psychiatric treat-
ment. The most widely used SAT were opioid substitution (44%) and traditional/faith-based 
treatment (43%). Accessing substitution treatment and residential drug-free treatment was 
significantly associated with HIV testing, whereas accessing substitution treatment and other 
medical services was significantly associated with HIV care. 
People who inject drug and their families often hide drug-related problems and avoid the 
regular SAT facilities, as this may further increase the social ostracism faced by the families. 
Because of unawareness or absence of easily accessible treatment facilities, particularly in 
resource-limited countries, people who inject drugs and family members may prefer to ap-
proach alternative service providers such as faith healers16. Access to these frequently utilized 
traditional/ faith based treatment do however results infrequently to HIV testing or HIV 
treatment. More collaboration between drug-intervention programs, HIV testing and care 
facilities, and traditional/faith-based treatment organisations is needed so that common goals 
are identified and HIV testing and care are offered to those in need for it17. 
People who inject drug often face multiple concurrent disorders
People who inject drug and who have physical, psychiatric, and substance use disorder co-
morbidities are likely to engage in high-risk behaviours, and when untreated, continue to 
fuel the HIV epidemic18. Some studies have also shown that physical19, psychiatric20, 21, and 
drug abuse co-occurring disorders22, 23 reduce the effectiveness of the methadone maintenance 
treatment (MMT). 
Chapters 5 describes the prevalence of physical, psychiatric, and drug abuse co-occurring 
disorders among MMT patients in Bandung, Indonesia and determine the association 
between the severity of the co-occurring disorders and the quality of life. The most frequent 
co-occurring disorders in 112 MMT patients were hepatitis C (92%), HIV (77%), benzo-
diazepine abuse (56%), and anxiety disorders (32%). Patients in MMT had one (26%), two 
(47%) or three (27%) co-occurring disorders. Severity of psychiatric and physical problems 
was associated with lower quality of life. 
One hundred fifty four people who inject drug but who were not enrolled in a MMT 
program were recruited by respondent driven sampling for comparison and showed similar 
co-occurring problems. It is concluded that comprehensive and preferably integrated treat-
ment facilities that can also address the common co-occurring disorders need to be formed 
in Indonesia to anchor significant impacts on reduction of risk behaviour, improve MMT 
effectiveness and the quality of life of people who inject drugs.
Psychiatric comorbidity in people who inject drugs has a multidimensional etiology
Psychiatric comorbidity in IDU is not only associated with poorer quality of life21, 24 but may 
influence substance abuse treatment outcome as well. Strikingly, psychiatric problems are 
rarely addressed while patients participate in substance abuse treatment programs25. 
A review in chapter 6 shows that psychiatric disorders can occur before or during drug abuse 
100
and are also associated with substance abuse and physical comorbidity and its treatments. 
Several psychiatric factors may increase the vulnerability to become a drug user. Frequently 
found are personality traits, such as negative temperament and disinhibition26; impulsivity, 
sensation-seeking, novelty seeking, reward-sensitivity25; antisocial personality27; and child-
hood trauma, including physical, sexual, and emotional abuse/neglect28. 
The abuse of several drugs (poly-drug use) is a common pattern among IDU and increases 
the vulnerability to suffer from psychiatric disorders23, 29. HIV infection may increase the 
vulnerability for having a psychiatric disorder via the effect of HIV on the central nervous 
system30, psychosocial factors31, and/or antiretroviral-related adverse effects such as cognitive 
impairment, depression, anxiety, and psychosis32, 33. Treatment for addictive and psychiatric 
disorders leads to an increase of adherence to medical regimes, thus reducing the risk of the 
early emergence of treatment-resistant HIV and tuberculosis18, 34, 35.
Research on psychiatric co-morbidities in people who inject drugs 
in Asia and Africa is needed 
The prevalence of HIV in IDU in many countries is stable or decreasing. However, in most 
of the low and middle income countries in Asia and Africa, the prevalence still increases sig-
nificantly36. IDU with psychiatric comorbidity are likely to engage in high-risk behaviour18. 
Little is known about psychiatric problems in IDU in Asia and Africa10, 36-39. 
Chapter 6 provides a review about psychiatric co-morbidities in IDU in Asia and Africa. The 
numbers of studies are scarce but we found that the prevalence of psychiatric co-morbidities 
is high and comparable with the prevalence in industrialized countries. Most of the scientific 
papers that were published in the last two years were focusing on physical co-morbidities, 
risk behaviours, and health policies. More research is needed in Asia and Africa addressing 
psychiatric problems in IDU using optimal methodology, such as large sample size, validated 
questionnaires, and standardized diagnosis. Finally, evidence-based interventions addressing 
psychiatric comorbidity in IDU are generally very limited and should be studied more in 
detail. 
The hope of family for the future of HIV patients is high although they 
perceive more worry about their sick relative
Involvement and support from the family are strongly associated with better physical and 
psychological adjustments in patients live with HIV40, 41. The intention to access substance 
abuse treatment in people who use drugs is also influenced by their family42. Characteristics 
that are most influential in family involvement include satisfaction in the care given 
by health care providers, perceptions of the problems, and believing that problems can
be changed43. 
In chapter 7 we explore the satisfaction in receiving care from health care providers, per-
ceived problems, and hope of family members in the care of HIV-infected patients with and 
without a history of injecting drug use compared to patients treated for tuberculosis. Family 
members (n = 123) were recruited through purposive sampling: 36 family members of HIV-
infected IDU patients; 43 family members of HIV-infected patients without IDU history; 
and 44 family members of patients with tuberculosis. 
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Compared to family members of patients with tuberculosis, the family of HIV-infected pa-
tients showed more satisfaction in the care given by health care providers especially regarding 
the information that was provided. Family members of HIV-infected IDU patients perceived 
more problems concerning their sick relatives than the two other groups. The problems were 
related to the harmful impact of smoking/ alcohol/ substance use on their sick relatives as 
well as on the family. Integration of HIV and substance abuse treatment programs has been 
proven to be more effective and may as such alleviate distress experienced by patients and 
their family members34, 35, 44. In addition, family-based interventions can support families to 
develop skills for confronting rather than avoiding problems45, 46. 
We found that hope for the future of sick relatives was generally high and comparable in the 
three groups. All of the HIV-infected patients were treated with ART and some of them par-
ticipated in MMT program. The effectiveness of both treatments is well recognised6, 47, 48. In 
conclusion, family members of HIV-infected IDUs experience many problems and attention 
of health care providers for these problems may strengthen family involvement and support 
of treatment of IDUs.
Strengths and limitations of the study
The study was conducted as part of the multidisciplinary IMPACT program. The results of 
the present studies in combination with the results from other IMPACT researchers will 
provide a comprehensive picture of the status of the prevention, control and treatment of 
HIV among IDU in West Java, Indonesia. The socio-demographic characteristics of people 
who inject drugs in our study are comparable with other studies from Indonesia44, 49-56. 
This indicates the representativeness of our samples.
Our studies have several important limitations. First, no meta-analysis or systematic review 
was used in the review article. Secondly, people who inject drug and their family are often 
difficult to reach, questioning how representative the samples are. Respondent driven sample 
was used (chapter 3 and chapter 4) to minimize this risk 57, 58. Still, some IDU who are not in 
the social networks with these participants can not be recruited through respondent driven 
sampling59. In the methadone clinic (chapter 5), data were obtained from 60% of the popu-
lation and not all of the participating patients completed the whole interview and examina-
tion. In chapter 7, purposive sampling was used in a single, urban clinic with a rather small 
sample size. Third, the generalization of the results to the overall Indonesia situation should 
be carefully considered, since substance abuse treatment facilities are mostly limited to the 
big cities. In 2010, only 49 opioid substitution treatment sites were present in Indonesia60, 
while it was estimated that there were more than 219,000 IDU61. Fourth, all of the studies 
are cross sectional studies. With this method it is not possible to find a causal relation.
Recommendation
Based on the result of the studies described in this thesis and taking the strengths and limita-
tions into account we would like to make some recommendations to policy makers, clinici-
ans, education experts, and recommendations for future research.
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Policy makers
Widen the scope from opioid substitution treatment towards addiction treatment
As has been the case in many countries, it was the HIV epidemic that first drew attention 
to changes in drug-taking practices in Indonesia62. A recent report from the national AIDS 
Committee shows that the trend of HIV transmission in Indonesia has shifted from injecting 
drug use to heterosexual transmission and mother to child transmission. In 2006, 52% of the 
patients acquired HIV-infection through use of unsterile needles while this figure is redu-
ced to 16% in 2011. Question is however how former IDU with sexual risk behaviour are 
categorized in 2011.
 
A very positive development is however that the estimated number of people who inject 
drugs in Indonesia is also decreasing: in 2006 the reported number of IDU was 219,000 
compared to 106,000 in 200963. Reduction of the programs provided for IDU by NGO will 
have consequences in increasing again the contribution of IDU in HIV transmission.
 
On the contrary with the number of IDU, the number of drug users in Indonesia is increa-
sing from 2.2 percent (4 million) in 2010 to 2.8 percent (5 million)64. This apparent contra-
diction is explained by the change from the route of administration of the drugs commonly 
used: mostly from injection to non-injection drug use but also vice versa2, 3. In addition the 
type of drug will also influence the route of administration and/or sexual risk behaviour. 
In chapter 2, it is shown that neither current IDU nor former IDU are abstinence from 
drugs. The use of amphetamine type stimulants (ATS) is increasing in Asia in recent 
years36, 65-67 and the use of ATS, heroin, or alcohol is indeed associated with increased in-
jecting or/and sexual risk behaviour65-70. Sexual risk behaviour may form the bridge between 
IDU and the general community. Many studies have shown that the prevalence of psychiatric 
disorders and drug use in people who conduct sexual risk behaviour is high and the use of 
mood elevating drugs such as SSRI may reduce the sexual risk behaviour71. It is important to 
care for these patients, not only because of their problems but also because they may be play 
a key role in the spreading of HIV. The new regulation by Indonesian government in 2011 
(Peraturan Pemerintah no 25 tahun 2011) states that narcotic drug users or their family 
should attend to selected treatment facilities appointed by the government. This regulation 
can be seen as an opportunity to provide substance abuse treatment but opens possibilities to 
simultaneously provide other treatment programs as well.
Provide comprehensive treatment for complex comorbidity
Most of the people who inject drugs suffer from physical, psychiatric, and drug use co-
occurring disorders. The HCV & HIV prevalence among IDU in Indonesia (chapter 2 and 
4) were among the highest compared to other countries 49, 72-75. The current and life time 
psychiatric problems and symptoms were high and comparable with other studies21, 72, 76-79. 
Most of people who inject dugs in Indonesia use heroin but the poly-drug use is common, 
especially in combination with benzodiazepine. This is in line with other studies32, 80-83. The 
overall coverage of the intervention programs is still low (84) and the link with care for co-
occurring problems is limited, although such link will increase the effectiveness and higher 
utilization of services6. 
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A major challenge is therefore to build alliances and networks which will allow the 
pooling of resources and collaboration between service providers and/or health care workers.  
For instance, presently services for HIV/AIDS, substance abuse treatment and psychiatric 
treatments are provided by different health care workers using different facilities. Providing 
comprehensive and integrated services in specialized treatment centres will greatly improve 
effectiveness since people who inject drug often do not adhere to referral advices85. Several 
approaches can be developed, such as training of staff so that they are able to deal with the 
various problems. If more complicated problems present, experts who visit facility on a 
regular basis might be consulted. Collaboration and agreement with several service providers, 
case discussion with different experts in different fields and other approaches will add to 
maximize the effectiveness of a comprehensive, multidisciplinary teamprogram.
Bringing services to the community level
Most of the budget for drug addiction and HIV programs in Indonesia come from external 
funding86. In order to make the programs sustainable, cost-effective programs are needed. 
One of the opportunities is to bring the services into a community level. Scaling up the com-
munity clinics for voluntary consultation and testing of HIV will improve access, promote 
earlier detection and treatment. Access for IDU still has to be improved since most of IDU 
who come to the drug treatment (chapter 5) and to HIV clinic in Bandung87 tend to have 
more advanced disease
Bringing services to the community level could reduce the burden of the hospital clinic to 
orient itself more towards the treatment of AIDS patients88. At present, HIV prevalence rates 
in the general community are however very low and we advice therefore to limit HIV services 
to accredited hospitals, primary health centres, and clinics with specialized health care wor-
kers. However, on the contrary, the prevalence of legal and illegal drug use in the general po-
pulation is quite high. Therefore, in 2011, the president instructs to improve the prevention, 
treatment, and rehabilitation for people who use drugs89. Drug use screening process which is 
implemented in integration with daily primary health services will lead to early detection and 
intervention. This can prevent the occasional drug users to become addicts. 
Increase the involvement of the family and spiritual based and non governmental 
organizations in treatment programs
Indonesia, like other Asian countries, is a collectivist society. People are integrated from birth 
onward into strong, cohesive in-groups, often extended families90. Involvement and support 
from the family are strongly associated with better physical and psychological adjustment in 
people live with HIV40, 41. Furthermore, existing health care services seem fragmented and 
lack a continuum of care for people who inject drugs. Health care providers are challenged to 
strengthen the role of family caregivers and other community services to work collaboratively 
in addressing HIV related prevention and care activities. Training and knowledge dissemina-
tion through interactive dialogues are key elements to develop effective models of commu-
nity health based care for people live with HIV91. 
Furthermore, most people in Indonesia are religious92. Beliefs and practices associated with 
religious/ spirituality are generally positively related to greater well-being, hope, optimism, 
purpose and meaning, adaptation to and coping with bereavement, and social support93. 
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Many families bring their relatives with drug or moral problems to spiritual/ traditional faith 
based treatment facilities. Spiritual leaders or people providing spiritual/ faith based  
treatment may however be insufficiently informed about medical problems such as blood 
borne infections like HIV and hepatitis B/C. Communication and training of providers of 
spiritual/ traditional faith based treatment services may increase access to HIV care. In ad-
dition, faith based organizations might contribute to daily care for HIV-infected patients. 
Faith based organizations are actually a type of NGO that basically operate on the basis of 
religious missions. In Indonesia, faith based organizations usually have a large number of fol-
lowers and/or members capable of  dissemination of knowledge throughout the country91, so 
influencing them to promote HIV testing and treatment could have a large effect.
Destigmatize people who use drugs and people with HIV
People who use drugs and have HIV are frequently stigmatized as they are associated with 
immoral behaviour45, 94. The stigma and discrimination is a common phenomenon not only 
at individual level, but also at the familial and institutional levels95, 96. Stigma and discrimi-
nation come on top of the stress already caused by the disease itself45. High stigmatization 
leads to less help-seeking and serves as a major barrier to treatment97. Television programs 
and advertisements are watched by most people in Indonesia and is a tool to disseminate 
information98, 99. It can be used improve the knowledge of the general public regarding the 
addiction and HIV and how to treat these conditions so that stigmatization is reduced while 
access to care is increased. 
The use of uniform variables in surveillances evaluating harm reduction programs
A recent review concluded that the calculation of the coverage of the HR programs was 
limited by inconsistent and imperfect data estimating the size of the IDU population84. 
For example, the term ‘injecting drug users’ tends to be used without a succinct definition, 
without specifying current or former drug use, frequency, duration, type of injected drug(s), 
context (e.g. imprisonment), and often without information on somatic, psychiatric and 
psycho-social problems etc. 
Confusing is also the term “coverage of opioid substitution treatment”. It is often not clear 
whether methadone maintenance treatment or buprenorphine or both are being evaluated. 
Is HIV treatment given to those that need it? The characterisation of the study population 
is also not always clear: inclusion of those still in care or those that were ever enrolled in the 
program. Standardisation of terms, conditions and time frames is a prerequisite for proper 
evaluation of intervention programs. 
Clinicians
Physical comorbidity
People who inject drugs may suffer from  several physical disorders at the same time, 
including blood born infections such as HIV and hepatitis B/C, skin abscesses, sepsis with 
or without endocarditis, drug toxicities due to drug-drug interactions or poly-pharmacy 
etc18. When properly prescribed and with optimal adherence, antiretroviral therapy has been 
shown to improve dramatically the prognosis of HIV infection and many of its comorbidi-
ties, including tuberculosis, viral hepatitis, and renal and cardiovascular disease18. 
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Many Indonesian clinicians are however still reluctant to prescribe HIV treatment to people 
who inject drugs. Some of them tell the patients that addiction treatment needs to be discon-
tinued before anti retroviral treatment can be initiated. Simultaneous clinical management of 
multiple comorbidities in HIV-infected drug users might result in complex pharmacokinetic 
drug interactions that must be adequately addressed. Moreover, interventions to improve 
treatment adherence by addressing psychiatric problems, drug use, and social support are 
needed18.
Psychiatric comorbidity
Assessment and treatment should be conducted carefully because psychiatric problems can be 
present independently or as a result of HIV, HCV, substance abuse, other comorbidity and 
their treatments. Interventions to increase referral and uptake from/ to mental treatment are 
needed. The psychiatric treatment is still underutilized, especially because of the stigmatiza-
tion of people with psychiatric problems100, 101.
Substance related comorbidity
Several psychiatric factors may increase the vulnerability to become a drug user. Frequently 
found are personality traits26, impulsivity, sensation-seeking, novelty seeking, reward-sensi-
tivity25, antisocial personality27, and childhood trauma28. These psychiatric factors influence 
treatment outcome and are rarely addressed in substance abuse treatment programs25. Drug 
use, especially poly drug use increases the vulnerability to psychiatric disorders23, 29. Beside 
substitution treatment with proven effectiveness49, 102, 103, psychosocial support should also 
be considered. Given the long-term social, emotional, and cognitive impairments associated 
with substance use, these effects are noteworthy and comparable to other impairments com-
monly found in psychiatry104.
Using a biopsychosocial approach to support a patient
A biopsychosocial model not only emphasizes the need to respect the unique circumstances 
and perspectives of each client, but it also supports the view of individuals as powerful agents 
for self-determination. Rather than having the view that individual outcomes are largely the 
complex product of external determinants, the biopsychosocial model appreciates the signi-
ficant role played by individual qualities of resiliency and personal agency. As a best practices 
model, biopsychosocial accommodates and supports non-linear systems theories which place 
individuals and behaviours within contexts of biological, family and socio-cultural systems, 
and which view individuals as active participants in on-going system maintenance and 
change dynamics 105. Management of chronic disease like addiction and HIV also requires 
an active role in decision making, problem solving, and implementation of a personalized 
treatment plan to achieve better health outcomes106. 
Education and training
Addiction medicine for addiction professionals
In Indonesia, addiction medicine is not yet recognized as a medical (sub)specialty and there 
is neither an addiction medicine curriculum nor formal addiction medicine training availa-
ble. Currently there are about 200 professionals working in addiction care, of which, accor-
ding to recent research, about 17% never received addiction training. Most of these addicti-
on care professionals only received a short training in opioid substitution therapy, consisting 
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of a few days training in methadone and buprenorphine prescription and dispensing. 
Only 30% of all Indonesian addiction professionals consider addiction as a brain disease, 
whereas about 70% consider faith-based and long-term residential treatments to be the most 
appropriate treatment modalities107. The lack of proper knowledge among professionals 
working with HIV-infected people who inject drugs, in combination with stigmatization, 
influence their attitude in the care for patients and limits the quality level of psychiatric and 
medical interventions to these groups91. Therefore, training modules for specialized health 
care workers need to be developed and given. These modules should not only include addic-
tion medicine but has blood borne infections as learning objective as well. Special certificati-
on from the ministry of health should be obtained to be able to work in addiction treatment. 
Each institution that has been appointed by ministry of health as a treatment centre should 
employ one doctor who possesses such certificate.
Addiction medicine as curriculum in medical school
Topics regarding addiction and HIV should be included in the curriculum of medical school. 
The curriculum should subsequently cover the psychological, behavioural, and immunolo-
gical aspects of these conditions. This training does not only supplies the basic knowledge 
that is needed to understand addiction and HIV but will also reduce stigma and provides the 
insight of a comprehensive and integrated approach to medical problems.
Addiction medicine as curriculum in primary and secondary school
Drug use starts in Indonesia mostly at a very young age (14 years) compared to other 
countries such as Australia, Canada, China, Iran, Israel, Netherland, Poland, Thailand, 
and USA20, 21, 23, 49, 74. Education to prevent drug use should therefore be provided in primary 
and secondary schools. 
In Indonesia sex and drug issues are often regarded as sensitive and life skills education was 
embraced a decade ago to prevent sexual intercourse and drug related risk behaviour in 
a culturally appropriate way. Life skills are defined as the ability of individuals to employ 
adaptive and positive behaviour to deal effectively with demands and challenges of daily life. 
The aim of life skills education is to strengthen abilities that help promote mental well-being 
and competence in young people as they face the realities of life108. Information regarding ad-
diction and reproductive health should be given in an appropriate way to increase awareness 
and understanding of students however not increasing their curiosity to try drugs or sexual 
intercourse.
Recommendation for future research
The findings in this thesis answer only a part of the complex problems in people who inject 
drugs in relation with HIV transmission. More information regarding estimation of the 
number of people who inject drugs in Indonesia is required to adjust the number of treat-
ment centres. Surveillance using the same variable criteria to understand the problems and 
evaluate the current intervention is needed to be done regularly so the intervention programs 
can be adjusted to the current situation. More studies regarding factors associate with the risk 
behaviour, such as drug use, psychiatric co-morbidities, in other most at risk groups for HIV 
transmission (commercial sex workers and men who have sex with men) are also important 
to develop more suitable intervention programs to prevent further HIV transmission. 
107
The high co-morbidities in people who inject drugs (chapter 2, 4, 5) indicate the needs to 
explore comorbidities.in all HIV patients.
All of the studies in this thesis are cross-sectional studies which are very important for asses-
sing the problems and to understand the characteristics of the target population. The next 
step is to translate these findings into action, for example for revising and developing the 
intervention programs. Below are several action researches that should be prioritized. 
The lack of information and services is mainly in psychiatric problems and their treatments 
(chapter 4, 5, and 6). Randomized control trial to find the effective psychiatric intervention 
(cognitive behavioural therapy (CBT), psychotropic drugs, and combination of CBT and 
psychotropic drugs) for HIV patients with ad without injecting drugs history can be done 
using adherence to HIV treatment, immunological response, drug use, risk behaviour, and 
quality of life as parameters.
The prevalence of physical, psychiatric, and substance use disorders in people who inject 
drugs is high (chapter 2, 3, 4, 5, 6) and access to treatment is still limited. Cohort for 
comparing community based service and hospital based service is needed to find the most ef-
fective approach. Baseline and follow-up data on physical, psychiatric, and drug use severity, 
quality of life, laboratory results (Hb, CD4), referral uptake, and adherence to treatments 
can be used as determinants.
Traditional/ faith based treatment/ organizations and social supports in Indonesian society 
are the strength which has not been involved adequately in the addiction and HIV inter-
vention programs (chapter 4 and 7). Information regarding HIV transmission, methods of 
preventing HIV infection, HIV treatments, factors that can increase vulnerability to use 
drugs, and addiction treatment is provided to religious leaders and their assistants, who in 
turn educated their communities during home visits and at religious gatherings. Knowledge, 
attitude, and practise regarding HIV and addiction treatment of religious leaders before and 
after training can be used as a direct parameter. The comparison of access to HIV and drug 
treatments, risk behaviour, and HIV prevalence in community between baseline data and 
follow-up data few years after the intervention can determine the successful of the interven-
tion programs.
The change from injecting to non-injecting drug use is common so the proportion of former 
injecting drug users among IDU is significant (chapter 3). The addiction severity is influen-
ced by many factors (chapter 2 and 6). Therefore, selection of appropriate addiction treat-
ment which is beneficial for patients and in public health point of view is crucial. Methadone 
treatment should only be provided to those who need it so it is not bring further harm. 
Good knowledge and skills in medical staffs who work in addiction field can reduce the inap-
propriate addiction treatment. Level of knowledge and skills in handling addiction patients 
before and after training can be used to determine the most effective addiction training 
programs.
The studies above can be done in the comprehensive way. A project like IMPACT gives 
an opportunity to study problems from different points of view, in different settings, and 
using interdisciplinary expertise. The result from the studies can be used as a background 
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for other studies. By working together, a comprehensive understanding of the problems are 
formulated. Such kind of project also facilitates learning of all program staff by grooming 
a positive and safe learning environment (we learn from mistakes and successes) and opens 
new horizons with new ideas. Using a learning organization approach, emphasizing common 
goals, applying multi-disciplinary learning, evidence-based interventions, and strengthening 
individual and organizational capacity proved to be successful109. Applying this approach also 
proved quite a challenge. Understanding the cultural differences and organizational manage-
ment are the important key success of future programs.
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Summary and general discussion in Indonesian
Ringkasan dan pembahasan umum
Pengguna narkoba suntik (penasun) menyebabkan epidemi HIV di sebagian besar daerah di 
Indonesia dan penanggulangan dampak buruk telah diimplementasikan untuk mencegah, 
mengontrol, dan mengobati HIV di kalangan pengguna narkoba suntik. Sebagian besar 
program intervensi untuk  menurunkan transmisi HIV di Indonesia didasarkan pada data 
dari negara-negara maju dan mungkin dibutuhkan suatu pengembangan program intervensi 
yang sesuai dengan keadaan sosio-kultural dan kondisi yang spesifik di Indonesia.  Tujuan 
umum dari tesis ini adalah untuk mempelajari karakteristik biopsikososial dari penasun da-
lam hubungannya dengan implementasi strategi pengurangan dampak buruk di Jawa Barat, 
Indonesia. Bagan alir tentang konsep dalam tesis ini ditunjukkan pada gambar di bawah ini: 
Gambar 8.1. Bagan alir dari tesis tentang penasun dan transmisi HIV di Indonesia: sebuah 
pendekatan biopsikososial. Beberapa faktor penentu seperti faktor-faktor genetik, 
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lingkungan, dan kepribadian mempengaruhi kerentanan seseorang untuk mengalami adiksi. 
Gangguan yang paling umum terjadi pada penasun adalah penggunaan narkoba jenis 
lainnya, gangguan psikiatrik, dan fisik. Semua komorbiditas ini berinteraksi dan dipengaruhi 
juga oleh terapinnya. Sebaliknya, gangguan dan terapinya juga mempengaruhi kepribadian, 
lingkungan, dan ekpresi gen yang pada akhirnya keseluruhan interaksi akan menentukan 
kualitas hidup. 
Kami mengimplementasikan konsep bagan alir di atas dengan mengulas teori-teori yang 
telah ada tentang penyebab adiksi dan interaksi adiksi, komorbiditas fisik serta psikiatris dari 
sudut pandang biopsikososial. Kami juga melakukan penelitian tentang karakteristik sosio-
demografik, perilaku berisiko, komorbiditas, akses terhadap layanan adiksi, kualitas hidup 
penasun di Indonesia, dan faktor-faktor yang mempengaruhi keterlibatan keluarga dalam 
penanganan HIV. Pada akhir bab ini akan dipresentasikan temuan utama dari penelitian 
kami, rekomendasi, dan kelebihan serta kekurangan dari penelitian tersebut.
Temuan utama
Adiksi merupakan  gangguan multidimensi sehingga intervensi individual diperlukan
Konsep tentang penasun seringkali terlalu disederhanakan, dengan sedikitnya perhatian pada 
masalah-masalah kompleks yang mendasari penggunaan NAPZA. Seringkali penyedia jasa la-
yanan dan pengambil kebijakan mempromosikan layanan pertukaran jarum suntik dan/ atau 
terapi obat sebagai strategi pengurangan dampak buruk yang sesuai untuk semua penasun 
tanpa memberi perhatian yang cukup pada berbagai masalah utama lainnya dari penasun. 
Bab 2 memberikan sebuah ulasan tentang penyebab adiksi, seperti genetik, perubahan pada 
otak akibat penggunaan narkoba, dan faktor-faktor lingkungan; perilaku berisiko; masalah 
fisik, psikiatrik, dan sosial yang terjadi bersamaan; pencegahan; dan terapinya. Kerentanan 
seseorang untuk mengalami adiksi adalah hasil dari kombinasi berbagai faktor biopsikososial 
yang unik untuk setiap orang. Hasil dari penelitian-penelitian yang kami tampilkan di bab 
3, 4, dan 5 menunjang kesimpulan ini. Penelitian kami menunjukkan bahwa mereka yang 
menyuntik narkoba di Indonesia tidak dapat dianggap sebagai satu kesatuan tunggal. Mereka 
terdiri dari mantan penasun dan penasun aktif yang memiliki masalah fisik, psikologis, dan 
adiksi yang berbeda-beda. Penilaian yang tepat diperlukan untuk mendiagnosis masalah 
individual dan mengembangkan rekomendasi terapi individual yang sesuai.1 Karena masalah 
pada penasun pada umumnya sangat kompleks, kami mengajukan penggunaan penaganan 
dengan pendekatan biopsikososial.
Perilaku berisiko tinggi di kalangan mantan penasun dan penasun aktif
Telah dilaporkan di berbagai literatur bahwa sejumlah besar penasun berubah dari pemakai 
narkoba menggunakan jarum suntik ke pengguna narkoba tanpa memakai jarum suntik2, 3. 
Oleh karena itu, kami melakukan suatu penelitian (bab 3) di Bandung, Jawa Barat dimana 
penasun direkrut menggunakan metode respondent driven sampling dan ditemukan bahwa 
92 dari 210 (44%) melaporkan dirinya adalah mantan penasun. Prevalensi infeksi HIV 
tinggi di kalangan mantan penasun (66%) and penasun aktif (60%).
Sebagai tambahan, kami menemukan bahwa tidak ada dari mereka terbebas dari 
penggunaan narkoba dalam 30 hari terakhir sebelum wawancara dan bahwa penggunaan 
alkohol secara berlebihan berhubungan erat dengan perilaku seksual berisiko. Baik mantan 
penasun maupun penasun aktif pada umumnya memiliki perilaku seksual berisiko dan juga 
penggunaan tato atau tindik yang berisiko, sementara 13% dari mantan penasun masih ter-
papar pada peralatan menyuntik yang terkontaminasi. Perilaku berisiko tidak berhubungan 
dengan pengetahuan tentang transmisi HIV yang lebih baik atau pernah tidaknya mengakses 
program terapi adiksi (bab 4 dan 5). 
Mantan penasun dapat berkontribusi secara nyata pada penyebaran epidemi HIV di Indo-
nesia karena prevalensi HIV pada kelompok ini tinggi sementara perilaku seksual berisiko 
di kelompok ini juga umum. Lebih lanjut, dibandingkan dengan penasun aktif, mantan 
penasun memiliki lebih banyak kontak seksual dengan populasi umum. Oleh karena itu, 
program pencegahan HIV sebaiknya juga menjadikan mantan penasun sebagai sasaran pro-
gram, dengan penekanan pada pengetesan dan terapi HIV dan infeksi menular melalui darah 
lainnya dan juga penekanan pada masalah perilaku seksual berisiko dan perilaku berisiko 
lainnya.   
Program terapi metadon dan pertukaran jarum suntik, yang telah terbukti sangat efektif 
dalam menurunkan perilaku menyuntik berisiko4-6, dapat merupakan terapi yang tidak 
diindikasikan atau bahkan dapat membahayakan untuk mantan penasun atau penasun 
sporadis. Mantan penasun mungkin akan lebih mendapat keuntungan melalui dari program 
pencegahan kekambuhan atau intervensi psikososial lainnya, menekankan pada penggunaan 
narkoba saat ini dan perilaku berisiko non suntik lainnya. 
Keterbatasan untuk mengakses fasilitas terapi narkoba
Secara umum, penasun memiliki akses yang buruk ke tempat-tempat terapi narkoba karena 
penggunaan narkoba ilegal dan sangat distigmatisasi7. Penelitian kami pada penasun yang 
pernah mengakses dan tidak pernah mengakses terapi narkoba (bab 4) menunjukkan bahwa 
mereka yang pernah mengakses terapi narkoba memiliki masalah narkoba yang lebih berat 
dan pengetahuan yang lebih baik dibandingkan dengan  mereka yang tidak pernah mengak-
ses layanan terapi narkoba. 
Perbandingan antara penasun yang sedang dalam terapi metadon dengan penasun yang tidak 
pernah mengakses terapi narkoba (bab 5) menunjukkan bahwa mereka yang tidak pernah 
mengakses terapi berusia lebih muda dibandingkan pasien metadon (28 ±4 vs. 30 ±4 tahun), 
memiliki masa penggunaan narkoba suntik yang lebih pendek, pendidikan yang lebih 
rendah, serta tingkat pekerjaan dan pendapatan yang lebih rendah. Walaupun demikian, per-
sepsi mereka tentang masalah dan kebutuhan terapi yang berhubungan dengan kondisi fisik, 
psikis, dan penyalahgunaan narkoba diantara kedua kelompok ini sebanding. 
Lebih lanjut, penasun yang pernah mengakses terapi narkoba  tapi tidak dalam 30 hari 
terakhir, memiliki masalah yang terberat dan kebutuhan terapi yang tertinggi, terutama 
dalam hubungannya dengan masalah psikiatri dan narkoba. Kesimpulannya, terapi narkoba 
sebagian besar hanya diakses oleh penasun dengan masalah narkoba yang berat dan mereka 
dengan kondisi sosio-ekonomi yang lebih tinggi. Hasil penelitian ini sejalan dengan peneliti-
an lainnya yang menunjukkan bahwa sebagian besar penasun hanya akan mengakses layanan 
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jika mereka berada dalam kondisi emergensi atau krisis (8, 9). Sebagai tambahan, laporan 
dari negara berpendapatan rendah lainnya menyediakan bukti yang penting bahwa penuru-
nan biaya terapi meningkatkan akses dan kepatuhan, yang pada gilirannya akan mensukses-
kan program kesehatan masyarakat (10-13). Kesimpulan yang serupa juga didapatkan dalam 
program IMPACT tetapi akan dilaporkan secara lebih mendalam di tempat lain.
 
Terapi subtitusi dan pengobatan tradisional merupakan fasilitas terapi narkoba yang 
paling banyak digunakan tetapi hanya terapi substitusi yang berhubungan dengan akses 
ke pelayanan HIV
Terapi antiretrovirus tidak hanya meningkatkan secara dramatis harapan hidup dan kualitas 
hidup tetapi juga telah terbukti menurunkan transmisi HIV14, 15. Dari laporan UNAIDS 
tahun 2010, dinyatakan bahwa cakupan terapi antiretrovirus adalah sekitar 30% di Asia 
Timur, Selatan, dan Tenggara. Penasun memiliki proporsi terbesar dari total subyek yang 
terinfeksi HIV dan oleh karena itu terapi narkoba dapat digunakan sebagai pintu masuk 
untuk terapi HIV. 
Kami melakukan sebuah penelitian (bab 4) dan melibatkan penasun dengan menggunakan 
metode respondent-driven sampling di daerah urban di Jawa, Indonesia dan menemukan 
bahwa 77% dari 210 penasun telah mengakses terapi narkoba sedikitnya satu kali (bab 4). 
Penasun yang mengakses terapi narkoba memiliki pengetahuan tentang HIV, akses pada tes 
dan terapi HIV, tes HCV, dan terapi psikiatri yang lebih baik. Terapi narkoba yang paling 
umum digunakan adalah terapi substitusi opioid (44%) dan pengobatan tradisional/ yang 
berbasis keagamaan (43%). Mengakses terapi substitusi dan terapi rehabilitasi tanpa obat 
berhubungan nyata dengan tes HIV sedangkan mengakses terapi substitusi dan pelayanan 
medis lainnya berhubungan erat dengan pelayanan HIV.
Penasun dan keluarganya seringkali menyembunyikan masalah penggunaan narkoba dan 
menghindari terapi narkoba umum karena kemudian akan meningkatkan pengasingan sosial 
yang harus dihadapi keluarga. Akibat ketidaktahuan atau tidak adanya fasilitas terapi yang 
mudah diakses, khususnya di negara-negara dengan sumber daya yang terbatas, penasun dan 
anggota keluarganya lebih memilih untuk menggunakan terapi alternatif seperti dukun16. 
Akses ke pengobatan tradisional atau terapi berbasis agama yang sering digunakan ini tidak 
menunjukkan peningkatan akses ke tes dan terapi HIV. Kolaborasi yang lebih baik antara 
program intervensi narkoba dan fasilitas layanan tes serta perawatan HIV diperlukan sehing-
ga tujuan umum dapat diidentifikasi dan pelayanan tes serta perawatan HIV dapat diberikan 
kepada mereka yang membutuhkan17. 
Penasun seringkali menghadapi berbagai gangguan yang terjadi bersamaan
Penasun yang memiliki komorbiditas gangguan fisik, psikiatrik, dan penggunaan narkoba 
lebih rentan untuk terlibat dalam perilaku berisiko tinggi, dan jika tidak diterapi, akan terus 
menyebabkan peningkatan epidemi HIV18. Beberapa penelitian juga menunjukkan bahwa 
komorbiditas gangguan fisik19, psikiatri20, 21, dan gangguan penggunaan narkoba22, 23 menu-
runkan efektivitas program terapi rumatan metadon (PTRM).  
Bab 5 mendeskripsikan prevalensi prevalensi komorbiditas gangguan fisik, psikiatrik dan 
penggunaan narkoba pada pasien PTRM di Bandung, Indonesia dan menentukan hubungan 
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antara keparahan dari berbagai komorbiditas gangguan dan kualitas hidup. Komorbiditas 
yang paling sering pada 112 pasien PTRM adalah hepatitis C (92%), HIV (77%), penyalah-
gunaan benzodiazepin (56%), dan gangguan anxietas (32%). Pasien di PTRM yang memiliki 
satu jenis gangguan (26%), dua gangguan (47%), atau tiga gangguan (27%). Keparahan 
masalah psikiatri dan fisik berhubungan dengan kualitas hidup yang lebih rendah. 
Seratus lima puluh empat penasun yang tidak mengikuti program PTRM direkrut menggu-
nakan metode respondent driven sampling untuk pembanding dan menunjukkan gangguan 
komorbiditas yang serupa. Dapat disimpulkan bahwa fasilitas terapi terintegrasi dan kompre-
hensif yang juga dapat menangani berbagai komorbiditas penyakit yang sering perlu untuk 
dibentuk di Indonesia untuk memberikan dampak nyata dalam penurunan perilaku berisiko, 
meningkatkan efektivitas PTRM dan kualitas hidup penasun. 
Komorbiditas psikiatri pada penasun memiliki penyebab yang multidimensional
Komorbiditas psikiatri pada penasun tidak hanya berhubungan dengan kualitas hidup yang 
lebih rendah21, 24 tetapi juga dapat mempengaruhi hasil terapi narkoba. Yang mengejutkan 
adalah bahwa masalah psikiatri jarang sekali ditangani selama pasien berada di program 
terapi narkoba25.
Ulasan pada bab 6 menunjukkan bahwa gangguan psikiatri dapat terjadi sebelum atau 
selama pemakaian narkoba dan juga berhubungan dengan penggunaan narkoba dan komor-
biditas fisik dan pengobatannya. Beberapa faktor psikiatri dapat meningkatkan kerentanan 
seseorang untuk menjadi pengguna narkoba. Yang paling banyak ditemukan adalah gang-
guan kepribadian seperti temperamen negatif dan disinhibisi26; impulsivitas, mencari sensasi, 
mencari hal yang baru, sensitif terhadap penghargaan25; kepribadian antisosial27; dan trauma 
masa anak-anak, termasuk pengabaian/ pelecehan fisik, seksual, dan emosional28.
Penyalahgunaan beberapa jenis narkoba merupakan pola yang umum di kalangan penasun 
dan meningkatkan kerentanan untuk mengalami gangguan psikiatri23, 29. Infeksi HIV  
mungkin meningkatkan kerentanan untuk mengalami gangguan psikiatri lewat efek HIV 
pada susunan saraf pusat30, faktor-faktor psikososial31, dan/ atau efek samping berkaitan 
dengan penggunaan antiretrovirus seperti gangguan kognitif, depresi, anxietas (kecemasan), 
dan psikosis32, 33. Terapi untuk gangguan psikiatri dan adiksi mengarah pada peningkatan 
kepatuhan pasien terhadap pengobatan sehingga menurunkan risiko untuk terjadinya resis-
tensi terhadap terapi HIV dan  tuberkulosis18, 34, 35.
Penelitian tentang komorbiditas psikiatri pada penasun di Asia dan Afrika diperlukan
Prevalensi HIV di kalangan penasun di banyak Negara sudah stabil atau menurun. Walau-
pun demikian, di sebagian besar negara dengan pendapatan menengah dan rendah di Asia 
dan Africa, prevalemsinya masih meningkat secara nyata (36). Penasun dengan komorbiditas 
psikiatri lebih cenderung untuk terlibat dalam perilaku berisiko (18). Sangat sedikit hal yang 
telah diketahui mengenai penasun di Asia dan Afrika (10, 36-39). 
Bab 6 memberikan ulasan tentang komorbiditas psikiatri pada penasun di Asia dan Afrika. 
Jumlah penelitian yang ada masih jarang tetapi kami menemukan bahwa prevalensi komorbi-
ditas psikiatri tinggi dan sebanding dengan prevalensinya di negara industri maju. 
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Sebagian besar dari jurnal ilmiah yang dipublikasikan dalam dua tahun terakhir terfokus 
pada komorbiditas fisik, perilaku berisiko, dan kebijakan kesehatan. Penelitian di Asia dan 
Afrika mengenai masalah psikiatri pada penasun perlu ditingkatkan dan menggunakan meto-
dologi yang optimal seperti jumlah sampel yang cukup besar, penggunaan kuesioner terva-
lidasi, dan metode penegakan diagnosis yang terstandar. Akhirnya, intervensi berbasis bukti 
dalam penanganan komorbiditas psikiatri pada penasun sangat terbatas dan perlu diteliti 
secara lebih mendalam.
Harapan keluarga pada masa depan pasien HIV masih tinggi walaupun mereka mem-
persepsikan lebih banyak kekhwatiran terhadap kerabat mereka yang sakit tersebut
Keterlibatan dan dukungan dari keluarga sangat berhubungan dengan penyesuaian fisik dan 
psikologis yang lebih baik pada orang dengan HIV/AIDS (ODHA)40, 41. Keinginan untuk 
mengakses terapi narkoba pada penasun juga dipengaruhi oleh keluarga mereka42. Karakte-
ristik yang sangat menentukan keterlibatan keluarga adalah kepuasan pada perawatan yang 
diberikan oleh pemberi layanan kesehatan, persepsi terhadap masalah, dan kepercayaan 
bahwa masalah dapat diubah43.
Pada bab 7 kami mengeksplorasi kepuasan dalam menerima perawatan dari penyedia layanan 
kesehatan, masalah-masalah yang dipersepsikan, dan harapan dari keluarga pada pasien HIV 
yang sedang mendapatkan perawatan dengan atau tanpa riwayat menggunakan narkoba 
suntik dibandingkan dengan pasien yang sedang mendapatkan terapi tuberkulosis. Anggota 
keluarga (n = 123) direkrut dengan metode purposive sampling: 36 anggota keluarga pe-
nasun yang terinfeksi HIV; 43 anggota kelurga pasien HIV tanpa riwayat penggunaan jarum 
suntik; dan 44 anggota keluarga pasien dengan tuberkulosis. Dibandingkan dengan anggota 
keluarga pasien tuberkulosis, keluarga pasien HIV lebih puas terhadap layanan yang diberi-
kan oleh petugas kesehatan khususnya mengenai informasi yang diberikan. Anggota keluarga 
dari penasun yang terinfeksi HIV mempersepsikan lebih banyak masalah pada keluarga me-
reka yang sakit dibandingkan dengan dua kelompok lainnya. Masalah tersebut berhubungan 
dengan pengaruh berbahaya dari merokok/ minum alkohol/ menggunakan narkoba terhadap 
keluarga mereka yang sakit dan juga efeknya pada keluarga. Integrasi program terapi narkoba 
dan HIV telah terbukti lebih efektif dan dapat menghilangkan stres yang dialami oleh pasien 
dan anggota keluarga mereka34, 35, 44. Sebagai tambahan, intervensi berbasis keluarga dapat 
mendukung keluarga untuk mengembangkan keterampilan untuk menghadapi masalah dan 
bukan menghindarinya45, 46. 
Kami menemukan bahwa harapan terhadap masa depan dari keluarga mereka yang sedang 
sakit secara umum tinggi dan sebanding dalam tiga kelompok tersebut. Semua pasien yang 
terinfeksi HIV diterapi dengan ART dan beberapa dari mereka berpartisipasi dalam PTRM. 
Effektivitas dari kedua program terapi tersebut telah dikenal dengan baik6, 47, 48. Sebagai 
kesimpulan, anggota keluarga dari penasun yang terinfeksi HIV mengalami banyak masalah 
dan perhatian dari petugas kesehatan terhadap hal ini dapat memperkuat keterlibatan dan 
dukungan keluarga bagi anggota keluarganya yang sedang sakit. 
Kekuatan dan keterbatasan dari penelitian 
Penelitian ini dilakukan sebagai bagian dari program IMPACT (Integrated Management of 
Prevention And Control and Treatment of HIV/AIDS) yang menggunakan pendekatan 
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multidisipliner. Hasil-hasil dari penelitian saat ini digabungkan dengan hasil-hasil dari 
peneliti-peneliti lain di IMPACT akan memberikan gambaran komprehensif tentang status 
pencegahan, kontrol, dan terapi HIV di kalangan penasun di Jawa Barat, Indonesia. Karak-
teristik sosio-demografik penasun di penelitian kami sebanding dengan penelitian lain dari 
Indonesia44, 49-56. Hal ini mengindikasikan bahwa sampel kami mewakili populasi yang ada.
Penelitian-penelitian kami memiliki beberapa keterbatasan yang penting. Pertama, tidak ada 
ulasan sistematik atau meta-analisis yang digunakan dalam artikel ini. Kedua, penasun dan 
keluarganya seringkali sulit untuk dijangkau, membawa pertanyaan seberapa mewakilikah 
sampel yang ada. Respondent driven sample digunakan (bab 3 dan bab 4) untuk memini-
malkan risiko tersebut57, 58. Walaupun demikian, beberapa penasun yang tidak berada dalam 
jejaring sosial dengan partisipan ini dapat tidak terikutsertakan melaui respondent driven 
sampling59. Di PTRM (bab 5), data didapatkan dari 60% dari populasi dan tidak semua 
pasien yang berpartisipasi melengkapi semua wawancara dan pemeriksaan secara lengkap. 
Pada bab 7, purposive sampling digunakan di satu klinik di daerah urban dengan jumlah 
sampel yang agak kecil. Ketiga, generalisasi hasil penelitian untuk kondisi Indonesia secara 
umum harus dipertimbangkan secara hati-hati, karena fasilitas terapi narkoba pada umum-
nya hanya terbatas di kota-kota besar. Pada tahun 2010, hanya terdapat 49 tempat substitusi 
opioid yang terdapat di Indonesia60, sementara estimasi penasun pada tahun yang sama 
adalah lebih dari 219,000 orang61. Keempat, seluruh penelitian yang dilakukan adalah pene-
litian potong lintang. Dengan metode ini tidak dimungkinkan untuk menemukan hubungan 
sebab akibat. 
Rekomendasi
Berdasarkan hasil-hasil penelitian yang dideskripsikan dalam tesis ini dan dengan memper-
timbangkan kekuatan dan keterbatasan, kami ingin memberikan beberapa rekomendasi ke 
pengambil kebijakan, klinisi, pakar pendidikan, dan rekomendasi untuk penelitian di masa 
yang akan datang.
Pengambil kebijakan
Perluas cakupan terapi substitusi opioid menjadi terapi adiksi
Seperti telah menjadi kasus di berbagai negara, adalah epidemi HIV yang pada awalnya me-
narik perhatian untuk merubah perilaku penggunaan narkoba di Indonesia62. Laporan baru-
baru ini secara nasional menunjukan bahwa pola transmisi HIV di Indonesia telah berubah 
dari penggunaan jarum suntik ke arah transmisi heteroseksual dan penularan ibu ke anak. 
Tahun 2006, 52% of dari pasien HIV mendapatkan HIV akibat penggunaan jarum suntik 
yang tidak steril sementara angka ini menurun menjadi 16% di 2011. Walaupun demikian 
terdapat pertanyaan bagaimana mantan penasun dengan perilaku seksual berisiko dikategori-
kan dalam laporan tahun 2011. 
 
Perkembangan yang sangat positif adalah bahwa estimasi penasun di Indonesia juga menu-
run: di tahun 2006, jumlah penasun yang dilaporkan adalah 219.000 sedangkan pada tahun 
2009, 106.000 orang63. Pengurangan program yang diberikan untuk penasun oleh lembaga 
swadaya masyarakat (LSM) akan memiliki konsekuensi dalam meningkatkan kembali kontri-
busi penasun dalam transmisi HIV. 
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Berkebalikan dengan jumlah penasun, jumlah pengguna narkoba di Indonesia meningkat 
dari 2.2 persen (4 juta) di 2010 menjadi 2.8 persen (5 juta)64. Kontradiksi yang tampak ini 
dapat dijelaskan dengan adanya perubahan rute administrasi narkoba yang paling sering 
digunakan: pada umumnya dari penggunaan narkoba suntik ke narkoba non suntik tetapi 
dapat juga sebaliknya2, 3. Sebagai tambahan, tipe narkoba juga akan mempengaruhi rute 
administrasi dan/ atau perilaku seksual berisiko. 
Di bab 2, telah ditunjukkan bahwa baik penasun aktif maupun mantan penasun tidak ada 
yang berhenti menggunakan narkoba. Penggunaan stimulan tipe amfetamin (STA) mening-
kat di Asia dalam beberapa tahun terakhir36, 65-67 dan penggunaan STA, heroin, atau alkohol 
tentu saja berhubungan dengan perilaku menyuntik dan seksual berisiko65-70. Perilaku seksual 
berisiko dapat menjadi jembatan hubungan antara penasun dengan komunitas umum. 
Banyak penelitian menunjukkan bahwa prevalensi gangguan psikiatri dan penggunaan 
narkoba pada orang-orang yang melakukan perilaku seksual berisiko tinggi dan penggun-
aan obat-obat peningkat suasana perasaan seperti SSRI dapat menurunkan perilaku seksual 
berisiko71. Adalah suatu hal yang penting untuk memberi perawatan pada pasien-pasien ini, 
tidak hanya karena masalah-masalah mereka tetapi juga karena mereka mungkin memegang 
peranan kunci dalam penyebaran HIV. Peraturan baru dari pemerintah Indonesia di tahun 
2011 (Peraturan Pemerintah no 25 tahun 2011) menyatakan bahwa pengguna narkotika atau 
keluarganya harus datang ke fasilitas terapi tertentu yang telah ditunjuk pemerintah. Peratu-
ran ini dapat dilihat sebagai peluang untuk memberikan terapi narkoba tetapi juga membuka 
kesempatan untuk memberikan program terapi lainnya secara simultan. 
Menyediakan terapi komprehensif untuk komorbiditas yang kompleks 
Sebagain besar dari penasun menderita gangguan fisik, psikiatrik, dan penggunaan narkoba 
di saat yang bersamaan. Prevalensi HIV dan HCV di kalangan penasun di Indonesia (bab 
2 dan 4) adalah termasuk yang tertinggi dibandingkan dengan negara-negara lainnya49, 72-75. 
Masalah gangguan psikiatri saat ini dan seumur hidup dan gejala-gejalanya tinggi dan seban-
ding dengan penelitian-penelitian lainnya21, 72, 76-79.
Sebagian besar penasun di Indonesia menggunakan heroin tetapi pola penggunaan narkoba 
multipel adalah umum, khususnya pengkombinasian dengan benzodiazepin. Hal ini sejalan 
dengan penelitian lainnya32, 80-83. Cakupan menyeluruh dari program intervensi masih 
rendah84 dan rujukan dengan perawatan untuk permasalahan komorbiditas masih sangat 
terbatas, walaupun rujukan tersebut akan meningkatkan efektivitas dan penggunaan 
layanan6. 
Oleh karena itu, tantangan utama adalah untuk membangun kerja sama dan jejaring yang 
akan memungkinkan pengumpulan sumber daya dan kolaborasi antara penyedia laya-
nan dan/atau tenaga kesehatan. Sebagai contoh, saat ini layanan untuk HIV/AIDS, terapi 
narkoba, dan terapi psikiatri diberikan oleh tenaga kesehatan yang berbeda di fasilitas yang 
berbeda. Penyediaan layanan yang komprehensif dan terintegrasi di pusat terapi khusus dapat 
meningkatkan efektivitas secara nyata karena penasun seringkali tidak patuh pada saran ru-
jukan85. Beberapa pendekatan dapat dilakukan, seperti pelatihan staf sehingga mereka dapat 
menghadapi berbagai masalah. Jika masalah yang lebih rumit ditemukan, dapat dikonsultasi-
kan dengan ahli yang mengunjungi fasilitas secara rutin. Kolaborasi dan kesepakatan dengan 
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beberapa penyedia layanan, diskusi kasus dengan berbagai ahli di berbagai bidang dan di 
berbagai pendekatan akan  menambah dan memaksimalkan efektivitas dari program tim 
multidisiplin yang komprehensif.
Membawa layanan ke tingkat komunitas 
Sebagain besar pembiayaan untuk program narkoba dan adiksi di Indonesia berasal dari 
pendanaan eksternal86. Agar program yang ada dapat berkesinambungan maka program yang 
pembiayaannya efektif (cost-effective) diperlukan. Salah satunya adalah dengan membawa 
layanan ke tingkat komunitas. Penambahan jumlah klinik komunitas untuk tes dan konsul-
tasi sukarela HIV akan meningkatkan akses, memungkinkan deteksi dan terapi dini. Akses 
untuk penasun juga perlu ditingkatkan karena sebagian besar penasun yang datang ke tempat 
terapi (bab 5) dan ke klinik HIV di Bandung87 cenderung datang pada kondisi penyakit yang 
sudah lanjut. 
Membawa layanan ke tingkat komunitas dapat menurunkan beban dari klinik di rumah sakit 
sehingga dapat berorientasi lebih ke arah terapi pasien AIDS88. Saat ini, prevalensi HIV di 
komunitas umum masih sangat rendah dan karenanya kami menyarankan untuk membatasi 
pelayanan HIV pada rumah sakit, puskemas, dan klinik dengan petugas kesehatan dengan 
spesialisasi yang telah terakreditasi. Namun, sebaliknya, prevalensi penggunaan narkoba 
legal dan illegal di populasi umum cukup tinggi. Oleh karena itu, di tahun 2011, presiden 
memberikan instruksi untuk meningkatkan upaya pencegahan, terapi, dan rehabilitasi untuk 
penasun89. Proses penapisan penggunaan narkoba yang diimplementasikan secara terinte-
grasi dengan pelayanan kesehatan di puskemas sehari-hari akan mengarah pada deteksi dan 
intervensi secara dini. Hal ini dapat mencegah pengguna narkoba sewaktu-waktu menjadi 
pengguna rutin (adiksi). 
Meningkatkan keterlibatan keluarga dan lembaga swadaya masyarakat dan organisasi 
keagamaan dalam program terapi 
Indonesia, seperti halnya negara Asia lainnya merupakan komunitas yang kolektivis. Orang-
orang terintegrasi dari saat lahir menjadi suatu kelompok yang kohesif dan kuat kadangkala 
bahkan dengan keluarga jauh90. Keterlibatan dan dukungan dari keluarga sangat berhubun-
gan erat dengan penyesuaian fisik dan psikologis pada orang dengan HIV40, 41. Lebih lanjut, 
layanan perawatan kesehatan yang ada saat ini tampak terpisah-pisah dan kekurangan keber-
lanjutan perawatan bagi penasun. Petugas kesehatan ditantang untuk memperkuat peranan 
dari pemberi perawatan dari keluarga dan layanan komunitas lainnya untuk berkerja secara 
bersama-sama dalam aktivitas perawatan dan pencegahan HIV. Penyebarluasan pengetahuan 
dan pelatihan melalui dialog interaktif adalah elemen kunci untuk mengembangkan model 
efektif perawatan kesehatan berbasis masyarakat untuk orang dengan HIV91.
Selanjutnya, sebagian besar orang di Indonesia adalah beragama92. Kepercayaan dan latihan 
yang berhubungan dengan religi/ spiritualitas secara umum berhubungan positif dengan 
kenyamanan, harapan, rasa optimis, tujuan dan makna, adaptasi, kemampuan mengatasi 
duka, dan dukungan sosial yang lebih baik93. Banyak keluarga membawa kerabatnya yang 
mengalami masalah narkoba atau moral ke fasilitas terapi spiritual/ kepercayaan tradisional. 
Pemimpin spiritual/ orang yang memberikan terapi spiritual/ kepercayaan mungkin kurang 
mendapat informasi mengenai masalah medis seperti infeksi yang menular melalui darah 
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seperti  HIV dan hepatitis B/C. Komunikasi dan pelatihan bagi penyedia layanan terapi spi-
ritual/ kepercayaan tradisional dapat meningkatkan akses ke layanan HIV. Sebagai tambahan, 
organisasi berbasis kepercayaan dapat berkontribusi dalam perawatan harian pasien HIV. Or-
ganisasi berbasis kepercayaan merupakan suatu tipe lembaga swadaya masyarakat yang pada 
dasarnya bekerja atas dasar misi keagamaan. Di Indonesia, organisasi berbasis kepercayaan, 
biasanya memiliki sejumlah besar pengikut dan/ atau anggota yang mampu untuk menyebar-
luaskan pengetahuan ke seluruh negara91, maka mempengaruhi mereka untuk mempromosi-
kan tes dan terapi HIV akan dapat memiliki efek yang besar. 
Destigmatisasi penasun dan orang dengan HIV
Penasun dan orang dengan HIV seringkali distigmatisasi karena mereka dihubungkan den-
gan perilaku immoral45, 94. Stigma dan diskriminasi merupakan fenomena yang umum tidak 
hanya pada tingkat individu, tetapi juga di tingkat institusi dan keluarga95, 96. Stigma dan 
diskriminasi merupakan sumber stres tambahan dari stres yang sudah ada akibat penyakit itu 
sendiri45. Stigmatisasi yang tinggi mengarah pada pencarian pertolongan yang lebih rendah 
dan menjadi hambatan untuk terapi97. Program telivisi dan iklan ditonton oleh sebagian 
besar masyarakat di Indonesia dan dapat dijadikan alat untk menyebarluaskan informasi98, 99. 
Hal tersebut dapat digunakan untuk meningkatkan pengetahuan masyarakat umum menge-
nai adiksi dan HIV dan bagaimana menagani masalah tersebut sehingga stigmatisasi dapat 
diturunkan dan akses ke pelayanan kesehatan dapat ditingkatkan. 
Penggunaan variabel yang sama dalam surveilans untuk mengevaluasi program pengurangan 
dampak buruk
Ulasan baru-baru ini menyimpulkan bahwa cakupan program pengurangan dampak buruk 
terbatas dengan estimasi data tentang jumlah populasi penasun yang inkonsisten dan tidak 
sempurna84. Sebagai contoh, istilah ‘penasun’ cenderung digunakan tanpa definisi yang 
memadai, tanpa menjelaskan secara spesifik penggunaan narkoba sekarang atau dahulu, fre-
kuensi, lama penggunaan, jenis narkoba yang disuntikan, konteks (misalnya di penjara), dan 
seringkali tanpa informasi mengenai masalah fisik, psikiatrik, dan psikososial, dll. 
Kebingungan juga terjadi pada istilah “cakupan terapi substitusi opioid”. Seringkali tidak 
jelas apakah terapi metadon atau buprenorfin, atau keduanya, yang dievaluasi. Apakah terapi 
HIV diberikan pada mereka yang memerlukannya? Karakterisasi dari populasi penelitian 
juga tidak selalu jelas; apakah yang diikutsertakan dalam penelitian tersebut adalah mereka 
yang sedang dalam perawatan atau mereka yang pernah mengikuti program terapi. Standar-
disasi istilah, kondisi, dan kurun waktu merupakan persyaratan untuk melakukan evaluasi 
program intervensi yang sepatutnya.
Klinisi
Komorbiditas fisik
Penasun dapat menderita berbagai gangguan fisik pada saat yang bersamaan termasuk 
infeksi yang menular melalui darah seperti HIV dan hepatitis B/C, abses pada kulit, sepsis 
dengan atau tanpa endokarditis, keracunan obat akibat interaksi berbagai macam obat atau 
polifarmasi, dll18. Jika diresepkan secara seharusnya dan dengan kepatuhan yang optimal, 
terapi antiretroviral telah terbukti meningkatkan secara dramatis prognosis dari infeksi 
HIV dan komorbiditas lainnya, termasuk tuberkulosis, hepatitis virus, penyakit ginjal dan 
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kardiovaskular18. 
Walaupun demikian, banyak klinisi Indonesia yang masih menolak untuk meresepkan terapi 
HIV pada penasun. Beberapa diantara mereka mengatakan pada pasien bahwa terapi adiksi 
perlu dihentikan sebelum terapi antiretroviral dapat dimulai. Manajemen klinis berkesi-
nambungan terhadap berbagai komorbiditas yang terjadi pada penasun yang terinfeksi HIV 
dapat mengakibatkan interaksi farmakokinetik obat yang harus diperhatikan secara adekuat. 
Lebih lanjut, intervensi untuk meningkatkan kepatuhan terapi dengan memperhatikan masa-
lah psikiatri, penggunaan narkoba, dan dukungan sosial diperlukan18.
Komorbiditas psikiatri
Penilaian dan pengobatan harus dilakukan secara hati-hati karena masalah psikiatri dapat ter-
jadi secara independen atau sebagai hasil dari HIV, HCV, penggunaan narkoba, dan komor-
biditas lainnya dan pengobatannya. Intervensi untuk meningkatkan rujukan dan menerima 
rujukan dari/ ke terapi jiwa dibutuhkan. Penggunaan terapi psikiatri masih rendah diban-
dingkan dengan kebutuhannya, khususnya akibat stigmatisasi pada orang dengan gangguan 
psikiatri100, 101.
Komorbiditas yang berkaitan dengan penggunaan narkoba
Beberapa faktor psikiatris dapat meningkatkan kerentanan seseorang untuk menjadi peng-
guna narkoba. Yang paling sering ditemukan adalah kepribadian turunan26, impulsivitas, 
pencarian sensasi, sesuatu yang baru, sensitif terhadap penghargaan25, kepribadian 
antisosial27, dan trauma masa anak-anak28.
Faktor-faktor psikiatrik mempengaruhi hasil dari terapi dan jarang diperhatikan dalam 
program terapi narkoba25. Penggunaan narkoba, khususnya penggunaan narkoba multipel 
meningkatkan kerentanan untuk menderita gangguan psikatri23, 29. Disamping terapi 
substitusi yang telah terbukti efektivitasnya49, 102, 103, dukungan psikososial harus 
dipertimbangkan. Disebabkan oleh adanya gangguan sosial, emosional dan kognitif jangka 
panjang disertai dengan penggunaan narkoba, efek-efek ini bermakna dan sebanding dengan 
gangguan lainnya yang banyak ditemukan di psikiatri 104.
Menggunakan pendekatan biopsikososial untuk mendukung pasien
Model biopsikososial tidak hanya menekankan pada kebutuhan untuk menghormati keadaan 
dan pandangan pasien yang unik, tetapi juga mendukung pandangan bahwa setiap indi-
vidu adalah agen yang penuh kekuatan untuk penentuan arah dirinya. Daripada memiliki 
pandangan bahwa hasil tiap individu adalah sebagian besar merupakan hasil dari determinan 
eksternal, model biopsikososial menghargai peranan nyata yang dimainkan dari kualitas 
setiap kelenturan individu dan agen personal. Sebagai model pelayanan yang terbaik, biopsi-
kososial mengakomodasi dan mendukung teori sistem non-linear yang menempatkan indi-
vidu dan tingkah laku dalam konteks sistem biologi, keluarga, dan sosio-kultural, dan yang 
memandang individu sebagai peserta aktif dalam sistem rumatan berkelanjutan dan dalam 
perubahan yang dinamik (105). Penatalaksanaan penyakit kronis seperti adiksi dan HIV juga 
memerlukan peranan aktif pasien dalam pengambilan keputusan, pemecahan masalah, dan 
implementasi dari rencana terapi personal untuk mencapai kondisi sehat yang lebih baik106. 
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Pendidikan dan pelatihan
Kedokteran adiksi untuk praktisi adiksi 
Di Indonesia, kedokteran adiksi belum dikenal sebagai (sub) spesialisasi medis dan tidak ada 
kurikulum kedokteran adiksi maupun pelatihan kedokteran adiksi yang tersedia. Saat ini, 
terdapat sekitar 200 profesional yang bekerja di perawatan adiksi, diantaranya, sesuai dengan 
penelitian terakhir, sekitar 17% belum pernah menerima pelatihan adiksi. Sebagian besar 
dari profesional pemberi layanan adiksi hanya mendapatkan pelatihan singkat mengenai 
terapi substitusi opioid, berupa pelatihan beberapa hari tentang peresepan dan pemberian 
metadon dan  buprenorphin.  
Hanya 30% profesional adiksi di Indonesia yang menganggap adiksi sebagai penyakit otak, 
sedangkan sekitar 70% menganggap terapi berbasis kepercayaan/ agama sebagai modalitas 
terapi yang paling sesuai107. Kurangnya pengetahuan yang sesuai diantara profesional yang 
berkerja dengan penasun yang terinfeksi HIV, disertai dengan stigmatisasi, mempengaruhi 
perilaku mereka dalam pemberian layanan bagi pasien dan membatasi tingkatan kualitas in-
tervensi medis dan psikiatris dalam kelompok ini91. Oleh karena itu, modul pelatihan untuk 
tenaga kesehatan khusus perlu untuk dikembangkan dan diberikan. Modul ini seharusnya ti-
dak hanya memasukan tentang kedokteran adiksi tetapi juga infeksi yang ditularkan melalui 
darah sebagai tujuan pengajaran. Sertifikasi khusus dari kementrian kesehatan harus didapat-
kan untuk dapat bekerja di terapi adiksi. Setiap institusi yang telah ditunjuk oleh kementrian 
kesehatan sebagai pusat terapi harus memperkerjakan seorang dokter yang memiliki sertifikat 
tersebut.
Kedokteran adiksi sebagai kurikulum di fakultas kedokteran
Topik mengenai adiksi dan HIV seharusnya dimasukan ke dalam kurikulum di fakultas 
kedokteran. Kurikulum tersebut seharusnya mencakup aspek psikologis, tingkah laku, 
dan imunologis dari kondisi ini. Pelatihan ini tidak hanya memberikan pengetahuan dasar 
yang dibutuhkan untuk mengerti adiksi dan HIV tetapi juga akan mengurangi stigma dan 
memberikan ide tentang pendekatan yang terintegrasi dan komprehensif untuk menghadapi 
masalah medis.
Kedokteran adiksi sebagai kurikulum di sekolah dasar dan menengah
Penggunaan narkoba di Indonesia dimulai pada usia yang sangat muda (14 tahun) diban-
dingkan dengan negara lain seperti Australia, Canada, Cina, Iran, Israel, Belanda, Polandia, 
Thailand, dan Amerika Serikat20, 21, 23, 49, 74. Oleh karena itu, pendidikan untuk mencegah 
penggunaan NAPZA seharusnya diberikan di sekolah dasar dan menengah. 
Di Indonesia, masalah seks dan penggunaan narkoba seringkali dianggap sebagai sesuatu 
yang sensitif dan pendidikan mengenai keterampilan hidup mulai dilakukan satu dekade 
yang lalu untuk mencegah hubungan seksual dan tingkah laku berisiko yang berhubungan 
dengan penggunaan narkoba yang diberikan dengan cara yang dapat diterima oleh budaya 
setempat. Ketermapilan hidup didefinisikan sebagai keterampilan seseorang untuk melaku-
kan perilaku yang adaptif dan positif untuk menghadapi kebutuhan dan tantangan sehari-
hari dengan cara yang efektif. Tujuan dari pendidikan keterampilan hidup adalah untuk 
memperkuat kemampuan yang membantu meningkatkan kesehatan mental dan keterampi-
lan orang muda saat mereka menghadapi realita kehidupan108. 
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Informasi mengenai adiksi dan kesehatan reproduksi harus diberikan dengan cara yang sesuai 
untuk meningkatkan kewaspadaan dan pengertian para murid tetapi tidak untuk meningkat-
kan keingintahuan mereka untuk mencoba narkoba dan hubungan seksual. 
Rekomendasi untuk penelitian di masa yang akan datang
Hasil penelitian dalam tesis ini menjawab hanya sebagian kecil dari masalah kompleks pada 
penasun yang berhubungan dengan penyebaran HIV. Informasi lebih lanjut tentang estimasi 
jumlah penasun diperlukan untuk penyesuaian penyediaan tempat terapi. Surveilans meng-
gunakan kriteria variabel yang sama untuk memahami permasalahan dan untuk mengeva-
luasi intervensi yang dilakukan saat ini diperlukan untuk dilakukan secara rutin sehingga 
program intervensi dapat disesuaikan dengan situasi terbaru. Penelitian lebih lanjut menge-
nai faktor-faktor yang berhubungan dengan perilaku berisiko, seperti penggunaan narkoba, 
komorbiditas psikiatri pada kelompok berisiko untuk penularan HIV (penjaja seks komersial 
dan laki-laki yang suka pada laki-laki) juga sangat penting dilakukan untuk mengembangkan 
program intervensi yang lebih sesuai untuk mencegah penularan HIV lebih lanjut. Banyak-
nya komorbiditas pada penasun (bab 2, 4, 5) mengindikasikan kebutuhan untuk mengekplo-
rasi berbagai komorbiditas pada pasien HIV. 
Semua penelitian dalam tesis ini adalah penelitian potong lintang yang penting untuk meni-
lai permasalahan dan memahami karakteristik dari populasi target. Tahap berikutnya adalah 
untuk menterjemahkannya ke dalam bentuk tindakan nyata, sebagai contoh dengan mem-
perbaiki dan mengembangkan program-program intervensi. Di bawah ini adalah beberapa 
penelitian aksi (action researches) yang perlu diutamakan.
Kurangnya informasi dan pelayanan adalah terutama mengenai gangguan psikiatri dan tera-
pinya (bab 4, 5, dan 6). Percobaan acak terkontrol (randomized control trial) untuk mene-
mukan intervensi psikiatri yang efektif (terapi kognitif dan perilaku (cognitive behavioural 
therapy (CBT)), obat psikotropika, atau kombinasi CBT dan  obat psikotropika) untuk 
pasien HIV dengan atau tanpa riwayat penggunaan narkoba suntik dapat menggunakan ber-
bagai paramaeter seperti kepatuhan minum ARV, respon imunologis, penggunaan narkoba, 
perilaku berisiko, dan kualitas hidup. 
Prevalensi gangguan fisik, psikiatri, dan penggunaan narkoba lainnya pada penasun tinggi 
(bab 2, 3, 4, 5, 6) dan akses ke pelayanan masih terbatas. Penelitian kohort untuk mem-
bandingkan pelayanan yang berbasis komunitas dan berbasis rumah sakit diperlukan untuk 
menemukan pendekatan yang paling efektif. Data dasar dan data follow-up untuk mengukur 
derajat keparahan gangguan fisik, gangguan psikiatri, penggunaan narkoba, kualitas hidup, 
parameter laboratorium (Hb, CD4), kepatuhan terhadap rujukan, dan kepatuhan terhadap 
pengobatan dapat digunakan sebagai faktor penentu. 
Terapi berbasis kepercayaan dan pengobatan tradisional serta dukungan sosial di masyarakat 
Indonesia adalah kekuatan pada masyarakat Indonesia yang belum cukup dilibatkan dalam 
program penganan adiksi dan HIV (bab 4 dan 7). Informasi mengenai penyebaran HIV, 
metode pencegahan infeksi HIV, faktor yang dapat meningkatkan kerentanan seseorang 
untuk menggunakan narkoba, dan terapi adiksi diberikan pada pemuka agama dan staf-
stafnya yang pada gilirannya dapat memberikan edukasi pada komunitas mereka melalui 
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kunjungan rumah dan pertemuan keagamaan. Pengetahuan, sikap, dan perilaku mengenai 
HIV dan adiksi narkoba dari pemuka agama sebelum dan setelah pelatihan dapat digunakan 
sebagai parameter penilaian langsung. Perbandingan akses terhadap terapi HIV dan narkoba, 
perilaku berisiko, dan prevalensi HIV di komunitas antara data dasar dan data follow-up 
yang dilakukan beberapa tahun setelah intervensi dapat menentukan kesuksesan program 
intervensi tersebut. 
Perubahan dari penggunaan narkoba suntik ke non suntik adalah sesuatu yang sering terjadi 
sehingga proporsi penasun non-aktif (former injecting drug users) di kalangan penasun 
cukup bermakna (bab 3). Derajat keparahan penggunaan narkoba dipengaruhi oleh banyak 
faktor (bab 2 dan 6). Oleh karena itu, pemilihan terapi adiksi yang sesuai dan memberi-
kan manfaat untuk pasien dan juga baik dilihat dari sudut pandang kesehatan masyarakat 
merupakan sesuatu hal yang sangat penting. Terapi metadon sebaiknya hanya diberikan pada 
mereka yang membutuhkan sehingga tidak menimbulkan dampak buruk. Pengetahuan dan 
keterampilan yang baik pada petugas medis yang bekerja di bidang adiksi dapat menurun-
kan pemberian terapi adiksi yang kurang tepat. Tingkat pengetahun dan ketrampilan dalam 
menghadapi pasien adiksi sebelum dan setelah pelatihan dapat digunakan untuk menentu-
kan program terapi adiksi yang paling efektif. 
Penelitian-penelitian di atas dapat dilakukan dengan cara yang komprehensif. Sebuah proyek 
seperti IMPACT memberikan kesempatan untuk untuk mempelajari masalah dari berbagai 
sudut pandang, di berbagai tempat, dan melibatkan tenaga ahli dari berbagai bidang ilmu. 
Hasil yang didapatkan dari penelitian-penelitian tersebut dapat digunakan sebagai latar 
belakang penelitian lainnya. Dengan bekerja sama, pemahaman komprehensif terhadap suatu 
permasalahan dapat dirumuskan. Proyek seperti ini juga memfasilitasi seluruh orang yang 
terlibat dengan memberikan lingkungan yang positif dan aman untuk belajar (kami belajar 
dari kegagalan dan juga kesuksesan) dan membuka sesuatu hal yang baru dengna ide-ide 
baru. Pendekatan organisasi pembelajaran, menekankan pada tujuan umum, menerapkan 
pembelajaran multi-disiplin, intervensi berbasiskan bukti, dan memperkuat kapasitas indi-
vidu dan organisasi telah terbukti berhasil109. Walaupun demikian, menerapkan pendekatan 
ini juga memiliki berbagai kendala. Pemahaman mengenai perbedaan kultur dan manajemen 
organisasi merupakan kunci kesuksesan program di masa yang akan datang. 
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